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Summary 
Skin cancers, like squamous cell carcinoma (SCC), which belongs to the most frequent tumors 
world wide, require novel strategies for treatment, since most malignant cancer cells resist current 
anti-tumour agents. In the recent years cytokines, such as TRAIL or CD95L, that activate 
apoptotic death receptor signalling pathways as well as synthetic compounds like poly (I:C) that 
may activate Toll-like receptor-3 (TLR3)-mediated cell death signalling pathways are discussed 
as potential targets for anti-tumour therapy. Overcoming apoptosis resistance of tumor cells is of 
paramount importance for the development of novel therapeutic strategies for specific elimination 
of cancer cells. However, many cancer cells resist apoptotic stimuli by up-regulation of anti-
apoptotic proteins such as cFLIP, IAPs and Bcl-2. cIAPs were postulated as crucial inhibitors of 
TLR3- as well as CD95-induced apoptosis but the mechanisms as well as proof of this hypothesis 
are lacking to date. The goal of this thesis was to contribute to the understanding of the functional 
relevance of IAPs for the regulation of TLR3- and DR-mediated cell death and non-apoptotic 
signalling pathways in primary keratinocytes and SCC cells.   
This work has demonstrated that cIAPs protect HaCaT keratinocytes from poly (I:C)- and CD95L-
induced cell death by inhibition of both caspase and RIP-1-kinase activities. Interestingly, cIAPs 
inhibit the formation of an intracellular RIP-1 signalling complex, which consists of caspase-8, 
RIP-1 cFLIP, and FADD. This RIP-1 complex is necessary, but insufficient for induction of cell 
death. Upon TLR3 stimulation in the absence of cIAPs thus RIP-1 complex is binding to TRIF, 
and promotes enhanced apoptosis. However, inhibition of caspase-8 activity in this complex by 
chemical inhibitors (such as zVAD-fmk or QVD) or by overexpression of cFLIPS (a prominent 
caspase-8 interacting molecule and inhibitor) unmasks a necrotic form of cell death. In this pro-
necrotic complex substantial accumulation of RIP-1 was observed, although this necrotic cell 
death was fully blocked by inhibition of RIP-1 kinase activity. Loss of RIP-1 in this complex 
mediated by specific shRNA protects cells from poly (I:C)/IAP antagonist and CD95L/IAP 
antagonist induced cell death.  
However, cells expressing high levels of cFLIPL are resistant to poly (I:C) and CD95L-induced 
apoptosis in the absence of cIAPs. Interestingly the long isoform cFLIPL, but not the short isoform 
cFLIPS conferred protection from IAP antagonist induced RIP-1-kinase-dependent necrotic cell 
death. Furthermore, degradation of cIAPs, induced by TWEAK signalling, duplicates findings with 
the IAP antagonist and shows the physiological relevance of cIAPs for the regulation of RIP-1 
dependent cell death signalling pathways. 
Studies of primary keratinocytes showed equal levels of sensitivity to TLR3-induced apoptosis of 
primary and immortalised keratinocytes (HaCaT). The IAPs protect these cells from TLR3-
induced cell death by inhibition of both caspase and RIP-1-kinase activities. Intriguingly, the 
downregulation of RIP-1 in primary keratinocytes conferred no protection, but switches TLR3-
induced cell death from apoptotic to necrotic cell death. Further inhibition of caspase activities by 
zVAD-fmk increases non-apoptotic cell death in RIP-1 knockdown primary keratinocytes and this 
cell death can only partially blocked by Necrostatin-1. Therefore poly (I:C) treated keratinocytes 
die in the absence of cIAPs in a caspase- and RIP-1-independent cell death and this cell death 
may be regulated by currently unknown factors.  
TLR3 and DRs can also activate pro-survival NF-κB and MAPK dependent signalling pathways 
that promote resistance to cell death stimuli and therefore induce carcinogenesis. In this study it 
was also found that IAPs block spontaneous activation of both canonical and non-canonical NF-
κB activation pathways in primary and SCC cell lines. TRAIL-induced signalling suppresses the 
spontaneous non-canonical NF-κB activation, induced by the absence of IAPs in primary and 
SCC keratinocytes. As well, TRAIL-induced canonical NF-κB activation was downregulated in the 
absence of IAPs. In contrast to NF-κB pathways, the MAPKs were not auto-activated upon IAP 
depletion, although TRAIL-induced p38 activation in the absence of IAPs was increased in cancer 
cells, unlike HaCaT and primary keratinocytes. TRAIL-induced JNK activation is not influenced by 
IAPs.  
Taken together, the results of this study implicate cIAPs as crucial negative regulators of TLR3 
and CD95 cell death signalling by modulation of RIP-1. Moreover, IAPs are critical inhibitors of 
both canonical and non-canonical NF-κB signalling. Furthermore, TWEAK signalling may 
modulate RIP-1-dependent necrosis, induced by different stimuli. Simultaneous treatment with 
IAP antagonists and pro-apoptotic stimuli, like TLR3- or DR-agonists, could thus be an interesting 
strategy for future anticancer therapy and may impact also anti-tumour immune response.  
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Zusammenfassung 
Hautkrebs, wie das Plattenepithelkarzinom (SCC), gehört zu den weltweit am meist 
verbreiteten Tumorerkrankungen der Haut. Die Entwicklung von neuen Strategien zur 
Behandlung dieses Hautkrebses ist notwendig, da eine Vielzahl von Krebszellen 
Resistenzen gegenüber bekannten Anti-Tumor-Therapien zeigen. In den vergangenen 
Jahren wurden Zytokine, wie TRAIL und CD95L, die apoptotische Signalwege durch 
Aktivierung von Todesrezeptoren (TR) als auch synthetische Komponenten, wie Poly (I:C), 
die Toll-like-Rezeptor-3 (TLR3)-vermittelte Zelltodsignalwege initiieren können, als potentielle 
Zielstrukturen für Antitumortherapien diskutiert. Die Überwindung von Apoptoseresistenz von 
Tumorzellen ist dabei von höchster Bedeutung für die Entwicklung neuer therapeutischer 
Strategien zur spezifischen Eliminierung von Krebszellen. Viele Tumorzellen zeigen 
Resistenzen gegenüber apoptotischen Stimuli durch Aufregulierung zentraler anti-
apoptotischer Proteine, wie cFLIP, IAPs und Bcl-2 Proteinen. cIAPs wurden als kritische 
Inhibitoren für die TLR3- und CD95-induzierte Apoptose postuliert, wobei sowohl diese 
Resistenzmechanismen bisher nicht genau bekannt sind, als auch die detaillierte 
Überprüfung dieser Hypothese zum jetzigen Zeitpunkt noch aussteht. Das Ziel dieser Arbeit 
bestand in der Identifizierung der funktionellen Relevanz von IAPs für die Regulierung des 
TLR3- und CD95-vermittelten Zelltods sowie der Bedeutung der cIAPs für die nicht-
apoptotische Signalgebung in primären Keratinozyten und SCC Zellen.  
In dieser Arbeit konnte demonstriert werden, dass cIAPs HaCaT Keratinozyten gegenüber 
Poly (I:C)- und CD95L-induzierte Zelltodinduktion durch Inhibition von Caspase- und RIP-1-
Kinase-Aktivitäten schützen. Interessanterweise inhibieren cIAPs die Formierung eines 
intrazellulären RIP-1 Signalkomplexes, der Caspase-8, RIP-1, cFLIP und FADD Moleküle 
beinhaltet. Dieser RIP-1 Komplex ist nicht in der Lage Zelltod zu induzieren. Nach 
Stimulation des TLR3 in der Abwesenheit der cIAPs kommt es zur Bindung des RIP-1 
Komplexes an TRIF, wodurch Apoptose gefördert und verstärkt wird. Die Inhibition der 
Caspase-Aktivität in diesem Komplex durch chemische Caspaseinhibitoren, wie zVAD-fmk 
oder QVD, oder durch Überexpression von cFLIPS (ein bekannter Caspase-8-
Interaktionspartner und -Inhibitor) führte zum Nachweis eines nekrotischen Zelltods. In 
diesem Nekrose-fördernden Komplex wurde eine substantielle Akkumulation von RIP-1 
beobachtet. Durch die Inhibition der RIP-1-Kinase Aktivität durch Necrostatin-1 in diesem 
Komplex kann die Poly (I:C)/IAP Antagonist geförderte Nekrose gehemmt werden. Auch der 
Verlust von RIP-1 in diesem Komplex, beispielsweise vermittelt durch spezifische shRNA, 
schützt die Zellen gegenüber Poly (I:C)/IAP Antagonist und gegenüber CD95L/IAP 
Antagonist induzierten Zelltods. Des Weiteren konnte gezeigt werden, dass die Expression 
von cFLIPL mit Resistenz gegenüber Poly (I:C)- und CD95L-induzierter Apoptose auch in 
Abwesenheit von cIAPs einhergeht. Interessanterweise schützt cFLIPL, jedoch nicht cFLIPS 
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vor dem IAP Antagonisten-induzierten RIP-1-Kinase-abhängigen nekrotischen Zelltod. Die 
physiologische Bedeutung der cIAPs für die Regulation von RIP-1-abhängigen 
Zelltodsignalwegen wird durch Experimente mit TWEAK deutlich. TWEAK bewirkt die 
Degradation von cIAPs und diese Experimente konnten die gefundenen Resultate mit dem 
IAP Antagonisten bezüglich der Mechanismen der Zelltodinduktion bestätigen.  
Studien mit primären Keratinozyten konnten eine ähnliche Empfindlichkeit gegenüber TLR3-
induzierte Apoptose von primären und immortalisierten Keratinozyten (HaCaT) zeigen. Auch 
hier schützen IAPs die Zellen gegenüber TLR3-induziertem Zelltod durch Inhibition von 
Caspase- und RIP-1-Kinase-Aktivitäten. Im Gegensatz zu HaCaT-Zellen führt eine 
Verminderung der RIP-1 Expression in primären Keratinozyten nicht zu einer Protektion des 
IAP Antagonist/Poly(I:C)-vermittelten Zelltods, sondern zu einem Wechsel von 
apoptotischem zum nekrotischem Zelltod. Ein weiterer Unterschied in der 
Todessignalgebung in primären Keratinozyten besteht darin, dass die Inhibition von 
Caspaseaktivitäten (mittels zVAD-fmk) in RIP-1-knockdown Zellen zu einer verstärkten 
Induktion des nicht-apoptotischen Zelltods führt, der aber nur teilweise durch Necrostatin-1 
inhibiert werden kann. Demnach sterben Poly(I:C)-behandelte Keratinozyten in der 
Abwesenheit von cIAPs durch einen Caspase- und RIP-1-unabhängigen Zelltod und dieser 
Zelltod wird wahrscheinlich durch bisher noch nicht bekannte Faktoren reguliert.  
TLR3 und TRs können auch überlebensfördernde NF-κB- und MAPK-abhängige Signalwege 
aktivieren, die Resistenzen gegenüber Zelltodstimuli und damit die Karzinogenese von 
Hautzellen fördern. In dieser Studie konnte weiterhin gezeigt werden, dass IAPs die 
spontane Aktivierung der kanonischen und nicht-kanonischen NF-κB Aktivierung in primären 
Keratinozyten und in SCC-Zellen hemmen. Des Weiteren wird die spontane nicht-
kanonische NF-κB-Aktivierung der TRAIL-vermittelten Signalkaskade in der Abwesenheit 
von cIAPs in primären Keratinozyten und SCC Zellen unterdrückt. Die TRAIL-induzierte 
kanonische NF-κB-Aktivierung wird ebenfalls in der Abwesenheit von cIAPs vermindert. Im 
Gegensatz zum NF-κB Signalweg, werden die MAPK nach IAP Depletion nicht autoaktiviert. 
Eine Steigerung der p38 Aktivierung in der Abwesenheit der IAPs und nach TRAIL 
Stimulation wurde in MET1 und A5RT3 SCC Zellen, jedoch nicht in HaCaT Zellen und 
primären Keratinozyten beobachtet. Im Gegensatz dazu wird die TRAIL-induzierte JNK 
Aktivierung nicht von IAPs beeinflusst.  
Zusammenfassend zeigen die Resultate dieser Studie zeigen somit, dass cIAPs durch 
Modulation der Funktion von RIP-1 TLR3- und CD95-Zelltodsignalwege negativ regulieren. 
Die cIAPs sind aber auch bedeutende Inhibitoren kanonischer und nicht-kanonischer NF-κB 
Signalgebung. Des Weiteren kann die kombinierte Signalgebung von TWEAK und anderen 
Stimuli die RIP-1-abhängige Nekrose modulieren. Die simultane Behandlung mit IAP 
Antagonisten und pro-apoptotischen Stimuli, wie zum Beispiel TLR3- oder TR-Agonisten, 
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könnte eine Strategie für Antitumortherapien darstellen, die auch für die antitumorale 
Immunantwort bedeutsam sein könnte.  
Diplom Genetikerin Feoktistova Maria Alexeevna 
The role of RIP-1 and cIAPs in apoptotic and non-apoptotic signalling via TLR3 and death receptors  
 7
Contents 
Summary…………………………………………………………………………………………. 3
Zusammenfassung……………………………………………………………………………… 4
Contents………………………………………………………………………………………….. 7
Figures and Tables……………………………………………………………………………… 10
1. Introduction…………………………………………………………………………………… 12
1.1.1. The role and function of the skin………………………………………….. 12
1.1.2. Skin cancer………………………………………………………………….. 12
1.2. Cell death…………………………………………………………………………….. 13
1.2.1. Cornification in the skin……………………………………………………. 13
1.2.2. Caspase-independent cell death (CICD): Necrosis and Autophagy….. 13
1.2.3. Apoptosis……………………………………………………………………. 14
1.2.3.1. The intrinsic apoptotic signalling pathway………………………. 15
1.2.3.2. The extrinsic apoptotic signalling pathway.……………………... 15
1.2.3.4. Initiation of apoptosis by death receptors……………………….. 16
1.2.4. Inhibition of Apoptosis……………………………………………………… 17
1.2.4.1. cFLIP – inhibitor of caspases…………………………………….. 17
1.2.4.2. Inhibitor of apoptosis proteins (IAPs)……………………………. 18
1.2.4.2.1. IAP and the ubiquitination process……………………… 20
1.2.4.2.2. Regulation of IAP’s function……………………………… 20
1.2.4.2.3 TWEAK-FN14 signalling regulates cIAPs level………… 21
1.2.4.2.4. Regulation of IAPs with synthetic antagonists…………. 21
1.3. Death receptor induced non-apoptotic signalling pathways……………………. 22
1.3.1. NF-κB activation……………………………………………………………. 22
1.3.2. NF-κB activation via Death receptors…………………………………….. 23
1.3.3. MAPK………………………………………………………………………… 23
1.4. Toll-like receptors……………………………………………………………………. 24
1.4.1. TLR-3 mediated signalling………………………………………………… 26
1.4.2. TLR3-induced NF-κB and MAPK activation……………………………... 26
1.4.3. TLR3-induced apoptosis…………………………………………………… 27
1.5. RIP-1 as the central signalling molecule………………………………………….. 28
1.5.1 The role of RIP-1 for cell death signal transduction……………………... 28
1.5.2. The role of RIP-1 for NF-κB and MAPK activation……………………… 29
1.5.3. Regulation of RIP-1 by ubiquitination…………………………………….. 30
1.6. Aims…………………………………………………………………………………... 31
2. Material and Methods……………………………………………………………………….. 33
2.1. Materials……………………………………………………………………………… 33
2.1.1. Enzymes and molecular biology reagents……………………………….. 33
2.1.2. Kits………………………………………………………………………….... 33
2.1.3. Phoshpatase and protease inhibitors…………………………………….. 33
2.1.4. Pharmacological stimulating substances………………………………… 34
2.1.5. Stimulating Cytokine……………………………………………………….. 34
2.1.6. Molecular weight markers ………………………………………………… 34
2.1.7. Buffers……………………………………………………………………….. 35
2.1.8. Primary antibodies for western blot analysis……………………………. 36
2.1.9. HRP-coupled secondary antibodies……………………………………… 36
2.1.10. Vectors……………………………………………………………………... 37
2.1.11. siRNA-sequences for knockdown of:…………………………………… 37
2.1.12. Bacteria cells………………………………………………………………. 38
2.1.13. Culture media and additives for bacterial cells………………………… 38
2.1.14. Human cells……………………………………………………………….. 38
2.1.15. Cell culture media and reagents for human cells……………………… 39
2.2. Methods………………………………………………………………………………. 39
2.2.1. Molecular biological methods……………………………………………... 39
2.2.1.1. Digestion of DNA with restriction endonucleases……………… 40
Diplom Genetikerin Feoktistova Maria Alexeevna 
The role of RIP-1 and cIAPs in apoptotic and non-apoptotic signalling via TLR3 and death receptors  
 8
2.2.1.2. DNA agarose gel electrophoresis……………………………….. 40
2.2.1.3. Cloning……………………………………………………………… 40
2.2.1.4. Heat shock transformation………………………………………... 40
2.2.1.5. Plasmid isolation…………………………………………………… 40
2.2.2. Cell culture techniques…………………………………………………….. 41
2.2.2.1. Ca-phosphate mediated Transfection of vector-DNA………….. 41
2.2.2.2. Generation and purification of stimulating cytokines…………... 41
2.2.2.3. Retroviral infection…………………………………………………. 42
2.2.2.4. Lentiviral infection………………………………………………….. 42
2.2.2.5. Stable siRNA expression…………………………………………. 42
2.2.2.6. Cytotoxicity assay…………………………………………………. 43
2.2.3. Cell lysate preparation……………………………………………..……… 43
2.2.3.1. For Western blot analysis………………………………………… 43
2.2.3.2. For phospho-protein analysis…………………………………….. 43
2.2.3.3. For EMSA…………………………………………………………... 44
2.2.4. Electrophoretic mobility shift assay (EMSA)…………………………….. 44
2.2.5. Western Blot analysis……………………………………………………… 44
2.2.6. Analysis of hypodiploid DNA content of the cells………………………. 44
2.2.7. Immunofluorescence microscopy………………………………………… 45
2.2.8. Co-immunoprecipitation of Caspase-8-bound complexes…………….. 45
3. Results………………………………………………………………………………………… 46
3.1. The role of cIAPs in TLR3-induced cell death……………………………………. 46
3.1.1. Loss of cIAPs sensitizes to poly (I:C)-induced cell death……………… 46
3.1.2. Loss of cIAPs sensitizes to poly (I:C)-induced cell death in a 
Caspase- and RIP-1-kinase dependent manner ………………………………. 49
3.1.3. Degradation of cIAPs by TWEAK sensitizes to poly (I:C)-induced cell 
death………………………………………………………………………………… 51
3.1.4. cFLIP isoforms negatively regulate poly (I:C) induced apoptosis but 
differentially control IAP antagonist/TWEAK-mediated caspase-dependent 
and independent cell death……………………………………………………….. 53
3.1.5. cFLIP isoforms differentially influence the modification and 
composition of the intracellular TLR3 signalling complexes…………………... 56
3.1.6. cIAPs are crucial negative regulators of RIP-1 recruitment in an 
apoptotic TRIF containing Caspase-8-interacting complex…………………… 57
3.1.7. RIP-1 overexpression induces cell death………………………………... 61
3.2. The role of cIAPs in CD95L-induced cell death………………………………….. 63
3.2.1. Loss of IAPs sensitizes to CD95L-induced cell death in both caspase-
dependent and independent manner……………………………………………. 64
3.2.2. The role of RIP-1 and cFLIP isoforms in CD95-mediated cell death in 
presence of TWEAK……………………………………………………………….. 66
3.3. Role of cIAPs in TLR3 cell death in primary keratinocytes……………………... 68
3.3.1. Loss of cIAPs sensitizes primary keratinocytes to poly (I:C)-induced 
cell death in a Caspase- and RIP-1-kinase dependent manner……………… 68
3.3.2. The function of RIP-1 in TLR3-induced cell death in primary 
keratinocytes……………………………………………………………………….. 71
3.4. The role of cIAPs in MAPK and NF-κB activation……………………………….. 74
3.4.1. Inhibition of cIAPs led to both canonical and non-canonical NF-κB 
activation…………………………………………………………………………… 74
3.4.2. The role of IAPs for NF-κB and MAPK activation in HaCaTs, SCC 
and primary keratinocytes………………………………………………………… 76
4. Discussion…………………………………………………………………………………….. 80
4.1. cIAPs are critical regulators of TLR3-induced cell death in transformed 
keratinocytes and SCC cells…………………………………………………………….. 80
4.2. cIAPs negatively regulate apoptotic and necrotic TLR3-induced signalling by 
limiting caspase and RIP-1 kinase activity in HaCaT keratinocytes………………… 81
 
Diplom Genetikerin Feoktistova Maria Alexeevna 
The role of RIP-1 and cIAPs in apoptotic and non-apoptotic signalling via TLR3 and death receptors  
 9
4.3. cFLIPL and cFLIPS differentially regulate apoptotic and necrotic TLR3 
signalling pathways in the absence of cIAPs………………………………………….. 
82
4.4. cIAPs control TLR3-induced cell death signalling by regulating the formation 
of intracellular complexes………………………………………………………………... 83
4.5. cIAPs control apoptotic and necrotic cell death induced by CD95L…………… 86
4.6. cIAPs are suppressors of RIP-1 complex formation…………………………….. 86
4.7. cIAPs and XIAP protect primary keratinocytes from TLR3 induced apoptotic 
and non-apoptotic cell death……………………………………………………………. 88
4.8. The impact of IAPs for the control of non-apoptotic signals activation in 
TRAIL stimulated primary keratinocytes and SCC cell lines………………………… 90
4.9. Perspectives…………………………………………………………………………. 92
5. Reference List………………………………………………………………………………… 93
6 Appendix………………………………………………………………………………………. 102
6.1. Abbreviations………………………………………………………………………. 102
6.2 Curriculum vitae……………………………………………………………………… 
6.3. Publications………………………………………………………………………….. 
6.4.Erklärung……………………………………………………………………………… 
104
105
106
 
Diplom Genetikerin Feoktistova Maria Alexeevna 
The role of RIP-1 and cIAPs in apoptotic and non-apoptotic signalling via TLR3 and death receptors  
 10
Figures and Tables 
Figure 1. The scheme of epidermis layers……………………………………………………. 13
Figure 2. Death receptors and their signalling complex…………………………………….. 16
Figure 3. Death receptor signalling……………………………………………………………. 17
Figure 4. Domain structure of caspase8 and cFLIP isoforms………………………………. 18
Figure 5. Domain structure of IAP family proteins…………………………………………… 19
Figure 6. Toll-like receptor signalling………………………………………………………….. 25
Figure 7. TLR3 signalling pathways…………………………………………………………… 26
Figure 8. Domain organization of RIP-1………………………………………………………. 28
Table 1: Molecular biology reagents…………………………………………………………... 33
Table 2: Kits used in biochemical and molecular biological assays……………………….. 33
Table 3: Phosphatase and protease inhibitors……………………………………………….. 33
Table 4: Pharmacological stimulating substances…………………………………………… 34
Table 5: Stimulating Cytokine………………………………………………………………….. 34
Table 6: Molecular weight markers for DNA and proteins………………………………….. 34
Table 7: Buffers used in biochemical and molecular biological assays…………………… 35
Table 8: Primary antibodies for western blot analysis………………………………………. 36
Table 9: HRP-coupled secondary antibodies for western blot analysis…………………… 36
Table 10: Vectors used for expression………………………………………………………... 37
Table 11: siRNA-sequences for knockdown…………………………………………………. 37
Table 12: Bacteria cells…………………………………………………………………………. 38
Table 13: Media and Reagents for bacterial cell culture……………………………………. 38
Table 14: Human cells………………………………………………………………………….. 38
Table 15: Media and reagents for human cell culture………………………………………. 39
Table 16: Media and references for cell culture……………………………………………... 41
Figure 9. Loss of cIAPs sensitizes cells to poly (I:C)-mediated cell death………………… 47
Figure 10. cIAPs regulate TLR3 induced cell death in XIAP independent manner………. 48
Figure 11. IAP antagonist sensitizes HaCaT cells to apoptotic and non-apoptotic cell 
death in caspase and RIP-1K dependent manner…………………………………………… 
50
Figure 12. TWEAK sensitizes HaCaT, but not MET1 and A5RT3 to poly (I:C)-induced 
cell death ………………………………………………………………………………………… 
 
51
Figure 13. TWEAK sensitizes HaCaT cells to apoptotic and non-apoptotic cell death in 
caspase and RIP-1K dependent manner and independent of autocrine activated TNF 
cell death…………………………………………………………………………………………. 
 
 
52
Figure 14. cFLIPL protects cells from poly (I:C)/IAP antagonist induced cell death, but 
cFLIPS induce spontaneous and poly (I:C) induced non-apoptotic cell death in the 
presence of IAP antagonist…………………………………………………………………….. 
 
 
54
Figure 15. TWEAK duplicates findings obtained with IAP antagonist for cFLIP 
overexpressing HaCaT cells…………………………………………………………………… 
 
55
Figure 16. cIAPs block formation of intracellular TLR3 signalling complex. cFLIPS 
enhances formation of the complex in the absence of IAPs……………………………….. 
 
57
Figure 17. RIP-1 is required for poly (I:C)/IAP antagonist-induced cell death. ………….. 58
Figure 18. RIP-1 is required for poly (I:C)/TWEAK-induced cell death……………………. 59
Figure 19. RIP-1 is required for intracellular TLR3 complex formation……………………. 60
Figure 20. Cloning of wild type and mutant variants of RIP-1 into the inducible 
expression vector system………………………………………………………………………. 
 
62
Figure 21. RIP-1 overexpression induces cell death in both caspase dependent and 
independent manner……………………………………………………………………………..
 
63
Figure 22. IAP antagonist sensitizes HaCaTs to CD95L induced cell death in both 
caspase dependent and independent manner……………………………………………….. 
 
65
Figure 23. CD95L duplicates findings obtained with poly (I:C)…………………………….. 67
Figure 24. Loss of cIAPs sensitizes primary keratinocytes to poly (I:C)-mediated 
apoptotic and non-apoptotic cell death is caspase and RIP-1K dependent manner…….. 
 
69
Diplom Genetikerin Feoktistova Maria Alexeevna 
The role of RIP-1 and cIAPs in apoptotic and non-apoptotic signalling via TLR3 and death receptors  
 11
Figure 25. Primary keratinocytes (donor E) are more sensitive to TLR3-induced cell 
death, than donors I and L and RIP-1 is essential for its execution………………………. 
 
70
 
Figure 26. RIP-1 protects primary keratinocytes (donors I and L) from poly (I:C) induced 
apoptosis in absence of IAPs…………………………………………………………………. 
 
73
Figure 27. IAPs are constantly blocking canonical and non-canonical NF-κB activation 
in HaCaTs…………………………………………………………………………………………
 
75
Figure 28. TRAIL induced MAPK and NF-κB activation in presence and absence of 
IAPs in HaCaT cells and primary keratinocytes……………………………………………… 
 
77
Figure 29. TRAIL induced MAPK and NF-κB activation in presence and absence of 
IAPs in MET1 and A5RT3 cell lines…………………………………………………………… 
 
78
Figure 30. The role of cIAPs during TLR3-mediated cell death in HaCaTs. ……………... 84
Figure 31. Cell death signalling in the absence of IAPs……………………………………. 87
Figure 32.The role of IAPs in TLR3-mediated cell death in primary keratinocytes………. 88
Figure 33. Canonical and non-canonical NF-κB activation in presence and absence of 
IAPs………………………………………………………………………………………………. 
 
91
  
Diplom Genetikerin Feoktistova Maria Alexeevna 
The role of RIP-1 and cIAPs in apoptotic and non-apoptotic signalling via TLR3 and death receptors  
 12
1. Introduction 
1.1.1 The role and function of the skin 
The skin is the largest organ of the human body, which possesses multiple functions. The 
epidermis suffers direct, frequent, and damaging encounters with the external world than any 
other tissue of the body. Therefore, the skin plays the most important role in protecting 
against pathogens, as well as allows for temperature regulation, sensation and vitamin D and 
B synthesis (Schauber and Gallo, 2008). Skin cells are constantly renewed by their 
respective progenitor cells and keratinocytes are the major cell type of the epidermis 
(Lippens et al., 2009). Homeostasis in the skin is achieved when the rate of cell proliferation 
of the tissue is balanced by cell death. An insensitivity to apoptotic stimuli or an uncontrolled 
cell proliferation in the epidermis can result in skin tumour formation (Fesik, 2005), whereby 
massive keratinocyte apoptosis can result in Toxic epidermal necrolysis (TEN, Lyell’s 
syndrome) (Trent et al., 2006) or Stevens Johnson syndrome (SJS). Both syndromes are 
rare acute dermatological diseases defined by epidermal cell death and mucosal erosions 
with extensive loss of contact between epidermis and dermis (LYELL, 1956). Further 
complicating the picture, keratinocytes also undergo a specialized form of programmed cell 
death, called cornification, which is different from classical apoptosis (Lippens et al., 2009). 
 
1.1.2. Skin cancer 
The three most common types of skin cancers are basal cell carcinoma (BCC), squamous 
cell carcinoma (SCC) and malignant melanoma.  
BCC and SCC are the most frequent tumours of mankind and their number is still increasing 
worldwide (Boukamp, 2005). Often patients suffer from a second and third lesion and the 
severity of these tumours is linked to their number. SCCs in transplant recipients also appear 
to be more aggressive. They tend to grow rapidly, show a higher rate of local recurrences 
and metastasize in 5–8% of these patients (Euvrard et al., 2003). This largely differs from 
BCCs which are more frequent in the general population—at a ratio of 4:1 as compared with 
SCCs—but the number is only increased by a factor of 10 in transplant recipients (Boukamp, 
2005).  
Most skin SCCs are treated surgically, if surgery is not possible, radiotherapy may be used 
as a treatment. Other treatments used include curettage and cautery or cryotherapy. 
Sometimes combinations of treatment are used for more aggressive skin SCC that has a 
high risk of recurring and spreading. Occasionally SCC of the skin returns, even after 
apparently successful treatment and may spread to other parts of the body (Lansbury et al., 
2010).  
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1.2. Cell death 
Deregulation of apoptosis or other cell death forms in keratinocytes can trigger skin 
carcinogenesis.  
 
1.2.1. Cornification in the skin 
Cornification, is a slow coordinated process that takes about 2 weeks, occurs simultaneously 
in the different suprabasal layers of the epidermis (Figure 1) and requires the consecutive 
expression of typical differentiation-associated proteins (Lippens et al., 2009). A keratin 
filament network is formed and at the transition from the granular to cornified layer, other 
structural proteins are crosslinked to this protein network. The keratinocytes become 
metabolically inactive, the organelles are degraded and the resulting fully differentiated 
squames are flattened dead cells. During assembly of the epidermal cornified cell envelope, 
the plasma membrane fuses with the membranes of the lamellar bodies. The latter contain 
lipids that eventually replace the original plasma membrane and play a role in water 
maintenance. Ultimately, corneocytes are sloughed into the environment. In contrast to 
apoptotic cells, corneocytes are not phagocytozed by other cells (Lippens et al., 2005).  
 
1.2.2. Caspase-independent cell death (CICD): Necrosis and 
Autophagy 
Caspase-independent cell death (CICD) is a type of cell death that ensues when a signal that 
normally induces apoptosis fails to activate caspases. Even so, CICD often shares common 
characteristics with apoptotic cell death (Tait and Green, 2008) such as upstream signalling 
pathways that are critical for both forms of death like mitochondrial outer membrane 
permeabilization. Interestingly, caspase-dependent events such as phosphatidylserine 
Cornified
Granular
Basal lamina
Basal
Spincus
Upper granular
Figure 1. The scheme of epidermis layers. Apoptosis is restricted to the basal layer, 
whereas cornification occurs in the supra-basal layers.  
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externalization and wide-scale chromatin condensation are absent during CICD. Cells 
undergoing CICD often display large-scale cytoplasmic vacuolization, autophagosome 
accumulation and peripheral nuclear condensation (Ekert et al., 2004). Furthermore, cells 
undergoing CICD may display very different characteristics depending on various factors like 
initial stimulus and cell type (Tait and Green, 2008).  
Necrosis is one type of CICD. Necrotic cell death can be induced by injury, infection, 
inflammation and toxins. Necrosis is caused by special enzymes that are released by 
lysosomes, which are capable of digesting cellular components or the entire cell. Since the 
disorderly death generally does not send early cell signals it is more complicated for the 
immune system to locate and recycle dead cells that have died through necrosis. 
Consequently, the release of intracellular content after cellular membrane damage is one 
potential cause of inflammation in necrosis (Festjens et al., 2006b). Several histological 
features convey the gradual, irreversible transformation into necrosis from sub-lethal 
damage. Sequential structural changes like an eosinophilic cytoplasm, fragmentation of the 
nucleus, lysis of the nucleus can be observed.  
Another type of CICD is autophagy. It is a process of isolation of cytoplasmic components 
into double membrane vesicles, followed by degradation upon fusion with lysosomal 
compartments (Reggiori, 2006). Depending upon the stimulus, autophagy can degrade 
cytoplasmic contents nonspecifically, or target the degradation of specific cellular 
components (Kundu and Thompson, 2008). In mammals, autophagy has been implicated in 
either the pathogenesis or response to a wide variety of diseases, including 
neurodegenerative disease, chronic bacterial and viral infections, atherosclerosis, and 
cancer, although the term “autophagic cell death” is controversial (Gozuacik and Kimchi, 
2007).  
 
1.2.3. Apoptosis 
Apoptosis is highly important for the maintenance of tissue homeostasis and anti-cancer 
protection. In contrast to cornification and CICD, apoptosis is a fast process and occurs in 
the basal layer of the skin (Figure 1). During the course of apoptosis, the function of 
organelles ceases, but the organelles themselves are not degraded. The plasma membrane 
remains intact preventing leakage of the cellular content into the environment. Membrane 
blebbing results in formation of separate apoptotic bodies that are finally recognized and 
phagocytozed by macrophages or neighbouring cells (Kerr et al., 1972). A cell undergoing 
apoptosis also shows a characteristic biochemical changes e.g. like activation of caspases 
that relate to a family of cysteine proteases, required for the execution of the apoptotic 
process. Apoptosis can occur in case of cell damage or virus infection (Sinkovics, 1991) 
response to stress or DNA damage (such as exposure to UV or ionizing radiation) (Hanawalt, 
Diplom Genetikerin Feoktistova Maria Alexeevna 
The role of RIP-1 and cIAPs in apoptotic and non-apoptotic signalling via TLR3 and death receptors  
 15
1996) and is of paramount importance for development and immune cell regulation. There 
are two distinct ways of apoptosis activation: intrinsic or mitochondrial, and extrinsic, which is 
initiated via death receptors.  
 
1.2.3.1. The intrinsic apoptotic signalling pathway 
The intrinsic (mitochondrial) pathway of apoptosis is initiated by various factors, like growth 
factor withdrawal or DNA damage. The molecules that integrate the signalling of these 
different cell death stimuli converge to the level of the release of mitochondrial factors like 
cytochrome c, which leads to formation of the apoptosome (protein complex, consisting of 
caspase-9, AIF and cytochrome c) and activation of procaspase-9. Apoptosome formation 
leads to activation of the executioner caspases (like caspase-3), that targets and inhibits 
other downstream pro-survival molecules, and finally leads to chromatin condensation, and 
DNA fragmentation, ultimately to cell death (Beere, 2005).  
The key players in the intrinsic pathway are the Bcl-2 family of proteins that are critical death 
regulators residing immediately upstream of mitochondria. The Bcl-2 family consists of both 
anti- and pro-apoptotic members. Detection of developmental death signals or intracellular 
damage is controlled by BH3-only members of the Bcl-2 family such as BID, BAD, NOXA, 
PUMA, BIM, and BMF, that act upstream in the pathway (Festjens et al., 2004; Sasi et al., 
2009). Pro-apoptotic members of Bcl-2 family proteins such as Bax and Bak act downstream 
in the signalling pathway, in mitochondrial disruption (Cory et al., 2003; Sasi et al., 2009). 
Other members of Bcl-2 family like Bcl-2 or Bcl-X, are called anti-apoptotic. One of the critical 
functions of Bcl-2/Bcl-XL proteins is to maintain the integrity of the mitochondrial outer 
membrane, endoplasmatic reticulum and nucleus. These Bcl family protein may function as 
oncogenes not only by blocking apoptosis but also by blocking autophagy (Pattingre and 
Levine, 2006). The balance between anti-apoptotic and pro-apoptotic Bcl-2 family proteins is 
crucial for decision of the cell fate. 
 
1.2.3.2. The extrinsic apoptotic signalling pathway  
The extrinsic pathway is characterized by the ligation of cell surface death receptors via 
specific death ligands to generate catalytically active initiator caspase-8 or/and caspase-10 
which depends on death receptor triggering. The extrinsic apoptotic pathway is also tightly 
linked to the mitochondrial pathway, which serves to amplify the apoptotic process. Bcl-2 
family member Bid is cleaved by caspase-8 in response to death receptor mediated 
signalling and its cleavage product associates with mitochondria, which leads to cytochrome 
c release and apoptosis (Makin et al., 2001). As described for the intrinsic pathway, the 
extrinsic pathway also lastly results in activation of executioner caspases (like caspase-3) 
and cleavage of their target substrates to induce apoptosis (Beere, 2005). 
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1.2.3.4. Initiation of apoptosis by death receptors 
The extrinsic apoptotic pathway is initiated by ligation of death receptors (TNF-R1/2, CD95, 
TRAIL-R1/2) and their respective ligands - TNF, CD95L, and TNF-related apoptosis-inducing  
ligand (TRAIL), which are members of the TNF superfamily (Wachter et al., 2004) (Figure 2 
A). The TRAIL system, consisting of the ligand, two apoptosis promoting receptors (TRAIL-
R1/2) and two decoy receptors, that are not able to induce apoptosis (TRAIL-R3 and 4), has 
attracted attention for its ability to preferentially kill tumour cells but not normal cells (Leverkus 
et al., 2000; Walczak et al., 1999). Binding of TRAIL to its receptors TRAIL receptor 1 
(TRAIL-R1) and TRAIL-R2 on the cell surface leads to recruitment of adaptor proteins (e.g. 
FADD for TRAIL DISC) as well as the initiator caspase-8 and -10 to the death-inducing 
signalling complex (DISC) (Wehrli et al., 2000) (Figure 2 B). This subsequently results in 
activation of caspase-8 in these membrane-bound receptor complexes and finally leads to 
effector caspase activation (e.g. caspase-3) and ultimately apoptosis (Figure 3). There are 
several hypotheses about the functions of TRAIL-R3 and TRAIL-R4 “decoy” receptors 
(Figure 2 A). The current hypothesis are that these receptors either compete with the normal 
receptors for the ligand, or form mixed complexes of both decoy and normal receptors, 
therefore blocking apoptotic signal. In addition TRAIL-R4 is known to initiate antiapoptotic 
signalling via NF-κB (Kimberley and Screaton, 2004). In summary either way the signalling 
initiated by these receptors inhibits apoptosis. 
Importantly, death receptors can also induce non-apoptotic signals, such as necrosis, 
inflammation, or proliferation via activation of MAPK or transcription factors (like AP-1 or NF-
Figure 2. Death receptors and their signalling complex. A. Domain structure of the 
members of TNF superfamily. Most of the represented receptors have intracellular death 
domain, except TRAILR3, which lacks and TRAILR4 which has truncated death domain. B. 
Proteins associated with the TRAIL DISC. DISC consists of adaptor molecules (FADD), 
pro-apoptotic molecules (pro-caspase-8), anti-apoptotic molecules (cFLIP) and molecules 
with various functions (RIP-1) 
CD95 TNF-R1 TRAIL-R1 TRAIL-R2
Death domain Cystein-rich domain N-Glycosylation
TRAIL-R4TRAIL-R3
A B
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κB) (Wachter et al., 2004) which may antagonise apoptotic pathways, induce inflammatory 
signals, or both (Figure 3) (Diessenbacher et al., 2008).  
 
1.2.4. Inhibition of Apoptosis 
Cell survival requires the active inhibition of apoptosis. This inhibition can be achieved by 
blocking the expression of pro-apoptotic factors, or by promoting the expression of 
antiapoptotic factors. These antiapoptotic factors can either directly block caspase activation 
like cFLIP or XIAP, or by blocking the release of pro-apoptotic factors and apoptosome 
formation, like antiapoptotic members of the Bcl-2 family such as Bcl-2 or Bcl-X.  
 
1.2.4.1. cFLIP – inhibitor of caspases  
The cellular FLICE-inhibitory protein (cFLIP) has 11 known isoforms, but only two are 
commonly detected in human cells: a long form (cFLIPL) and a short form (cFLIPS) (Figure 
4). cFLIPL, a 55 kDa protein, contains two DEDs and a caspase-like domain which however 
lacks some active site residues. Thus, FLIPL resembles caspase-8 in structure. In contrast, 
cFLIPS, a 26 kDa protein, consists of only two DEDs and has high homology to the protein 
domains of viral FLIP isoforms (Scaffidi et al., 1999; Thurau et al., 2009).  
Figure 3. Death receptor signalling. Schematic picture of death receptor signalling 
pathways. 
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Both isoforms of cFLIP form heterodimers with procaspase-8 and prevent its activation by 
blocking caspase cleavage in the DISC. Intriguingly, the mechanism of action differs for 
distinct cFLIP isoforms: while cFLIPS blocks caspase-8 cleavage by preventing the initial 
cleavage step of pro-caspase-8, cFLIPL allows this initial processing to a p43 fragment but 
inhibits the final cleavage step, thereby preventing the release of active caspase-8 into the 
cytosol and therefore blocks apoptosis (Geserick et al., 2008; Krueger et al., 2001). High 
expression of cFLIP is an important factor of melanoma resistance to pro-apoptotic stimuli 
(Geserick et al., 2008). 
 
1.2.4.2. Inhibitor of apoptosis proteins (IAPs) 
The IAP proteins are another family of caspase inhibitors. IAPs inhibit caspases by 
promoting the degradation of active caspases, or by sequestering the caspases away from 
their substrates (Tenev et al., 2005). There are eight members of IAP family found in 
humans: XIAP, cIAP1, cIAP2, MLIAP, ILP2, NAIP, BRUCE and Survivin (LaCasse et al., 
2008)  
IAP family members are characterized by the BIR (baculovirus inverted repeats) domain 
(Crook et al., 1993), which consist of approximately 70 amino acids containing the 
characteristic sequence CX2CX16HX6C. BIR has both hydrophobic and hydrophilic residues 
on its surface and therefore is theoretically capable of supporting protein-protein interactions. 
There are three subtypes of BIR domain, BIR1, BIR2, and BIR3, classified by their 
evolutionary relationship in phylogenesis (Wei et al., 2008). The protein domain structures of 
cIAP1 and 2 as well as XIAP, members of IAP family, are shown in Figure 5.  
Some IAPs have RING (really interesting new gene) finger domain (C3HC4) at the C-
terminus. It contains one zinc atom chelated to three cysteines and one histidine and another 
zinc atom bound to four cysteines. Some IAP family members also contain other structures, 
such as the caspase activation recruitment domain (CARD) found in cIAP1 and 2 (Wei et al., 
DED2DED1 221 aacFLIPS
p18 p10DED2DED1 496 aaProcaspase-8
Caspase
p20 p12DED2DED1 480 aacFLIPL
Caspase-like
Figure 4. Domain structure of caspase8 and cFLIP isoforms. DED – death effector 
domain.  
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2008). The IAP protein sequences are highly conserved, some of baculoviral IAPs can even 
suppress apoptosis in mammalian cells (Huang et al., 2000).  
Recently one group has described a novel ubiquitin-binding domain of IAPs (Figure 5) (Gyrd-
Hansen et al., 2008), that was later conformed by Blankenship et al. (Blankenship et al., 
2009) The UBA (ubiquitin-associated) domain of IAPs is located between the BIR domains 
and the CARD or the RING domain of cIAP1 and cIAP2, or XIAP, respectively. The cIAP1 
UBA domain binds mono-ubiquitin and Lys48- and Lys63-linked polyubiquitin chains with 
low-micromolar affinities. The results suggested that ubiquitin binding may be an important 
mechanism for rapid turnover of auto-ubiquitinated cIAP1 and cIAP2 (Blankenship et al., 
2009; Gyrd-Hansen et al., 2008).  
 
IAPs act as endogenous regulators of caspases (Fan et al., 2005). Multiple BIR domains, 
even in the same IAP can use different functions to inhibit different caspases, therefore 
regulating caspase functions. XIAP is generally considered as the most potent endogenous 
caspase inhibitor (Wei et al., 2008). Interestingly, the larger body of research seems to prove 
that only a few IAP proteins, like DIAP1 in Drosophila and XIAP in mammals, possess the 
ability to inhibit caspase (Wilkinson et al., 2004). Eckelman and Salvesen suggested that 
cIAP1 and cIAP2, which can also bind caspases 3, 7, and 9 but with lesser affinity as XIAP, 
lost or never acquired the caspase inhibitory ability. Thus, cIAP1 and cIAP2 could only 
execute their binding function to caspase, rather than caspase inhibition (Eckelman and 
Salvesen, 2006). 
The IAP family members are differentially overexpressed in many malignant tissues and not 
in their healthy counterparts, e.g. XIAP is highly expressed in melanomas (Nachmias et al., 
2004). IAP family members are crucial in keeping the tumor cells alive and causing 
resistance to high doses of chemotherapy. 
 
BIR 1 BIR 2 BIR 3 RINGCARD
U
B
A
604 aacIAP1
BIR 1 BIR 2 BIR 3 RINGCARD
U
B
A
BIR 1 BIR 2 BIR 3 RING
U
B
A
618 aa
497 aa
cIAP2
XIAP
Figure 5. Domain structure of IAP family proteins. All three proteins have three BIR 
domains, UBA and RING. XIAP lacks CARD. 
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1.2.4.2.1. IAP and the ubiquitination process 
IAPs can also inhibit the activity of caspases by modulation of the ubiquitination process. 
Ubiquitination is a post-translational protein modification procedure that plays important role 
in apoptosis and signal transduction. By operating the processes of ubiquitin activating 
enzyme (E1), ubiquitin conjugating enzyme (E2), and ubiquitin protein ligase (E3), target 
proteins are attached by ubiquitins. They are in turn recognized and degraded by 
proteasomes or represent modules able to modify binding or signalling properties (Broemer 
and Meier, 2009). The C-terminus RING domain of IAPs has been identified as the essential 
motif for the activity of ubiquitin ligase (E3) that is sufficient to cause ubiquitination and 
subsequent proteasome-mediated proteolysis (Vaux and Silke, 2005a). The RING domain in 
mammalian IAPs, including cIAP1, cIAP2, XIAP possesses E3 ligase activities (Vaux and 
Silke, 2005b), as well XIAP has been reported to ubiquitinate caspase-9 (Morizane et al., 
2005). 
Certain IAPs can negatively regulate their own activity by autoubiquitination. This process 
can functionally inactivate IAPs and allow the cell to undergo apoptosis. In cIAP2, either full-
length protein or its RING domain alone could execute E3 ligase activity in vitro to promote 
autoubiquitination, as well as monoubiquitination of caspase-3 and caspase-7. The C-
terminal RING domain of cIAP1 is required for binding to XIAP and promoting XIAP 
degradation in several cells (Silke et al., 2005). cIAP1 can heterodimerize with XIAP through 
a RING-RING interaction to regulate the endogenous XIAP abundance. These two 
mechanisms (ubiquitination and autoubiquitination) seem to work in counteraction to keep a 
fine balance, to regulate cell death and survival. Moreover IAPs appear to enhance the 
degradation of themselves or their targets in an unclear regulatory mechanism (Wei et al., 
2008). 
 
1.2.4.2.2. Regulation of IAP’s function 
IAPs, which are at the centre of virtually all apoptotic pathways, are also strictly regulated 
through feedback mechanisms. There are several kinds of endogenous pro-apoptotic 
proteins that function on almost every kind of IAP (Wei et al., 2008). Recently, neutralization 
between IAP and IAP antagonists has become a broadly discussed issue for the treatment of 
cancers. 
These endogenous IAP binding proteins were first identified in Drosophila. They were 
defined as critical inhibitors of IAP activity. Later, mammalian counterparts of the IAP 
antagonists were identified, named second mitochondrial activator of caspases/direct IAP 
binding protein with low pI (Smac/DIABLO) (Du et al., 2000) and high-temperature-regulated 
A2/Omi (HtrA2/Omi) (Suzuki et al., 2001). These proteins are mitochondrial-derived proteins. 
X-linked IAP-associated factor 1 (XAF1) (Liston et al., 2001) is a nuclear protein that 
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operates as inactivator of XIAP. The IAP binding proteins in Drosophila and mammal all have 
a highly conserved homologous sequence, named the IAP-binding motif domain, at the N-
terminus that can bind IAP BIR domains and compete for interaction with IAPs, thus 
displacing the bound caspases that are then free to amplify the caspase cascade 
continuously.  
 
1.2.4.2.3 TWEAK-FN14 signalling regulates cIAPs level 
The other way to alter the cellular levels of cIAP1 and 2 is the signalling via TNF-like weak 
inducer of apoptosis (TWEAK)-FN14 interaction. TWEAK is a cytokine of the TNF 
superfamily that activates the FN14 receptor (Chicheportiche et al., 1997). TWEAK is known 
to regulate cell proliferation, cell death, cell differentiation, angiogenesis and inflammation 
(Ortiz et al., 2009). The expression of TWEAK and FN14 is increased during vascular and 
renal injury (Sanz et al., 2008). Inflammatory cytokines increase FN14 receptor expression in 
tubular and vascular smooth muscle cells (Ortiz et al., 2009).  
Unlike IAP antagonists that cause rapid proteasomal degradation of cIAP1 (Bertrand et al., 
2008; Gaither et al., 2007; Petersen et al., 2007; Varfolomeev et al., 2007; Vince et al., 
2007), signalling by FN14 promotes the lysosomal degradation of cIAP1–TRAF2 in a cIAP1-
dependent manner (Vince et al., 2008). TWEAK-induced loss of the cIAP1–TRAF2 complex 
sensitizes immortalized and minimally passaged tumour cells to TNF-induced death, 
whereas primary cells remain resistant. Lysosomal degradation of cIAP1–TRAF2 by 
TWEAK/FN14 therefore critically alters the balance of life/death signals arising from TNF-R1 
in immortalized cells (Vince et al., 2008).  
 
1.2.4.2.4. Regulation of IAPs with synthetic antagonists 
XIAP was shown to be highly expressed in many tumours, as well as induce the resistance 
of tumours to therapeutic agents (Nachmias et al., 2004). In order to restore the sensitivity of 
these tumours to pro-apoptotic stimuli synthetic IAP antagonists were developed. IAP 
antagonists are synthetic compounds that were modelled on the N-terminal IAP-binding motif 
of the mitochondrial protein Smac/DIABLO (Wright and Duckett, 2005). The XIAP-interfering 
function of Smac-mimetic compounds (IAP antagonists) is crucial for therapeutic efficiency of 
TNF-related apoptosis-inducing ligand (TRAIL) in xenograft tumour models (Li et al., 2004; 
Vogler et al., 2008). Recently, it has become apparent that compounds principally designed 
to target XIAP also target cIAPs by rapid autoubiquitination and proteasomal degradation of 
cIAP1 and -2 (Bertrand et al., 2008; Gaither et al., 2007; Petersen et al., 2007; Varfolomeev 
et al., 2007; Vince et al., 2007). 
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1.3. Death receptor induced non-apoptotic signalling pathways 
The death receptor-mediated pathways that initiate the described variety of responses do not 
act independently in a parallel manner but are interconnected to a TRAIL-R as well as 
TNFR1-signalling network through various mechanisms. For example NF-κB activation is 
blocked by initiator as well as effector caspases that become activated during death receptor 
induced apoptosis (Wajant et al., 2003). In recent years, there is growing evidence that the 
balance between NF-κB activation and apoptosis induction in the context of TNFR1 
signalling is critically regulated via MAPKs, specifically by the JNK pathway (Wicovsky et al., 
2007) . 
 
1.3.1. NF-κB activation 
The NF-κB (Nuclear Factor kappa B) is a nuclear transcription factor found in all cell types 
and is involved in cellular responses to stimuli such as stress, cytokines, free radicals, 
ultraviolet irradiation, death receptor stimulation, and bacterial or viral antigens. Consistent 
with this role, incorrect regulation of NF-κB has been linked to cancer, inflammatory and 
autoimmune diseases, viral infection and improper immune development (Liang et al., 2006). 
The NF-κB family contains five members: p50, p52, RelA (also named p65), RelB, c-Rel. 
While all members of the NF-κB family share a Rel homology domain in their N-terminus, a 
subfamily including RelA, RelB and c-Rel also contain a trans-activation domain in their C-
terminal protein domain (Karin and Ben-Neriah, 2000). NF-κB dimers bind to κB sites within 
the promoters/enhancers of target genes and regulate transcription through the recruitment 
of co-activators and co-repressors. 
In its inactive state, NF-κB dimers are associated with one of three typical IκB proteins, IκBα, 
IκBβ, or IκBε, or the precursor proteins p100 and p105, which maintain NF-κB dimers in the 
cytoplasm and are crucial for signal responsiveness. The prototypical and most extensively 
studied member of the family is IκBα. During activation of canonical NF-κB pathways, IκBα is 
rapidly degraded leading to the release of multiple NF-κB dimers, although the p65/p50 
heterodimer is likely the primary target of IκBα (Hayden and Ghosh, 2008).  
Degradation of IκB is a rapidly induced signalling event that is initiated upon specific 
phosphorylation of these molecules by activated IKK. The IKK complex contains two highly 
homologous kinase subunits, IKKα/IKK1 and IKKβ/IKK2 and a regulatory subunit NEMO 
(NF-κB essential modulator)/IKKγ (Hacker and Karin, 2006). 
The non-canonical or alternative NF-κB pathway, however, proceeds through proteasomal 
processing of p100 to p52, liberating p52 containing NF-κB dimers that drive a transcriptional 
response. The non-canonical NF-κB pathway is also characterized by its independence from 
IKKβ and NEMO. Instead the alternative pathway relies on the activation of IKKα by the NF-
κB-inducing kinase (NIK) (Hacker and Karin, 2006; Scheidereit, 2006). In the resting state, 
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NIK is ubiquitinated and degraded, but upon stimulation it is accumulated, which leads to 
activation of the non-canonical pathway (Liao et al., 2004). 
In part because IκBα degradation and p100 processing regulate different populations of NF-
κB dimers, canonical and non-canonical NF-κB pathways regulate distinct sets of target 
genes. 
NF-κB controls the expression of gene products linked with invasion, angiogenesis, and 
metastasis of cancer (Prasad et al., 2010). As well, constitutive NF-κB activation was 
detected in SCC (Tamatani et al., 2001) and melanoma (Uffort et al., 2009) cells.  
 
1.3.2. NF-κB activation via Death receptors 
NF-κB can be sufficiently activated by activation of death receptors (e.g. TNFR1/2). The TNF 
induced NF-κB activity may involve the five mammalian NF-κB/Rel proteins. The adaptor 
molecule TRADD interacts with TNFR1 and recruits additional adapter proteins like Receptor 
interacting protein 1 (RIP-1), TRAF2 and cIAP1. cIAP1 ubiquitinates several components of 
the formed complex, which causes ubiquitin-dependent recruitment of the linear ubiquitin 
chain assembly complex (LUBAC), ubiquitin receptor proteins TAB2 and TAB3, associated 
with kinase TAK1, which is activated by TAB2 and 3, and finally NEMO/IKKα/IKKβ complex, 
via their respective ubiquitin-binding domains (Haas et al., 2009). Once recruited LUBAC 
further ubiquitinates NEMO via linear ubiquitin chains, and most likely also other components 
of receptor complex. Several components of this complex harbour ubiquitin binding domains 
(UBDs) that bind to linear ubiquitin chains, thereby stabilizing complex and supporting further 
recruitment, retention, ubiquitination, and activation of NEMO/IKKα/IKKβ complex (Bianchi 
and Meier, 2009). The IKK complex induces phosphorylation and further degradation of IκB, 
which is associated with NF-κB. The free NF-κB translocates to the nucleus and induces 
transcriptional activation of certain genes (Hacker and Karin, 2006).  
In most cells, TRAIL-induced NF-κB activation is most prominent when cell death pathways 
are caspase inhibitors (Wachter et al., 2004). In addition to its potent pro-inflammatory 
function, NF-κB has been demonstrated to regulate the transcription of numerous anti 
apoptotic target genes, for example cIAPs. Respectively, inhibition of NF-κB was shown to 
sensitize keratinocytes to death ligands such as TNF (Diessenbacher et al., 2008). In 
contrast, sensitization to TRAIL-induced apoptosis by NF-κB inhibition appears to be more 
cell type-restricted and does not play an important role in cell death of keratinocytes 
(Wachter et al., 2004). 
 
1.3.3. MAPK 
Mitogen-activated protein kinases (MAPKs) are one group of signal-transducing enzymes 
that have important functions in mediating responses to various extracellular stimuli. 
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Activation of MAPKs is one of the many cellular responses to the death ligands, such as 
TRAIL and TNF. Three subgroups of MAPKs have been identified: extracellular signal-
regulated kinases (ERKs), c-Jun amino-terminal kinases (JNKs; also known as stress-
activated protein kinases (SAPKs)) and p38 MAPKs (Pearson et al., 2001).  
The JNKs are classic examples of stress-activated protein kinases. A number of stress 
stimuli, including UV radiation, heat shock, inflammatory cytokines, and chemotherapeutic 
drugs, induce potent and preferential activation of JNKs. Numerous reports show that JNK 
may regulate apoptosis (Lin et al., 2000). TNF was identified to activate all three types of 
MAPK, but this activation is highly cell-type-specific (Karin, 1998; Liu and Han, 2001; 
Whitmarsh and Davis, 1999; Wicovsky et al., 2007). However, in human epidermis MAPKs 
play important roles in cellular recovery. For example, inhibition of p38 completely abolishes 
the capacity of cells to recover from attack by α-toxin (Husmann et al., 2006), and the 
phosphorylated form of JNK, JunB is associated with protection from psoriasis-like skin 
disease and arthritis (Zenz et al., 2005). Furthermore TRAIL resistance in malignant cells 
was shown to be differentially mediated by p38, whereas in normal cells, resistance was 
mediated by NF-κB (Steele et al., 2006). Taken together, these studies point to a critical role 
of MAPK, in particular p38 and JNK as a potential resistance factor for apoptosis and a 
possible deviator of non-apoptotic signalling and prompted us to examine these signalling 
pathways in more detail.  
 
1.4. Toll-like receptors 
The first line of defence against pathogens is the initiation of innate immune responses 
induced by toll-like receptors (TLRs)-mediated recognition of pathogen-associated molecular 
pattern (PAMPs). These receptors are different from the above described DRs, but the 
signalling pathways share some similarities.  
There are at least 10 TLRs identified so far in humans (Figure 6), and they recognize and 
specifically bind to a variety of pathogenic agonists such as lipopeptide (via TLR2), double-
stranded RNA (via TLR3), lipopolysaccharide (LPS) (via TLR4), flagellin (via TLR5), and 
deoxycytidylate-phosphate-deoxyguanylate DNA (via TLR9) by molecular pattern recognition 
(Chao, 2009). TLRs usually form homo- or heterodimers (TLR1 and TLR2 or TLR2 and 
TLR6) and all, except TLR3, signal through the key adaptor myeloid differentiation primary-
response gene 88 (MyD88). Some of TLRs, such as TLR2 and TLR4, require MyD88 
adaptor-like protein (Mal) for recruiting MyD88. TLR3 signals through the adaptor TIR-
domain-containing adaptor protein inducing interferon-β (IFN-β)-mediated transcription-factor 
(TRIF). In addition to Mal/MyD88-dependent pathway, TLR4 can also signal through TRIF. 
These signalling pathways lead to activation of transcription factors such as NF-κB and IFN 
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regulatory factor (IRFs), which result in production of various pro-inflammatory cytokines 
such as tumour necrosis factor (TNF), ILs, and IFNs (Figure 6).  
Previous studies have demonstrated that human keratinocytes express TLRs 1–6 and 9 
(Baker et al., 2003; Kawai et al., 2002; Kollisch et al., 2005; Mempel et al., 2003; Miller et al., 
2005; Pivarcsi et al., 2003; Song et al., 2002). In addition, some of these studies have 
demonstrated that TLRs on keratinocytes are functional and respond to their respective 
ligands to produce cytokines and chemokines, and to activate NF-κB. For example TLR2 and 
TLR4 are expressed by human keratinocytes and can be activated by their ligands, bacterial 
lipopeptides and lipopolysaccharide, respectively (Kawai et al., 2002; Kollisch et al., 2005; 
Mempel et al., 2003; Pivarcsi et al., 2003; Song et al., 2002). Furthermore, additional studies 
have demonstrated that TLR3 and TLR5 are also expressed by human keratinocytes and 
can be activated by their ligands, double-stranded RNA (poly-I:C) and bacterial flagellin, 
respectively (Baker et al., 2003; Dai et al., 2006; Kollisch et al., 2005; Miller et al., 2005). 
 
Figure 6. Toll-like receptor signalling. All TLRs are transmembrane proteins with a 
large extra-cellular domain containing leucine-rich repeats and a unique cytoplasmic 
Toll/IL-1 receptor (TIR) domain. TLR signalling pathways lead to activation of transcription 
factors such as NF-κB and IRFs, which result in production of various proinflammatory 
cytokines such as TNF, ILs, and IFNs. 
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Taken together, these studies highlight the importance of keratinocytes not only as a barrier 
to infectious microorganisms but also for detection of components of these organisms and 
activation of initiate immune responses via activation of TLRs (Miller and Modlin, 2007). 
 
1.4.1. TLR-3 mediated signalling 
TLR3 has been found in endosomal compartments or at the cell surface. The localization of 
TLR3 is cell type dependent, which may reflect the participation of cell type-specific 
pathways in antiviral IFN induction via TLR3. Human fibroblasts (e.g., the MRC-5 cell line) 
express TLR3 on the cell surface. However, in most cell types, including dendritic cells, 
macrophages, TLR3-transfected HEK293 cells and keratinocytes (Kollisch et al., 2005), 
TLR3 is detected predominantly in intracellular compartments (Vercammen et al., 2008) 
TLR3 recognizes virus-derived double stranded RNA as well as its synthetic homologue poly 
(I:C) (Alexopoulou et al., 2001). TLR3 signals through the adaptor TIR-domain-containing 
adaptor protein inducing interferon-β (IFN- β)-mediated transcription-factor (TRIF) (Chao, 
2009). TRIF knockout mice show defective responses to poly(I:C), indicating that TRIF is 
essential for TLR3-mediated signalling pathways (Yamamoto et al., 2003). The TIR domain 
of TLR3 binds the TIR domain of TRIF, which indirectly activates several transcription 
factors, including NF-κB, IRF3, and activating protein 1 (AP-1) (Vercammen et al., 2008).  
Thus TLR3-mediated signalling is an important part of the inflammatory response upon 
injuries (Lai et al., 2009) and virus infection (Kalali et al., 2008). 
 
1.4.2. TLR3-induced NF-κB and MAPK activation 
TLR3-induced signals regulate inflammatory responses initiated by NF-κB activation 
(Santoro et al., 2003). The activation of NF-κB via TLR3 is achieved by two different 
signalling pathways bifurcating from TRIF. Different regions of TRIF can bind the ubiquitin 
ligase TRAF6 and the kinase RIP-1. In murine embryonic fibroblasts deficient in RIP-1, 
poly(I:C)-induced NF-κB is completely blocked, indicating that RIP-1 is an essential mediator 
of the TRIF pathway leading to NF-κB activation (Meylan et al., 2004). The interaction of 
TRIF and RIP-1 is mediated through the RIP homotypic interaction motif (RHIM) present in 
both proteins is mediated by the C-terminal part of TRIF and the intermediary domain of RIP-
1 and RIP-3.  
TRAF6 is recruited to the N-terminal domain of TRIF, but the role of TRAF6 is somewhat 
controversial and probably cell type specific (Gohda et al., 2004; Sato et al., 2003). At least 
in mouse embryonic fibroblasts, TRAF6 is recruited to TRIF along with RIP-1, followed by 
polyubiquitination of RIP-1 (Cusson-Hermance et al., 2005). 
The activity of TRIF-associated TRAF6 might be responsible for the ubiquitination of RIP-1 in 
the TLR3 pathway. RIP-1 ubiquitination is recognized by the ubiquitin receptor proteins TAB2 
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and TAB3, leading to the activation of the kinase TAK1, which is part of the same complex. 
TAK1 phosphorylates and activates IKKα and IKKβ, which are part of a bigger IKK complex 
with the IKK adaptor protein NEMO. IKKβ is known to be the crucial IKK in TLR signalling 
and phosphorylates IκBα, which binds and keeps NF-κB (here depicted as a 
p65/p50 dimer) in an inactive state in the cytoplasm. IκBα phosphorylation leads to its 
recognition and degradation by the proteasome, thus allowing NF-κB to translocate to the 
nucleus, where it binds and activates specific gene promoters (e.g. cIAP1 and 2) (Figure 7) 
(Vercammen et al., 2008).  
Poly(I:C)-induced NF-κB activation is decreased in TAK1-deficient mouse embryonic 
fibroblasts, showing that TAK1 is specifically needed for TLR3-induced NF-κB activation 
(Shim et al., 2005). TAK1 also activates the mitogen-activated protein kinases c-jun N-
terminal kinase, p38, and extracellular signal-regulated kinase, leading to the 
phosphorylation and activation of members of the AP-1 family of transcription factors.  
 
1.4.3. TLR3-induced apoptosis 
TLRs have also been implicated in tumour cell proliferation and as well confer apoptosis 
resistance (for review see (Huang et al., 2008)). Contrasting the proinflammatory role of 
TLR3, it has also recently been suggested that this receptor may as well induce apoptosis in 
Figure 7. TLR3 signalling pathways. Ligation of the dsRNA to TLR3 can lead to NF-κB 
activation and apoptosis. 
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a TRIF-dependent manner (Weber et al., 2010). The recruitment and binding of the kinase 
RIP-1 to TRIF by the RIP homotypic interaction motif (RHIM) domain is required for the 
transduction of apoptotic signals (Kaiser and Offermann, 2005; Weber et al., 2010). The 
binding of RIP-1 to TRIF not only activates NF-κB but also recruits the DD-containing adaptor 
protein FADD via a homotypic DD-DD interaction. FADD in turn interacts with procaspase-8 
through the death effector domain (DED) present in both proteins (Figure 7). This signalling 
platform further initiates cell death induction (Vercammen et al., 2008).  
Since TLR3 agonists induce apoptosis and the TLR3 is widely expressed on cancer cells 
(Rydberg et al., 2009), TLR agonists have been postulated as adjuvants for cancer vaccines 
(Salaun et al., 2007; Salem et al., 2005).  
 
1.5. RIP-1 as the central signalling molecule  
Protein kinases of the receptor interacting protein (RIP) family are important for death 
receptor signalling and regulation of cell death. RIP-1, the founding member of the RIP 
protein family was proposed to mediate the cell death as well as pro-survival signalling 
pathways, initiated by DRs as well as TLR3 (Kaiser and Offermann, 2005; Weber et al., 
2010).  
 
1.5.1 The role of RIP-1 for cell death signal transduction  
RIP-1 is constitutively expressed in 
many tissues such as the skin 
(Meylan and Tschopp, 2005). 
RIP-1 consists of a C-terminal death 
domain (DD), intermediate domain 
(ID), which has a RIP homotypic 
interacting motive (RHIM) and a 
kinase domain (Figure 8). The DD of 
RIP-1 can be recruited to several 
death receptors (e.g. CD95, TRAIL, 
TNF) (Stanger et al., 1995).  
TRADD and RIP-1 compete with 
each other for binding to TNFR1 
through DD interactions and mediate 
separate events for programmed cell 
death. Recruitment of 
TRADD/FADD/caspase-8/10 triggers 
the execution of apoptosis, whereas 
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Figure 8. Domain organization of RIP-1. 
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the receptor association of RIP-1 initiates a serine/threonine kinase-dependent necrosis-like 
death program that involves ROS accumulation (Zheng et al., 2006). 
Dispensable for CD95L-induced apoptosis, RIP-1 is important for CD95L-, TRAIL- and TNF-
induced necrosis (Festjens et al., 2006b). In line, reconstitution of a RIP-1-deficient Jurkat T-
cell line with a kinase inactive form of RIP-1 fails to restore CD95L-induced necrosis. RIP-1, 
and specifically its DD, was reported to be critical for CD95-mediated necrosis independent 
of NF-κB–inducing activity or RIP-1 kinase (RIP-1K) activity (Degterev et al., 2005; Holler et 
al., 2000). The recent development of specific RIP-1K inhibitors has facilitated experiments 
examining the functional role of RIP-1K in necrosis (Degterev et al., 2008), but the potential 
targets of the kinase activity of RIP-1 are unknown (Degterev et al., 2008). 
RIP-1 can interact with TRIF via its RHIM, and interact with FADD by the DD. This interaction 
is required for the transduction of apoptotic signals from TLR3 (Figure 7) (Kaiser and 
Offermann, 2005; Weber et al., 2010).  
In summary, RIP-1 seem to play a role as an adaptor or scaffolding molecule during 
apoptosis and necrosis signalling in both DR and TLR3-induced signalling.  
 
1.5.2. The role of RIP-1 for NF-κB and MAPK activation 
The physiological function of RIP-1 in the TNF pathway was addressed with the generation 
of RIP-1-deficient mice and analysis of a RIP-1-deficient Jurkat T-cell line. Previous studies 
showed that cells devoid of RIP-1 do not mount strong NF-κB responses upon TNF 
stimulation, but still activate c-Jun N-terminal kinase (JNK) (Devin et al., 2003). Surprisingly, 
the recent studies, done in MEF cells have shown that RIP-1 in not essential for NF-κB 
activation (Wong et al., 2010).  
CD95-induced apoptosis is normal in cells lacking RIP-1; these cells are not sensitized to 
TNF-induced apoptosis (Wong et al., 2010). In mice, loss of RIP-1 results in massive cell 
death of lymphoid and adipose tissues, reflecting one of the major roles of RIP-1 as a 
signalling intermediate of pro-survival pathways. RIP-1 does not require its kinase activity for 
the activation of NF-κB because reintroduction of a kinase-dead form of RIP-1 into the RIP-1-
deficient T-cell line completely restores NF-κB activation. Thus, RIP-1 might function as a 
scaffolding protein instead (Devin et al., 2000). The intermediate region of RIP-1, which is 
important for downstream NF-κB signalling, not only binds to TRAF2 but also recruits IKKs to 
the activated TNF-R1 complex via interaction with NEMO (Hur et al., 2003).  
In contrast, during TLR3 signalling RIP-1 is bound to TRIF and rapidly ubiquitinated, probably 
by TRAF6 resulting in canonical NF-κB activation (Vercammen et al., 2008). 
Therefore, the intermediate domain of RIP-1 is crucial for NF-κB signal transduction in both 
DR and TLR signalling by interaction with a variety of signalling proteins. Although the 
importance of each interaction remains to be determined, certain observations have been 
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made, for example, ubiquitination of RIP-1 seems to modulate the duration of NF-κB-
signalling activity and TNF-R1 stimulation results in massive RIP-1 ubiquitination, which 
enhances its proteasomal degradation.  
 
1.5.3. Regulation of RIP-1 by ubiquitination  
Protein ubiquitination has emerged as an important secondary protein modification that 
regulates various biological processes (Fang and Weissman, 2004). Following stimulation 
with TNF, RIP-1 binds to TNF-R1 and NEMO. TNFR1-associated RIP-1 undergoes 
polyubiquitination by A20 (an ubiquitin ligase that inhibits NF-κB signalling), leading to RIP-1 
degradation (Wertz et al., 2004). A20 was shown to exert two opposing activities: sequential 
de-ubiquitination as well as ubiquitination of RIP-1, thereby targeting RIP-1 to proteasomal 
degradation (Heyninck and Beyaert, 2005). The stabilization of RIP-1 required interaction 
with NEMO through the polyubiquitin-binding region of the latter protein (Wu et al., 2006). 
Binding to NEMO may prevent conversion of Lys 63-linked RIP-1 to Lys 48-linked 
polyubiquitination, potentially by impairing interaction of RIP-1 with A20 (Wertz et al., 2004). 
More recently Bertrand et al. showed that that cIAP1 and cIAP2 directly ubiquitinate RIP-1 
and induce constitutive RIP-1 ubiquitination in cancer cells. Constitutively ubiquitinated RIP-1 
then associates with the pro-survival kinase TAK1 (Bertrand et al., 2008). 
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1.6. Aims 
The skin is the first line defence against infections with pathogens. Numerous processes 
such as inflammation, activation and regulation of the innate and adaptive immune response 
are initiated by the skin cells, in particular keratinocytes. In contrast to this processes, 
infections of the skin with pathogens can result in initiation of autoimmune diseases and 
carcinogenesis of the skin (Wolska et al., 2009). However the mechanisms of bacterial and 
viral promotion of skin cancer progression are poorly understood to date. Virus-derived 
molecules such as vFLIP proteins are significant regulators of apoptotic processes (Thurau 
et al., 2009). The resistance to apoptotic stimuli is one way to evade host specific elimination 
by suppression of caspase activitiy of the tumour cells. Therefore overcoming apoptosis 
resistance by antagonism or downregulation of inhibitors of caspase activity has been 
advocated as a major improvement of tumour therapy (Fesik, 2005).  
Agonists of TLR3 such as poly (I:C) can induce apoptosis in melanoma cells and were 
suggested for anti-cancer treatment (Salaun et al., 2007), whereas many other malignant cell 
lines are resistant to poly (I:C) induced cell death. These controversial findings raise the 
hypothesis that intracellular molecules regulate TLR3-induced cell death as well as other 
non-apoptotic signalling pathways. The role of cIAPs in regulation of TLR3 and DR-induced 
cell death and non-apoptotic signalling pathways was largely unclear at the beginning of this 
thesis.  
Therefore the aim of this work was to contribute to the understanding of the mechanisms 
involved in TLR3- and DR-mediated cell death and non-apoptotic signalling pathways. The 
identification of the impact of cIAPs for the regulation of cell death processes in TLR3 and 
DR signalling is the object of this thesis and will be responded by following questions. 
 
1. What is the relevance of cIAPs in TLR-3-mediated cell death in primary and 
transformed keratinocytes (HaCaT) and SCC cell lines? 
In order to achieve this aim, the responsiveness of primary keratinocytes as well as 
HaCaT and SCC cells to TLR3 agonist (poly (I:C)) will be analyzed. The inhibition of 
cIAPs and XIAP function will be performed with either specific shRNA-mediated 
knockdown or with a chemical IAP antagonist. The possible cell death induction will be 
characterized by biochemical and morphological analysis.  
 
2. Which molecules are regulating the apoptotic and survival outcome of TLR3 
signalling complexes?  
To target this question the formation and composition of intracellular protein complexes in 
HaCaT keratinocytes upon TLR3 stimulation in the presence and absence of cIAPs will 
be analyzed. The expression, recruitment, activation and modification of TLR3 complex-
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related molecules such as RIP-1, TRIF, cFLIP and caspase-8 will be checked by co-
immunoprecipitation studies with caspase-8 specific antibody. In addition, to verify the 
role of other cell death regulating molecules such as cFLIP and RIP-1 for TLR3 
signalling, the protein expression levels of cFLIP isoforms and RIP-1 will be modified by 
generation of knockdown and overexpressing HaCaT cells.  
 
3. What is the impact of cIAPs on regulation of CD95L-induced cell death in human 
keratinocytes?  
Since CD95-induced cell death is tightly regulated by molecules that are also involved in 
TLR3 signalling, the role of cIAPs in controlling CD95-induced signalling pathways will be 
analyzed under the same condition as indicated in 1. This study could help in comparing 
if similar signalling platforms that regulate cell death signalling pathways exist.  
 
4. What is the role of IAPs for the control of non-apoptotic signals such as NF-κB and 
MAPK activation in TRAIL stimulated keratinocytes and SCC cell lines? 
To clarify this question the canonical and non-canonical NF-κB activation after TRAIL 
stimulation will be studied in the presence and absence of IAPs in primary human 
keratinocytes and SCC cell lines. MAPK activation will be studied by checking the 
phosphorylation status of respective MAPK in primary keratinocytes and SCC cell lines. 
 
Taken together, this study will further the understanding of molecular mechanisms of 
resistance of skin tumours and possibly the use of IAP antagonist together with TLR3 
agonists as a potential therapeutic strategy to overcome therapeutic resistance of skin 
tumour cells.  
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2. Material and Methods 
2.1. Materials 
The kits and chemicals that were used in this work were purchased from the described 
companies. The quality of the reagents was of analytical grade. If special reagents were 
used for experiments, it is described at the beginning of each section. 
 
2.1.1. Enzymes and molecular biology reagents 
Item Company 
Alkaline Phosphatase from calf intestine (CIAP) Promega 
Deoxynucleoside Triphosphate Set (dNTPs) Promega, Fermentas 
Endonucleases (Restriction enzymes) Promega, Fermentas 
NuPAGE® Novex 4-12% Bis-Tris Gels Invitrogen 
Oligonucleotides (Primer) MWG-operon 
Polyvinylidene fluoride (PVDF) membrane GE Healthcare 
Protein G beads Roche 
T4 DNA ligase Promega 
Taq DNA polymerase Promega, Fermentas 
NheI  Promega 
XbaI Promega 
Bam HI Promega 
The buffers for the enzymes were purchased from the same companies. 
 
Table 1: Molecular biology reagents 
 
2.1.2. Kits 
Item Company 
ECL Detection Reagents GE Healthcare 
ECL Plus™ Western Blotting Detection Reagents GE Healthcare 
EndoFree Plasmid Maxi Kit Qiagen 
Wizard Plus SV miniprep DNA Purification System Promega 
Wizard® SV Gel and PCR Clean-Up System Promega 
DC Protein assay Bio-Rad 
Table 2: Kits used in biochemical and molecular biological assays 
 
2.1.3. Phoshpatase and protease inhibitors 
Inhibitor Company (Catalog number) 
AEBSF Hydrochlorid  AppliChem (A1421) 
Aprotinin Roth (A162.3) 
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Benzamidine  Fluka (12072) 
Complete (Protease Inhibitor Cocktail Tablets) Roche (11836145001) 
β-Glycerophosphate disodium salt hydrate Sigma-Aldrich (G6376) 
Leupeptin hemisulfate salt Sigma-Aldrich (L2884) 
Sodium orthovanadate Sigma-Aldrich (S6508) 
Sodium pyrophosphate tetrabasic decahydrate Sigma-Aldrich (S6422) 
Table 3: Phosphatase and protease inhibitors 
 
2.1.4. Pharmacological stimulating substances 
Substance Company (Catalog number) 
Compound A (CompA) provided by TetraLogic Corp. 
(Vince et al., 2007)  
LBW-242 Novartis (TRD 1223-139) 
Necrostatin-1 Sigma-Aldrich (N9037) 
4-Hydroxytamoxifen (4-HT) Sigma-Aldrich (H7904) 
z-Val-Ala-DL-Asp(OMe)-fluoromethylketone (zVAD-fmk) Bachem (N-1560) 
Q-VD-OPH (QVD) Biovision (#1170) 
Poly (I:C) Sigma (p1530) 
Table 4: Pharmacological stimulating substances 
 
2.1.5. Stimulating Cytokine 
Cytokine Source 
TNF-R2-Fc M. Feoktistova (Geserick et al., 2009)  
His-Flag-TRAIL (HF-TRAIL) P. Diessenbacher (Diessenbacher et al., 2008)  
CD95L-Fc M. Feoktistova (Geserick et al., 2009)  
TWEAK-Fc The construct for producing of recombinant cytokines 
was provided by J. Silke, the TWEAK-Fc supernatant 
was produced and purified as described later. 
Table 5: Stimulating Cytokine 
 
2.1.6. Molecular weight markers  
DNA molecular weight markers Company 
GeneRuler™ 1 kb DNA Ladder, ready-to-use Fermentas 
GeneRuler™ 100 bp Plus DNA Ladder, ready-to-use Fermentas 
Protein molecular weight markers Company 
SeeBlue® Pre-Stained Standard Invitrogen 
Table 6: Molecular weight markers for DNA and proteins 
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2.1.7. Buffers 
Buffer Composition 
1 x PBS 2.7mM KCl, 1.5mM KH2PO4, 137mM NaCl, 8mM 
Na2HPO4, pH 7.4 
1 x T-PBS 1xPBS, 0.1% Tween 20 
5 x Laemmli sample buffer 60mM Tris-HCl (pH 6.8), 2% SDS, 10%l Glycerol, 5% 
β-Mercaptoethanol, 0.01% Bromophenol blue 
AB-buffer 3% non-fat dry milk, 1.5% BSA in 1 x T-PBS 
Blocking buffer 5% non-fat dry milk, 3% BSA in 1 x T-PBS 
Crystal violet staining solution 0.5% crystal violet, 20% methanol 
DNA sample buffer 
 
30% (v/v) Glycerine, 50mM EDTA, 0.25% 
Bromophenol-blue, 0.25% Xylene Cyanol 
Cell lysis buffer for isolation of 
total cell proteins  
30mM TRIS-HCL (pH 7.5), 120mM NaCl, 10% Glycerol, 
1% Triton X, 2 tablets Complete (Protease Inhibitor) per 
100 ml 
Triton lysis buffer for phospho-
protein assays 
20mM Tris (pH 7,4),137mM NaCl, 10% (v/v) glycerol, 
1% (v/v) Triton X-100, 2mM EDTA, 50mM Na β 
glycerophosphate, 1mM Na orthovanadate. Before us 
added: 1mM Pefabloc (ABSF), 5µg/ml aprotinin, 5µg/ml 
Leupeptin hemisulfate salt, 5mM benzamidine 
SDS Running Buffer (MES) 
 
50mM MES, 50mM Tris-base, 0.1% (w/v) SDS, 1mM 
EDTA, pH 7.3 
SDS Running Buffer (MOPS)
   
50mM MOPS, 50mM Tris-base, 0.1% (w/v) SDS, 1mM 
EDTA, pH 7.7 
TAE buffer 40mM Tris Base, 20mM Acetic acid, 10mM EDTA 
HBS buffer 140mM NaCl, 50mM Hepes, 1.5mM Na2PO4, pH 7.05 
Transfer buffer 25mM Tris, 192mM glycine, 10% methanol 
EMSA Buffer-A 
 
 
 
10mM Tris pH-7,9, 10mM KCl, 1,5mM MgCl2, 10% 
Glycerol, 10mM K2HPO4,  
shortly before use added: 1mM Sodium vanadate, 
10mM NaF, 0.5mM DTT, 1mM ABSF and protease 
inhibitors (Roche Diagnostik GmbH) 
EMSA Buffer-C 20mM Tris pH-7.9, 0,42M NaCl, 1,5mM MgCl2, 0,2mM 
EDTA, 10% Glycerol, 10mM K2HPO4,  
shortly before use added: 1mM Sodium vanadat, 10mM 
NaF, 0,5mM DTT, 1mM ABSF and protease inhibitors  
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Hypotonic fluorochrome solution  Sodium citrate 0,1% (w/v), Triton X 100 0,1% (v/v), 
Propidium Iodide (PI) 50μg/ml 
Table 7: Buffers used in biochemical and molecular biological assays 
 
2.1.8. Primary antibodies for western blot analysis 
Antibody (clone) Company (Catalog number)  
Caspase-8 (C15) provided by P.H. Krammer, (DKFZ, Heidelberg, Germany) 
Caspase-8 (C20) Santa Cruz (sc-6136) 
Caspase-3 CPP32, provided by H. Mehmet, Merck Frost 
FADD (1) BD Transduction Laboratories (F36620) 
cFLIP (NF-6) Enzo Life Sciences, Inc 
cIAP-1 (1E1) provided by J. Silke (Silke et al., 2005) 
cIAP-2 (207) provided by J. Silke (Vince et al., 2009) 
RIP-1 (38) BD Transduction Laboratories (R41220) 
RIP-3 provided by F. Chan (Cho et al., 2009) 
TRADD (37) BD Transduction Laboratories (T50320) 
β-actin (A2103) Sigma (A2103) 
β-tubulin Sigma (T4026) 
IκBα Sigma (sc-371) 
p38 Sigma (sc-535) 
XIAP (48) BD Transduction Lab (H62120) 
TRIF Cell Signaling Technology (#4596) 
p-IκBα Cell Signaling Technology (#9246) 
NIK Cell Signaling Technology (#4994) 
NF-κB p100/p52  Cell Signaling Technology (#4882) 
p-HSP27  Cell Signaling Technology (#2401S) 
p-p38  Cell Signaling Technology (#9215S) 
p-JNK  Cell Signaling Technology (#9251S) 
JNK  Cell Signaling Technology (#9252) 
HMGB1 Abcam (ab18256) 
Table 8: Primary antibodies for western blot analysis 
 
2.1.9. HRP-coupled secondary antibodies 
Antibody (clone) Company (Catalog number)  
Mouse IgG Southern biotech (1031-05) 
Mouse IgG1 Southern biotech (1070-05) 
Mouse 1gG1 Southern biotech (1050-05) 
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Mouse IgG2a Southern biotech (1080-05) 
Mouse IgG2b Southern biotech (1090-05) 
Rabbit IgG Southern biotech (4030-05) 
Rat IgG Southern biotech (3050-05) 
Table 9: HRP-coupled secondary antibodies for western blot analysis 
 
2.1.10. Vectors 
Vector Reference 
Expression vector: PCR-3 Invitrogen 
Lentiviral packaging vector: pMD2.G (Rubinson et al., 2003) 
Lentiviral packaging vector: pMDlg/pRRE (Rubinson et al., 2003) 
Lentiviral packaging vector: pRSV-Rev (Rubinson et al., 2003) 
Lentiviral vector: pFGEV16-Super-PGKHygro (Vince et al., 2007) 
Lentiviral vector: pF5xUAS-W-SV40-Puro (Vince et al., 2007) 
Lentiviral vector: pLKO.1 (Geserick et al., 2009) 
Retroviral vector: pCF65-IEGZ (Denk et al., 2001)  
Retroviral vector for siRNA: pRS puro 
(pSuper.retro)  
(Diessenbacher et al., 2008) 
Retroviral vector for siRNA: pRS MIG (derived 
from pSuper.retro)  
(Geserick et al., 2008) 
Table 10: Vectors used for expression 
 
2.1.11. siRNA-sequences for knockdown of: 
Target Sequence 
cIAP2 64-mer oligomers containing cIAP2-targeting sequence 
nucleotide start position +316 
cIAP1 64-mer oligomers containing cIAP1-targeting sequence 
nucleotide start position +3398 
cIAP1 64-mer oligomers containing cIAP1-targeting sequence 
nucleotide start position +1685 
RIP-1 64-mer oligomers containing RIP-1-targeting sequence 
nucleotide start position +193 
HRS 64-mer oligomers containing a hyper random sequence not 
matched by any gene in the NCBI database  
Table 11: siRNA-sequences for knockdown 
 
2.1.12. Bacteria cells 
Bacterial Cells Company 
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E.coli DH5α Clontech 
E.coli M15 (pREP4) Qiagen 
E.coli TOP10F Invitrogen 
E.coli XL10 Gold  Stratagene 
Table 12: Bacteria cells 
 
2.1.13. Culture media and additives for bacterial cells 
Item Company (Catalog number) 
Ampicillin sodium salt (100µg/ml) Roth (K029.2) 
Kanamycin sulfate (30µg/ml) Roth (T832.1) 
LB-Agar (Lennox) Roth (X965.2) 
LB-medium (Lennox) Roth (X964.2) 
SOC Medium Sigma-Aldrich (S1797) 
Table 13: Media and Reagents for bacterial cell culture. All media were autoclaved at 
121°C for 15min. The additives were filtered with a 0.2μm filter-unit and stored at -20°C. 
 
2.1.14. Human cells 
Human cells Source 
A5RT3 parental (SCC cell line)  
 
Mueller et al., 2001: provided by P. 
Boukamp (DKFZ, Heidelberg, Germany) 
HaCaT parental (transformed keratinocytes) 
 
Boukamp et al., 1988: were provided by P. 
Boukamp (DKFZ, Heidelberg, Germany) 
HaCaT pCF65 M. Feoktistova (Geserick et al., 2009) 
HaCaT cFLIPL M. Feoktistova (Geserick et al., 2009) 
HaCaT cFLIPS M. Feoktistova (Geserick et al., 2009) 
HaCaT pRS puro HRS M. Feoktistova (Geserick et al., 2009) 
HaCaT pRS puro shRNA cIAP2 (316) M. Feoktistova (Geserick et al., 2009) 
HaCaT pLKO.1  M. Feoktistova (Geserick et al., 2009) 
HaCaT pLKO.1 shRNA cIAP1 (1685 and 
3398) 
M. Feoktistova (Geserick et al., 2009) 
HaCaT pRS MIG shRNA HRS M. Feoktistova (Geserick et al., 2009) 
HaCaT pRS MIG shRNA RIP-1 (RIP-193) M. Feoktistova (Geserick et al., 2009) 
HaCaT GEV16 control M. Feoktistova 
HaCaT GEV16 RIP-1 WT M. Feoktistova 
HaCaT GEV16 RIP-1 K45A M. Feoktistova 
HaCaT GEV16 RIP-1 D324K M. Feoktistova 
HEK 293T (Human Embryonic Kidney 293 
that stably express the large T-antigen of 
American Type Culture Collection (ATCC) 
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SV40) 
MET1 parental (SCC cell line) 
 
Poppet al., 2000: provided by I. Leigh (Skin 
Tumor Laboratory, London, UK) 
ΦNX (amphotropic producer cell line derived 
from HEK 293T) 
American Type Culture Collection (ATCC) 
Primary keratinocytes. Donor 11 isolated from human skin  
Primary keratinocytes. Donor I isolated from human skin 
Primary keratinocytes. Donor L isolated from human skin 
Primary keratinocytes. Donor E isolated from human skin 
Table 14: Human cells 
 
2.1.15. Cell culture media and reagents for human cells 
Item Company (Catalog number) 
Dulbecco’s Modified Eagle Medium (D-MEM) Invitrogen (41965-062) 
Fetal Bovine Serum “Gold” (FBS) PAA (A15-151) 
Ultra Low IgG Fetal Bovine Serum Invitrogen  
HEPES Sigma-Aldrich (H3375) 
Hygromycin B MERK (400050) 
MEM Amino Acids PAA (M11-003) 
MEM Vitamins PAA (N11-002) 
Dulbecco’s Phosphate-Buffered Salines (D-PBS) Invitrogen (14190) 
Puromycin dihydrochloride Sigma-Aldrich (P9620) 
Sodium Pyruvate PAA (S11-003) 
Trypsin EDTA PAA (L11-004) 
Zeocin™ Invitrogen (R250-01) 
CnT-07 CellNTec (CnT-07.BM) 
Table 15: Media and reagents for human cell culture 
 
2.2. Methods 
 
2.2.1. Molecular biological methods 
All molecular biological work was carried out corresponding to standard protocols provided 
by the manufacturers. All methods are described in the literature in detail: Current Protocols 
in Molecular Biology (Ausubel et al., 1990) and Molecular Cloning (Sambrook et al., 1989). 
Therefore, only a brief description will be given and the modifications will be described in 
more detail if this applies. 
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2.2.1.1. Digestion of DNA with restriction endonucleases 
The restriction reaction was performed in 20µl mix, containing 10-15 U of respective enzyme, 
compatible buffer and 1µg of analysed DNA solved in water. The reaction was performed for 
1-1,5 h by 37°C.  
 
2.2.1.2. DNA agarose gel electrophoresis 
DNA fragments were separated according to their size by one-dimensional agarose (0,8-
1,2%) gel electrophoresis. To visualize the DNA under UV light, 5-10μl Ethidium bromide 
solution (10 mg/ml in H2O) was added before gel polymerization. The DNA samples were 
prepared in DNA sample buffer and were loaded onto the gel. Gels were run at 3-5V/cm, 
depending on the required quality, in TAE buffer. The DNA fragments were visualized under 
UV-light and photographed.  
 
2.2.1.3. Cloning 
DNA fragments of interest were purified (for kits look table 2) subjected to enzymatic 
digestion and ligated with T4 DNA ligase to the pre-digested and dephosphorylated vector 
(pF5xUAS-W-SV40-Puro). The ligations were performed at 16-20°C for 2-8 h. The used DNA 
fragment/vector ratio was 3:1 (sticky end cloning). The ligated fragment-vectors were 
transformed into competent bacterial cells and plated on antibiotic containing agar plates for 
bacteria colony formation. The DNA of formed bacteria colonies was isolated for restriction 
digestion, sequencing (by Agowa) and maxi plasmid preparations.  
 
2.2.1.4. Heat shock transformation 
The DNA ligation mixture was incubated with 100μl of heat shock competent bacteria cells 
for 30min on ice, followed by transformation, heat shock 45 sec by 42°C, followed by 
incubation on ice for 5min. Then 400µl of SOC Medium was added and the tube incubated at 
37°C for 1 h shaking speeding bacterial shaker (80 rpm). Bacterial cells were pelleted by 
centrifugation at 1000 g for 1min and the supernatant was decanted. The pellet was 
resuspended by vortexing in the remaining drops of liquid. The entire suspension was plated 
on LB-Agar plates containing the respective antibiotics. Plates were incubated over night at 
37°C.  
 
2.2.1.5. Plasmid isolation 
DNA plasmids were purified using Plasmid Kits (Table 2) and following manufactures 
protocols. The DNA concentration was determined by spectrophotometrical quantification at 
260 nm by A260 * 50 = xμg/μl. 
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2.2.2. Cell culture techniques 
Cells were cultured in their respective media in 5% CO2 at 37°C and a humidity of 95%. All 
media were pre-incubated at 37°C before addition to cells. 
Human cells Medium 
A5RT3/HEK 
293T/HaCaT 
D-MEM, 1% HEPES, 1% Sodium Pyruvate, 10% heat inactivated FBS 
MET1 
 
D-MEM, 1% HEPES, 1% Sodium Pyruvate, 1% MEM NEAA, 1%MEM 
Vitamins, 10% heat inactivated FBS 
ΦNX ampho 
 
D-MEM, 1% HEPES, 1% Sodium Pyruvate, 1% MEM Amino Acids, 
10% heat inactivated FBS, 
Primary 
keratinocytes 
CnT-07 including the supplements 
Table 16: Media and references for cell culture 
 
2.2.2.1. Ca-phosphate mediated Transfection of vector-DNA 
293T or ΦNX-ampho cells were grown in 10 cm plates 3x106 per plate. Then the medium 
was changed with 6ml of respective medium per plate + 25µM Chloroquin followed by 40’-1h 
at 37°C in 5% CO2. For generation of Ca-Phosphate-DNA precipitate 25µM CaCl2, 20μg 
DNA were mixed with water up to final volume of 300µl (per plate), followed by addition 
dropwise into 300µl of 2x HBS buffer. Upon 30-40’ incubation at RT the mix was added on 
the plate and incubated over night at 37°C in 5% CO2 atmosphere before exchange of 
growth media.  
 
2.2.2.2. Generation and purification of stimulating cytokines 
For generation of CD95L-Fc (the construct was kindly provided by P. Schneider) and 
TWEAK-Fc (the construct was kindly provided by J. Silke) the corresponding constructs were 
transiently expressed in HEK 293T cells, cultured in IgG stripped medium. Supernatants 
were harvested and filtered (0.2µm, Millipore). The proteins from supernatant were 
precipitated with saturated solution of Ammonium sulfate, followed by dialysis with 20mM 
NaPO4 pH-7,0 as dialysis buffer. Then the dialyzed solution was purified with protein-G 
agarose column. The activity of purified protein was tested by functional assays (e.g. Cristal 
violet staining upon stimulation of the cells). 
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2.2.2.3. Retroviral infection 
The amphotrophic producer cell line ΦNX was transfected with 20μg of the retroviral vectors 
(pCF65 or pRS MIG) containing cDNA or shRNA of interest. The supernatants were 
harvested 48-72h post-transfection and filtered (0.45, Millipore). The virus containing 
supernatants were added to target cells with 5µg/ml Hexadimethrine bromide (Polybrene). 
Target cells were spin-infected (1,5 h at 30°C by 2100 rpm in a Hareaus centrifuge). Stable 
cell lines were selected with respective antibiotics: Zeocin 300µg/ml for 10-14 days for 
pCF65 and puromycine 3µg/ml for 3 days for pRS MIG. Western blot analyses were 
performed on polyclonal cells to confirm knockdown and ectopic expression of the respective 
molecules. 
 
2.2.2.4. Lentiviral infection 
To generate lentiviral supernatants, HEK 293T cells were transfected with pMD2.G, 
pMDlg/pRRE, and pRSV-Rev of the lentiviral packaging vectors together with the target 
vectors (e.g. pFGEV16-Super-PGKHygro, pF5xUAS-W-SV40-Puro and pLKO.1 vectors 
containing molecules of interest or respective shRNA). The supernatants were harvested 48-
72h post-transfection and filtered (0.45µm, Millipore). The virus containing supernatants were 
added to target cells with 5µg/ml Hexadimethrine bromide (Polybrene). Target cells were 
spin-infected (as described before). Stable cell lines were selected either with hygromycin 
(100-150µg/ml for 1 week) or puromycin (3µg/ml for 3 days). Cells were subsequently tested 
for expression of the respective proteins. For the inducible protein expression the 24h 
transduced cells were stimulated with 10 to 100nM 4-HT (4-Hydroxytamoxifen) for 24h and 
total cell lysates were analysed by western blot.  
 
2.2.2.5. Stable siRNA expression 
RIP-1 siRNA as well as a hyper random sequence (HRS) not matched by any gene in the 
National Center for Biotechnology Information database (Vogler et al., 2007) were used. The 
random sequence construct was provided by S. Fulda (Ulm University, Ulm, Germany). For 
generation of the constructs, cDNA 64-mer oligomers containing RIP-1 targeting sequence 
(nucleotide start position +193) were cloned into the pRS-MIG retroviral vector using HindIII 
and BglII restriction sites. For generation of the cIAP2, cIAP1 and RIP-1 constructs, 
complementary DNA 64-mer oligomers containing either cIAP2 (nucleotide start position 
+316 or +466), cIAP1 (nucleotide start positions +3398 and +1685) or RIP-1 (nucleotide start 
position +193) targeting sequences were cloned either into the pRS-MIG retroviral vector 
using HindIII and BglII restriction sites (cIAP2 and RIP-1 shRNAs) or into pLKO.1 (cIAP1 
shRNAs).  
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The resulting vectors were transfected either into the amphotrophic producer cell line ΦNX 
(pRS MIG) or into 293T cells together with the respective packaging plasminds (for pLKO.1, 
as was described before). The virus containing supernatants were used for spin infection of 
the target cells as described before (2.2.2.3 and 2.2.2.4.). Stable cell lines were selected in 
Puromycin (3µg/ml) for 3 days. Western blot analyses were performed on polyclonal cells to 
analyze expression of the downregulated proteins. 
 
2.2.2.6. Cytotoxicity assay 
Crystal violet staining of attached, living cells was performed 18-24 h after stimulation with 
the indicated concentrations of stimulating agents (DL or poly (I:C) and/or inhibitors (e.g. IAP 
antagonist zVAD-fmk, Necrostatin-1) in 96-well plates. Plates were washed two times with 
water. Subsequently, 50μl of Crystal violet staining solution (Table 7) were added per well. 
After incubation for 20min at room temperature, plates were washed several times with water 
to remove the non-intercalated dye. Plates were air dried, and 200μl methanol were added 
per well followed by 30min incubation at RT to solve the incorporated dye. The optical 
density of the wells was subsequently measured by a plate reader (Victor3; 1430 Multilabel 
counter, PerkinElmer). The optical density of control cultures was normalized to 100% and 
compared with stimulated cells. For statistical analysis, the Standard Error of Mean (SEM) 
was determined for at least of medium of three independent experiments of each cell line 
and stimulatory condition. 
 
2.2.3. Cell lysate preparation  
2.2.3.1. For Western blot analysis 
For generation of total cell lysates parental and virally transduced cells were washed twice 
with ice-cold 1 x PBS and lysed for 30min on ice by the addition of Cell lysis buffer (Table 7). 
Cellular debris was removed by centrifugation at 20,000 g for 10min. The total amounts of 
isolated cell proteins were quantified by Bradford assay. 5μg of total cellular proteins was 
supplemented with 5 x Laemmli sample buffer and boiled at 95°C.  
 
2.2.3.2. For phospho-protein analysis 
For analysis of phospho-proteins the respective cells were starved in serum free medium for 
6h to get rid of the basal phosphorylated MAPKs, activated by the FBS. Then the cells were 
scraped from the plate and resuspended in triton lysis buffer (see table 7). To quickly disrupt 
the cell membranes the lysates were pushed three times through a syringe with 0,4 mm 
needle, followed by 14 000rpm for 10min centrifugation and transfer of the supernatant to the 
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fresh tube for further experiments. The total amounts of isolated cell proteins were quantified 
by Bradford assay.  
 
2.2.3.3. For EMSA 
For generation of cytosolic and nuclear lysates for EMSA the respective cells were seeded in 
amount of 1,7x106 cells in 10cm dishes. After desired stimulations on day 2, the cells were 
trypsinized and washed with PBS. Then the cells were resuspended in 300μl of EMSA 
Buffer-A (Table 7) followed by immediate addition of 0,125% NP-40 (Sigma NP-40). After 
incubation on ice for 5min, the cells were spun down for 10min at 1000 g at 4°C. The 
supernatant was transferred into fresh tube (represents cytosolic extracts). The pellet was 
washed with 300μl of EMSA Buffer-A. Then the pellet was resuspended in EMSA Buffer-C 
(Table 7). Then the lysates were centrifuged at 12,000g at 4°C for 10min. The supernatant 
represents the nuclear extracts which were used further for EMSA. 
 
2.2.4. Electrophoretic mobility shift assay (EMSA) 
The oligonucleotide probe used was a consensus NF-κB binding site derived from the κB 
element of the IL-2 promoter (“TCEdA>C”): 5′-CTAAATCCCCACTTTAGGGAGAACCAG-3′. 
For the procedure: 4µg nuclear proteins were incubated with 10000cpm (equivalent of 
approximately 0.2ng) of a 32P-labeled oligonucleotide probe and 2 pg poly (dI-dC) as 
nonspecific competitor. The samples were incubated for 30min on ice, separated on a non-
denaturing 5% polyacrylamide (PAA) gel at 200 V/15 cm at room temperature followed by 
autoradiography. 
 
2.2.5. Western Blot analysis 
Proteins were separated by SDS-PAGE on 4-12% gradient gels (Invitrogen) using SDS 
Running Buffer and Invitrogene Power Ease 500 system. Proteins were transferred to PVDF 
membrane using Transfer buffer (Table 7). Membranes were incubated for 1 h in blocking 
buffer, washed with 1 x T-PBS, and incubated AB-buffer and primary antibodies overnight. 
After washing in 1 x T-PBS, blots were incubated with HRP-conjugated isotype-specific 
secondary antibody in 1 x T-PBS. After washing of the blots with 1 x T-PBS, bands were 
visualized with ECL detection kits by chemiluminescence and films (AGFA Curix HT and 
Amersham Hyperfilms). 
 
2.2.6. Analysis of hypodiploid DNA content of the cells.  
Around 150 000 cells per well were seeded in 6-well plate. The cells are treated with desired 
reagents for respective time. The cells and supernatants together were collected in 15 ml 
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falcon tubes, pelleted (200-400g for 5min) and washed 2 times with 1xPBS. Then 500 l of 
cold hypotonic fluorochrome solution (Table 7) were gently added to the cells. Then the 
tubes were placed at 4°C in the dark for 36-48h before the flow cytometric analysis. The 
diploidy was measured by FACScan analysis (BD FACS Canto II). 
 
2.2.7. Immunofluorescence microscopy 
For detection of nuclear morphology and integrity of the cell membrane, 5x104 cells of the 
respective cells were seeded per well in a 12-well plate. Following 24h of incubation for 
adherence, cells were stimulated as indicated in the figure legends for 24h. Subsequently, 
cells were incubated with Hoechst 33342 (5μg/ml; Polysciences Europe, Eppelheim, 
Germany) and SYTOX® Green (5pM; InvitrogenTM, Molecular ProbesTM, Eugene, Oregon, 
USA) for 15min at 37°C immediately followed by phase contrast or fluorescence microscopy 
using a Zeiss HBO 50 microscope (Jena, Germany). Digital images were processed in an 
identical manner using the advanced SPOTSOFTWARE, Version 4.6 (Diagnostic 
Instruments Inc, MI, USA). 
 
2.2.8. Co-immunoprecipitation of Caspase-8-bound complexes 
For the precipitation of Caspase-8-bound proteins, 5x106 cells were seeded and incubated 
for over night. Cells were washed once with medium at 37°C and subsequently pre-
incubated for 1h with 100nM IAP antagonist at 37°C. Subsequently cells were treated with 
20µg/ml of poly (I:C) for 2h. Stimulation was stopped by washing the monolayer four times 
with ice-cold PBS. Cells were lysed on ice by addition of 2 ml lysis buffer. After 30min lysis 
on ice, the lysates were centrifuged two times at 20,000xg for 5min and 30min, respectively, 
to remove cellular debris. A minor fraction of these clear lysates were used to control for the 
input of the respective proteins (TL- total lysates). Subsequently 1μg caspase-8 antibody (C-
20) was added to all lysates. The caspase-8 containing complexes were precipitated from 
the lysates by co-incubation with 40μl protein G-beads (company) for 16 - 24h on an end-
over-end shaker at 4°C. Ligand affinity precipitates were washed 4 times with lysis buffer 
before the protein complexes were eluted from dried beads by addition of standard reducing 
sample buffer and boiling at 95°C. Subsequently, proteins were separated by SDS-PAGE on 
4-12% NuPAGE gradient gels, before detection of proteins by Western blot analysis. 
Diplom Genetikerin Feoktistova Maria Alexeevna 
The role of RIP-1 and cIAPs in apoptotic and non-apoptotic signalling via TLR3 and death receptors  
 46
3. Results 
3.1. The role of cIAPs in TLR3-induced cell death 
Recent studies show that TLRs are expressed in various types of tumours, such as multiple 
myeloma (Chiron et al., 2009) or melanoma (Salaun et al., 2007) and activation of tumour 
cell TLRs not only promotes tumour cell proliferation and resistance to apoptosis, but also 
enhances tumour cell invasion and metastasis (Huang et al., 2008). In contrast, active TLR3 
signalling also promotes apoptosis induction (Salaun et al., 2006). Such dramatic differences 
indicate that the outcome of TLR3 signalling is controlled by intracellular downstream 
processes. Recently the probable role of TRL3 as a target for anti-cancer therapy has been 
proposed (Salaun et al., 2007). Previous studies (McEleny et al., 2004; Wang et al., 2005) 
have shown that cIAPs play a critical role in cell death signalling. Therefore it was proposed 
that cIAPs could be negative regulators of TLR3-induced cell death. The major goal of this 
study is to identify the functional relevance of cIAPs in regulating of apoptotic and non-
apoptotic TLR3 signalling pathways.  
 
3.1.1. Loss of cIAPs sensitizes to poly (I:C)-induced cell death  
To identify the role of IAPs in regulation of TLR3 cell death signalling pathways the function 
of XIAP was inhibited and endogenous expression of cIAP1 and cIAP2 was downregulated 
by an IAP antagonist, compound A (Vince et al., 2007) in spontaneously transformed 
keratinocyte (HaCaT) and squamous cell carcinoma (SCC) cell lines. First the endogenous 
expression levels of cIAP1, cIAP2, XIAP, RIP-1 and RIP-3 proteins in HaCaT keratinocytes, 
MET1 SCC and metastatic A5RT3 SCC cell lines were compared to determine the basal IAP 
expression. These three cell lines show remarkable heterogeneous expression levels of 
IAPs. Both HaCaT and A5RT3 cells do not express XIAP at the protein level, whereas MET1 
cells highly express XIAP (Figure 9 A). A5RT3 cells weakly express cIAP1, but high 
expression of cIAP2 was observed, compared to MET1 and HaCaT (Figure 9 A). RIP family 
members were also heterogeneously expressed in all three of described cell lines. RIP-1 was 
strongly expressed in HaCaT and MET1 cell lines, whereas in A5RT3 it was expressed at 
lower levels. RIP-3 was expressed in HaCaT, lower in A5RT3 and in MET1 cells RIP3 
expression was absent. All three cell lines thus have different levels of IAP expression. To 
examine the effect of IAP antagonist on cIAP expression the HaCaT cells were incubated 
with IAP antagonist (Compound A) for the indicated time. This treatment induced a rapid 
degradation of cIAP1 and cIAP2 in all cell lines (Figure 9 B). In the next experiments the 
sensitivity to poly (I:C) was examined in IAP antagonist treated cells. HaCaT and MET1 cells, 
but not A5RT3 cells, show increased sensitivity to poly (I:C) induced cell death (Figure 9 C 
black bars). These results clearly show cIAPs as critical regulators of TLR3 induced cell 
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death in HaCaT cells independent of the anti-apoptotic function of XIAP. MET1 cells, in 
contrast to HaCaT and A5RT3, express high levels of XIAP. Therefore, it cannot be excluded 
that the observed increased sensitivity to poly (I:C) in the presence of IAP antagonist is due 
the inhibited function of XIAP (Figure 9 C black bars).  
 
Figure 9. Loss of cIAPs sensitizes cells to poly (I:C)-mediated cell death. A. 5µg of 
total cell lysates from parental cells were analysed by Western-blot for the respective 
proteins. -tubulin served as internal control for even protein loading. One of four 
representative experiments is shown (the lysates for these experiment were kindly 
provided by Dr. P. Geserick). The star indicates the non-specific band recognised by the 
antibody. B. HaCaT cells were treated for respective time with 100nM of IAP antagonist 
with further analysis of 5µg of the lysates by Western blot for the respective proteins, -
tubulin serves as a control. C. Parental HaCaT, MET1, or A5RT3 cells were pre-treated 
with 100nM IAP antagonist for 1h and subsequently stimulated with 50µg/ml of poly (I:C) 
in triplicate wells. Viability of cells was analyzed by crystal violet staining after 18-24h. 
Unstimulated cells served as control and were set as 100 % to allow comparison of poly 
(I:C)-independent sensitivity to IAP antagonist. The result of three independent 
experiments is shown, error bars describe standard error of mean (SEM). 
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To prove whether cIAP1 or cIAP2 is more critical for TLR3 apoptosis resistance, a specific 
shRNA knock-down of cIAP1 or cIAP2 in XIAP deficient HaCaT cells was performed. The 
sensitivity to poly (I:C) of these cell lines (Figure 10 B) was analyzed. In line with our 
previous findings (Geserick et al., 2009), a robust up-regulation of cIAP2 expression in cIAP1 
knockdown cells was found (Figure 10 A) that might be explained by posttranslational 
regulation of cIAPs (Conze et al., 2005) or by increased NF-κB activation (J. Vince and 
J.Silke, unpublished observation). However knockdown of cIAP1 promoted poly (I:C)-induced 
cell death, providing further evidence that cIAP1 is a crucial negative regulator of TLR-
induced cell death signalling (Figure 10 A white bars). Of note IAP antagonist further 
sensitized cIAP1 knockdown cells indicating that the additional downregulation of the 
upregulated cIAP2 level in this cell lines is relevant for the poly (I:C) induced cell death 
(Figure 10 B black bars). These results show that cIAP2 also controls the apoptotic TLR3 
signalling pathway. In contrast, knockdown of cIAP2 did not affect cIAP1 expression, when 
compared to the respective control vector that substantially upregulated cIAP2. Despite this 
experimental limitation the marginal increase in cell death in these cells in cIAP2 knockdown 
cells suggests that cIAP2 is less important for the regulation of poly (I:C)-induced cell death 
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Figure 10. cIAPs regulate TLR3 induced cell death in XIAP independent manner. 
A. Parental HaCaT cells were either retrovirally transduced with specific shRNA for 
cIAP1 or cIAP2 or with the respective vector controls (control1 for cIAP1 and control2 
for cIAP2). 5µg of total cell lysate from bulk infected cells were analysed for cIAP1 and 
cIAP2 expression by Western-blot analysis. -tubulin and -actin served as loading 
controls. B. For viability assays the transduced cells were either pre-treated IAP 
antagonist (100nM, 1h) and subsequently stimulated with 2µg/ml of poly (I:C) for 24h in 
triplicate wells. Viability of cells was analyzed by crystal violet assay after 18-24h. 
Unstimulated cells served as control and were set as 100 % to allow comparison of poly 
(I:C)-independent sensitivity. The summary of three independent experiments is shown 
and error bars show the standard error of mean (SEM).  
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than cIAP1. Taken together these results demonstrate that cIAPs are important factors 
regulating TLR3-induced apoptosis resistance.  
 
3.1.2. Loss of cIAPs sensitizes to poly (I:C)-induced cell death in a 
Caspase- and RIP-1-kinase dependent manner  
Loss of cIAPs substantially increases the sensitivity of cells to TNF-induced cell death (Vince 
et al., 2007). In addition it was found that cIAPs also regulate TLR3-induced cell death 
(Figures 9-10). Furthermore, apoptotic cell death is strongly regulated by active caspases 
and necrotic cell death is critically controlled by the kinase activity of RIP-1. In addition, 
cIAPs are poor caspase inhibitors (Eckelman and Salvesen, 2006) but critical regulators of 
RIP-1 (Bertrand et al., 2008). Therefore, cIAPs could negatively regulate poly (I:C) induced 
cell death by controlling RIP-1 activity. To follow this hypothesis the experiments with the 
pan-caspase inhibitor zVAD-fmk and the recently described RIP-1-kinase inhibitor 
necrostatin-1 were performed (Degterev et al., 2008). zVAD-fmk completely blocked poly 
(I:C)-induced cell death in the presence of cIAPs (Figure 11 A panel 3). In the absence of 
cIAPs, both inhibitors were needed for protection against cell death implicating that a 
caspase-independent RIP-1 kinase-dependent form of cell death is operative whenever 
cIAPs are absent (Figure 11 A panel 10). To exclude the possibility that autocrine TNF-
production induced by IAP antagonist (Vince et al., 2007) was responsible for the increased 
sensitivity to poly (I:C), a soluble TNF-R2-Fc was used to block autocrine TNF signalling. 
However TNF-R2-Fc treatment was ineffective to protect from poly (I:C), supporting a direct 
effect of cIAPs for TLR3-induced death signalling (Figure 11 A black bars). To further 
characterize the observed cell death the cell death morphology was analyzed by 
fluorescence microscopy studies in presence of caspase- and RIP-1-kinase inhibitors in poly 
(I:C)/IAP antagonist stimulated cells. The cells were stained with Hoechst-33342, to detect 
the chromatin condensation during the apoptosis and with SYTOX Green (high-affinity 
nucleic acid stain) which is able to stain nucleus only when the integrity of the membrane is 
disrupted. The SYTOX Green staining allows detection of late apoptotic events and necrosis. 
Increased numbers of typical apoptotic cells demonstrating membrane blebbing, DNA 
condensation and fragmentation were detectable after poly (I:C) stimulation even in the 
presence of RIP-1-kinase inhibitor whereas zVAD-fmk fully protected cell death and 
membrane integrity (Figure 11 B, left panel). In contrast, whenever IAPs were absent, zVAD-
fmk only partially protected from poly (I:C) induced cell death. However a change in cell 
death morphology was observed as indicated by a rounded shape, a lack of DNA 
condensation and a retarded disruption of cell membranes (Figure 11 B, right panel). 
Combined addition of zVAD-fmk and Necrostatin-1 resulted in complete resistance to poly 
(I:C)/IAP antagonist mediated cell death (Figure 11 B lowest panel). These results 
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demonstrate that in the absence of cIAPs and caspase activity an alternative caspase-
independent cell death signalling pathway was activated via TLR3. This TLR3 non-apoptotic 
cell death pathway critically depends on RIP-1 kinase activity. To further characterise the 
non-apoptotic cell death the release of high mobility group box 1 protein (HMGB-1) in the 
cellular supernatant was analysed as a characteristic of caspase-independent necrotic cell 
death (Scaffidi et al., 2002). HMGB-1 release, induced by TLR3-stimulation was unaffected 
by caspase inhibition, whereas Necrostatin-1 decreased HMGB-1 release to some extent. 
Most importantly, TLR3-induced HMGB-1 release was completely suppressed by the 
combination of zVAD-fmk and Necrostatin-1 (Figure 11 C). 
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Figure 11. IAP antagonist sensitizes HaCaT cells to apoptotic and non-apoptotic cell 
death in caspase and RIP-1K dependent manner. A. Parental HaCaT cells were either 
separately or in combination pre-treated with 100nM IAP antagonist (1h), TNFR2-Fc 
(10μg/ml, 1h), zVAD-fmk (10µM; 1h), Necrostatin-1 (50µM, 1h), and subsequently stimulated 
with 2µg/ml of poly (I:C) in triplicate wells. Viability of cells was analysed and statistical 
analysis was performed as described before. The summary of three independent 
experiments is shown. B. For characterization of cell death morphologies, HaCaT cells were 
either pre-treated with zVAD-fmk (10µM, 1h), Necrostatin-1 (50µM, 1h) or IAP antagonist 
(100nM, 30min) and subsequently stimulated with poly (I:C) (2µg/ml) for 24h. Cells were 
stained with Hoechst-33342 (5µg/ml) and Sytox Green (5pM) for 15min at 37°C immediately 
followed by transmission and fluorescence microscopy. One representative of a total of three 
independent experiments is shown. C. HaCaT cells were stimulated as described in D. and 
the supernatants as well as the total cell lysates were analysed for HMGB-1 protein 
expression by Western blot analysis. -tubulin served as loading control. One representative 
of three independent experiments is shown (This experiment was done together with Dr. P. 
Geserick). 
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These results suggest that RIP-1 kinase activity, in the absence of cIAPs, is critical for non-
apoptotic TLR3-induced cell death signalling pathway. Furthermore, in the absence of 
caspase activity a necrotic cell death is unmasked in these cells. Taken together, our data 
demonstrate that cIAPs negatively regulate TLR3-mediated caspase-dependent as well as 
non-apoptotic (necrotic) cell death pathways. In the absence of cIAPs, RIP-1-kinase activity 
plays a critical role for the induction of non-apoptotic cell death.  
 
3.1.3. Degradation of cIAPs by TWEAK sensitizes to poly (I:C)-
induced cell death.  
To examine the role of cIAPs in a more physiologically relevant setting was employed. The 
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Figure 12. TWEAK sensitizes HaCaT, but not MET1 or A5RT3 to poly (I:C)-induced 
cell death. A. TWEAK leads to rapid downregulation of cIAP1 and -2 expression in HaCaT. 
Cells were stimulated with 0,5µg/ml TWEAK for the indicated time. Subsequently, total 
cellular lysates were analyzed for expression of cIAP1 or -2 by Western blotting. -tubulin 
served as a loading control (this blot was kindly provided by Dr. P. Geserick). B, C. Viability 
of cells was analysed by crystal violet staining and statistical analysis was performed as 
described before. The summary of three independent experiments each condition is 
shown. Error bars represent SEM. B. For quantification of poly (I:C) induced cell death 
HaCaT cells were pre-incubated for 1h with either TWEAK or IAP antagonist alone and/or 
in combination with indicated concentrations of poly (I:C) for 24h in triplicate wells. C. For 
quantification of poly (I:C) induced cell death HaCaT, A5RT3 and MET1 cells were pre-
incubated with 0,5µg/ml of TWEAK (1h) followed by poly (I:C) stimulation (50µg/ml for 24h). 
Error bars represent SEM. 
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cytokine TWEAK (TNF-like weak inducer of apoptosis) was used. TWEAK binds to FN-14 
receptor and the signal negatively regulates cIAP protein expression (Vince et al., 2008). 
Treatment with purified TWEAK substantially decreased the endogenous expression of cIAP 
proteins within one hour (Figure 12 A), but up-regulation of both cIAPs after 24h of TWEAK 
stimulation was observed. This could be due to the degradation of IAP antagonist of due to a 
possible increase in NF-κB activation and, therefore, increased transcription of NF-κB target 
genes (cIAPs). 
 The hypothesis was that TWEAK may also influence poly (I:C) induced cell death pathways 
similar to the IAP antagonist. TWEAK effectively enhanced poly (I:C) induced cell death in a 
similar manner as the IAP antagonist (Figure 12 B). The A5RT3 cells, which were not 
sensitized by IAP antagonist (Figure 9 C) were also not sensitized by TWEAK (Figure 12 C). 
Surprisingly the MET1 cells which could be sensitized by IAP antagonist (Figure 9 C) were 
not sensitized by TWEAK (Figure 12 C). This data indicate that the function of XIAP which is 
not affected by TWEAK, is also crucial for TLR3-induced cell death.  
This cell death, observed in HaCaT cells, upon treatment with TWEAK and poly (I:C) was 
independent of autocrine TNF signalling (Figure 13 A, black bars), which duplicated the 
results with IAP antagonist (Figure 11 A and B). At the same time this cell death was RIP-1 
kinase- and caspase-dependent (Figure 13 A, white bars, and figure 13 B, right panel). 
Furthermore, similar to our findings with the IAP antagonist (Figure 11 B), apoptotic cell 
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Figure 13. TWEAK sensitizes HaCaT cells to apoptotic and non-apoptotic cell death in 
caspase and RIP-1K dependent manner and independent of autocrine activated TNF cell 
death. A, B. For quantification and characterization of poly (I:C) induced cell death, parental 
HaCaT cells were either pre-treated or co-stimulated with zVAD-fmk (10µM, 1h), Necrostatin-1 
(50µM, 1h), TNF-R2-Fc (10µg/ml, 1h, only in B.) or TWEAK (0,5µg/ml, 1 h) and subsequently 
stimulated with poly (I:C) (2µg/ml) for 24hrs in triplicate wells. A. For quantification of poly (I:C) 
induced cell death HaCaT cells were pre-incubated for 1h with either TWEAK or IAP 
antagonist alone and/or in combination with indicated concentrations of poly (I:C) for 24h in 
triplicate wells. Viability of cells was analysed by crystal violet staining and statistical analysis 
was performed as described before. The summary of three independent experiments each 
condition is shown.  B. For characterization of cell death morphology, cells stimulated as 
described before were stained with Hoechst-33342 and Sytox Green dyes immediately 
followed by transmission and fluorescence microscopy. 
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death morphology of the cells upon poly (I:C) stimulation was detected (Figure 13 B left 
panel). In the presence of TWEAK the cells treated with poly (I:C) also showed apoptotic 
morphology during the cell death (Figure 13 B, right panel). This cell death was independent 
of RIP-1 kinase activity, since in presence of Necrostatin-1 the cell death had same apoptotic 
morphology (Figure 13 B right panel). However, when poly (I:C) induced apoptosis was 
suppressed by pan-caspase inhibitor zVAD-fmk, TWEAK promoted a necrotic cell death as 
shown by the markedly changed cell death morphology (Figure 13 B; right panel). This 
caspase-independent cell death was completely blocked by the combination of zVAD-fmk 
and Necrostatin-1 that highlights the essential role of RIP-1-kinase activity for necrotic cell 
death (Figure 13 B, right panel). TWEAK-FN14-mediated depletion of cIAPs thus reproduced 
our findings with IAP antagonist and highlighted the physiological relevance of cIAPs in TLR3 
cell death pathways.  
 
3.1.4. cFLIP isoforms negatively regulate poly (I:C) induced 
apoptosis but differentially control IAP antagonist/TWEAK-mediated 
caspase-dependent and independent cell death 
Both members of the cFLIP protein family, cFLIPL and cFLIPS, are competent inhibitors of 
death ligand (DL) induced cell death mediated by direct suppression of Caspase-8 activation 
in and release from the death inducing signalling complex (Geserick et al., 2008; Geserick et 
al., 2009). Caspase-8 has been suggested to be a crucial activator molecule for the 
execution of TLR-3 induced apoptosis (Kaiser and Offermann, 2005). To investigate the 
functional role of caspase-8 in the context of IAP antagonist-induced apoptotic and necrotic 
cell death, the caspase-8 inhibitors cFLIPL or cFLIPS were overexpressed in HaCaT cells 
(Geserick et al., 2008). The sensitivity to poly (I:C)/IAP antagonist were analysed in these 
cells (Figure 14 A). However, vector control transduced HaCaT cells are resistant to poly 
(I:C) mediated cell death (Figure 14 B, white bars, panel 2 and Figure 11 B, left panel). In line 
with the findings in parental HaCaT cells (Figure 11 A, white bars), loss of cIAPs promoted 
increased poly (I:C)-induced cell death (Figure 14 B; white bars; panel 7) in a RIP-1-kinase 
independent manner (Figure 14 B; white bars; panel 9 and Figure 14 C; left panel). This cell 
death can be partially inhibited by zVAD-fmk (Figure 13 B; white bars; panel 8) that promotes 
the switch to the necrotic cell death (Figure 14 C; left panel) and is completely suppressed by 
both inhibitors (Figure 14 B; white bars; panel 10) as also shown by microscopic analysis 
(Figure 14 C, left panel). Interestingly, a substantial basal sensitivity to the IAP antagonist 
was observed in cells overexpressing cFLIPS (Figure 14 B; gray bar, panel 6), but no 
increased sensitivity to poly (I:C) was detected (Figure 14 B; gray bar, panel 7). These data 
demonstrate that in the absence of cIAPs cFLIPS itself promotes a caspase-independent 
form of cell death (Figure 14 C, middle panel), but sufficiently protects against TLR-3 
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mediated apoptosis. However, necrostatin-1 conferred complete protection against IAP 
antagonist induced cell death (Figure 14 B, gray bars, panel 9) and necrotic cell death 
morphology (Figure 14 C, middle panel), indicative of the important role of RIP-1-kinase 
activity in this cell death process. In contrast, cells expressing cFLIPL are fully resistant to 
any TLR-3-mediated cell death signalling (Figure 14 B, black bars and Figure 14 C; right 
panel). These results show a differential regulatory function of the cFLIP proteins in TLR-3 
cell death signalling.  
To further investigate the role of cFLIP and its isoforms in TLR3 signalling in the absence of 
IAPs TWEAK was used. In line with the data gained with IAP antagonist, shown in Figure 14, 
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Figure 14. cFLIPL protects cells from poly (I:C)/IAP antagonist induced cell death, but 
cFLIPS induce spontaneous and poly (I:C) induced non-apoptotic cell death in the 
presence of IAP antagonist. A. For overexpression of cFLIP proteins, HaCaT cells were 
retrovirally transduced with vectors containing cDNA coding for cFLIPL, cFLIPS or vector as 
control. The transduced cells were lysed with subsequent analysis of 5µg of protein by 
Western blot for indicated proteins. -tubulin served as a loading control. One of three 
independent experiments is shown. B. The transduced cells were pre-treated or co-
stimulated with zVAD-fmk (10µM; 1h), Necrostatin-1 (50µM, 1h), and IAP antagonist (100 
nM, 1 h) and subsequently stimulated with 2µg/ml of poly (I:C) for 24h in triplicate wells. 
Viability was assayed by crystal violet staining. The summary of three independent 
experiments is shown and error bars describe SEM. C. For characterization of cell death 
morphology, bulk infected HaCaT cells were stimulated as described in (B.) followed by 
Hoechst-33342 and Sytox Green staining immediately followed by transmission and 
fluorescence microscopy.  
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cFLIPL overexpression fully protected the cells from cell death induced by poly (I:C) as well 
as in the absence of IAP induced by TWEAK (Figure 15 A black bars and B, right panel). 
TWEAK, similar to IAP antagonist, induced necrosis in cFLIPS expressing cells even in the 
absence of TLR-3 stimulation (Figure 15 B; middle panel and Figure 15 A; gray bars; lane 6 
and 9), a further increase of this cell death was achieved by adding poly (I:C) or zVAD/poly 
(I:C) (Figure 15 A, compare panels 6 , 7, and 8; gray bars and Figure 15 B; middle panel). 
Furthermore, this cell death was fully blocked by Necrostatin-1, indicating that cFLIPS 
promotes necrotic cell death whenever cIAPs are absent (Figure 15 A, gray bars; panels 9 
and 10; and Figure 15 B, middle panel).  
Taken together, these data suggest that cIAPs block TLR3-induced cell death signalling both 
in a caspase and RIP-1 kinase dependent manner. Thus downregulation of cIAPs, either by 
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Figure 15. TWEAK duplicates findings obtained with IAP antagonist for cFLIP 
overexpressing HaCaT cells. A and B. For quantification and characterization of poly 
(I:C)-induced cell death, cells expressing cFLIPL and cFLIPS were either pre-treated or co-
stimulated with zVAD-fmk (10µM, 1h), Necrostatin-1 (50µM, 1h), or TWEAK (0,5µg/ml, 1 
h) and subsequently stimulated with poly (I:C) (2µg/ml) for 24h in triplicate wells. A. 
Viability of cells was analysed by crystal violet staining and statistical analysis was 
performed as described before. The summary of three independent experiments for each 
cell line under each condition is shown, the error bars represent SEM. B. For 
characterization of cell death morphology, cells stimulated as described before were 
stained with Hoechst-33342 and Sytox Green dyes immediately followed by transmission 
and fluorescence microscopy.  
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synthetic IAP antagonists or by ligand-induced degradation as exemplified by TWEAK, is 
able to overcome apoptosis resistance in TLR3 apoptosis signalling. Moreover, these data 
suggest that the stoichiometry of cFLIPL and cFLIPS is important to determine the sensitivity 
to caspase-independent cell death once cIAPs are inactivated in a given cell irrespective of 
the mode of their degradation. 
 
3.1.5. cFLIP isoforms differentially influence the modification and 
composition of the intracellular TLR3 signalling complexes  
The observed switch from the apoptotic to the necrotic cell death in cells stimulated with IAP 
antagonist/poly (I:C) in the absence of caspase activity led to the hypothesis that molecules 
involved in the TLR3 cell death signalling cascade are either differentially modified or 
recruited in potentially different apoptotic or necrotic intracellular signalling platforms. To 
identify the differences in the function of cFLIPL and cFLIPS for the TLR3 cell death signalling 
platform caspase-8 immunoprecipitation was performed (Figure 16 A). Caspase-8 was 
chosen since it was proposed to be the key molecule on the apoptotic pathway in TLR3 
signalling (Kaiser and Offermann, 2005). Therefore caspase-8 could be present in the 
receptor signalling complex and molecules associated with apoptotic and necrotic cell death 
could be identified. Since cFLIPS but not cFLIPL spontaneously induced caspase-
independent cell death in the absence of cIAPs, the hypothesis was that resistance to and 
alterations of the poly (I:C) induced cell death characteristics might be explained by 
modification, activation and recruitment of molecules involved in the TLR-3 cell death 
signalling platform. It was found that upon TLR3 stimulation an intracellular complex, 
consisting of Caspase-8, TRIF, RIP-1 FADD and cFLIP isoforms is formed (Figure 16 B 
panel 3). Interestingly in the absence of cIAPs this complex formation was also detected at a 
lower level, although this complex lacked TRIF (Figure 16 B panel 2). Both cIAPs were 
absent in the complex, indicating that modification of molecules by cIAPs is probably taking 
place outside of this complex. In the absence of cIAPs, but in the presence of TLR3 
stimulation the complex was formed more robustly than in presence of IAPs (Figure 16 B 
panel 4). This indicates that cIAPs are blocking the formation of this complex and therefore 
the TLR3-induced signalling. 
When compared to control cells, the absence of cIAPs in cFLIPS overexpressing cells led to 
a robustly increased Caspase-8 binding complex consisting of TRIF, RIP-1 and FADD 
(Figure 16 B, compare panels 4 and 8). Interestingly, IAP antagonist alone in cFLIPS 
expressing cells also let to strongly increased spontaneous complex formation that contained 
caspase-8, FADD, cFLIPS and RIP-1, and lacked TRIF (Figure 16 B; panel 6). These results 
indicate that TRIF is not critical for the induction of IAP antagonist mediated spontaneous 
necrotic cell death and propose a TLR-3 stimulation independent complex formation 
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whenever cFLIPS is dominantly expressed.  However, in cFLIPL expressing cells a partial 
suppression of complex formation upon IAP antagonist/poly (I:C) stimulation was observed. 
This correlated with decreased recruitment of FADD, TRIF, cFLIPL, caspase-8 and 
decreased RIP-1 modification in the absence of cIAPs when compared to control cells 
(Figure 16 B, compare panels 4 and 12). These results indicate that cFLIPL inhibit TLR-3 
mediated cell death by limiting the formation of caspase-8 interaction with RIP-1 and TRIF.  
the data suggest diverse impacts of different cFLIP isoforms for TLR3 signalling complex 
formation and RIP-1 recruitment to this complex. The enhanced RIP-1 recruitment to the 
signalling complex in cFLIPS could be responsible for increased necrotic cell death.  
 
3.1.6. cIAPs are crucial negative regulators of RIP-1 recruitment in 
an apoptotic TRIF containing Caspase-8-interacting complex  
To further investigate the relevance of RIP-1 molecule for TLR 3 signalling HaCaT cells with 
manipulated RIP-1 expression were analysed for sensitivity to poly (I:C) in presence or 
absence of cIAPs. Since cIAPs regulate RIP-1 function and block the recruitment of RIP-1 to 
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Figure 16. cIAPs block formation of intracellular TLR3 signalling complex. cFLIPS 
enhances formation of the complex in the absence of IAPs. A. The schematic picture 
shows the intracellular complex, precipitated with Caspase-8 antibody. B. For caspase-8-
containing protein complexes analysis, the complex was immune precipitated (IP) from bulk 
infected HaCaT cells expressing cFLIPL, cFLIPS or vector after stimulation with poly (I:C) 
(40µg/ml for 2 h). Equal amounts of IP and total cell lysates (TL) were subsequently analyzed 
by Western blot for the indicated molecules.  
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the TLR3 complex the hypothesis arose that cIAPs promote resistance to poly (I:C) induced 
cell death by blocking a pro-death function of RIP-1 in TLR-3 signalling. To test this 
hypothesis HaCaT cells with decreased levels of RIP-1 were generated (Figure 17 A) and 
their sensitivity to poly (I:C)/IAP antagonist induced cell death (Figure 17 B) was quantified. 
0
20
40
60
80
100
120
su
rv
iv
in
g 
at
ta
ch
ed
 c
el
ls
 
[%
cr
ys
ta
l v
io
le
t O
D]
shRNA HRS
shRNA RIP-1
IAP antagonist - +- +- +- +
zVAD-fmk - ++ +- -+ -
Necrostatin-1 - +- -- -+ -
+
-
+
-
-
+
poly (I:C) - ++ ++ ++ - ++
Panel 1 103 82 75 6 94
Hoechst Hoechst
IAP antagonist
Hoechst Hoechst
IAP antagonist
poly (I:C)
control
SYTOX
Green
SYTOX
Green
SYTOX
Green
SYTOX
Green
poly (I:C)
zVAD-fmk
poly (I:C) 
zVAD-fmk
Necrostatin-1
poly (I:C)
Necrostatin-1
shRNA HRS shRNA RIP-1
100µm
A B
C
RIP-1
sh
R
N
A
H
R
S
sh
R
N
A
R
IP
-1
-tubulin 6451
MW
[kDa]
Figure 17. RIP-1 is required for poly (I:C)/IAP antagonist-induced cell death.  
A. HaCaT cells were retrovirally transduced with HRS and RIP-1 specific shRNA. 
Knockdown of RIP-1 protein expression was analysed by Western-Blot analysis. -tubulin 
expression served as an internal loading control. One representative of three independent 
experiments is shown. B. For viability analysis, bulk infected HaCaT cells were either pre-
treated with zVAD-fmk (10µM, 1h), Necrostatin-1 (50µM, 1h) or IAP antagonist (100 nM, 
30min) and subsequently stimulated with poly (I:C) (2µg/ml) for 24h followed by crystal 
violet staining. The summary of three independent experiments is shown, the error bars 
represent SEM. C. For characterization of cell death morphology, bulk infected HaCaT 
cells were stimulated as described in (B.) followed by Hoechst-33342 and Sytox Green 
staining immediately followed by transmission and fluorescence microscopy. 
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Interestingly, infection with retroviral vectors substantially protected cells from poly (I:C)-
induced cell death, when compared to parental cells (Figure 17 B white bars, C left panel). 
This induced resistance to cell death might be explained by the retroviral shRNA transfer into 
the cells, as plausible by the fact that TLR3 recognize viral derived dsRNA, which in turn 
could induce NF-κB activation and therefore increased protection form apoptosis. However, 
in the absence of cIAPs control-infected cells were still substantially sensitized to poly (I:C) 
induced apoptotic cell death (Figure 17 B white bars, C left panel). In contrast, the 
knockdown of RIP-1 fully protected cells from all types of TLR3-induced cell death in 
presence and absence of cIAPs (Figure 17 B black bars; C right panel). These data provide 
evidence that in the absence of cIAPs RIP-1 is a crucial regulator of non-apoptotic TLR-3-
mediated cell death.  
In addition, the stimulation of RIP-1 knockdown cells with TWEAK duplicated the findings 
with the IAP antagonist. These results indicate that during execution of other signalling 
pathways cIAP levels could be altered and this could trigger RIP-1 dependent TLR3 death 
signals. TWEAK was able to sensitize control cells to poly (I:C)-induced cell death (Figure 
18, white bars, panel 7), which could be fully blocked by inhibiting both caspases and RIP-1 
kinase activity (Figure 18, white bars, panel 10). In the absence of RIP-1 full resistance to all 
types of cell death induced by poly (I:C) as well as TWEAK/poly (I:C) was observed (Figure 
18 black bars). Thus, RIP-1 is not only a crucial regulator of necrosis, as shown in previous 
experiments, but also a critical pro-apoptotic regulator of TLR3 signalling that is negatively 
regulated by cIAPs.  
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Figure 18. RIP-1 is required for poly (I:C)/TWEAK-induced cell death. For viability 
analysis, bulk infected HaCaT cells were either pre-treated with zVAD-fmk (10µM, 1h), 
Necrostatin-1 (50µM, 1h) or TWEAK (0,5µg/ml, 1 h) and subsequently stimulated with poly 
(I:C) (2µg/ml) for 24h followed by crystal violet staining. The summary of three independent 
experiments is shown, the error bars represent SEM. 
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To further determine the intracellular regulation of poly (I:C)-induced cell death by cIAPs and 
more specifically the impact of RIP-1 in this signalling pathway, the caspase-8-interacting 
protein complexes in both control and RIP-1 knockdown cells were analyzed (Figure 19 A). 
TLR3 ligation induced the interaction of RIP-1, FADD and marginal amounts of TRIF with 
endogenous caspase-8 (Figure 19 B panel 3) in control cells, similar to control 
cells in the cFLIP experiments (compare Figure 16 B). Interestingly, in the presence of IAP 
antagonist alone, which did not led to cell death, (compare figure 8 B panel 6), a robust 
caspase-8 interaction with RIP-1, but not TRIF and to a lesser extent FADD was noted 
(Figure 19 B; panel 2), comparable to the cFLIP experiments. In contrast TLR3-induced 
interaction of RIP-1, FADD and TRIF to the intracellular caspase-8 interacting complex in the 
absence of cIAPs was substantially increased (Figure 19 B; panel 4). These results 
demonstrate a cIAP-dependent negative regulation of TLR-3 induced cell death by limiting 
TRIF and RIP-1 recruitment to the caspase-8 containing complex. In line with our functional 
data (compare figure 8 B, black bars), knockdown of RIP-1 blocked the formation of this 
signalling platform from caspase-8 complex, as indicated by the blocked ligand/IAP 
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Figure 19. RIP-1 is required for intracellular TLR3 complex formation. A. The schematic 
picture showing the composition of the intracellular complex in RIP-1 downregulated cells. B. 
For complex analysis, the caspase-8-containing complex was precipitated from bulk infected 
HaCaT cells upon stimulation with poly (I:C) (40µg/ml, 2 h) using caspase-8 co-
immuneprecipitation (IP). Equal amounts of immunoprecipitates were subsequently analyzed 
by Western blotting for the indicated molecules. Equal amounts of total cellular lysates (TL) 
were loaded on the same gels to allow comparison of signal strength between IP and TL. 
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antagonist-induced recruitment of TRIF into this complex (Figure 19 B, panel 8). 
Interestingly, the cIAP2 expression level in RIP-1 downregulated cells was significantly 
decreased (Figure 19 B), indicating that RIP-1 is promoting the expression of cIAP2, 
probably by participating in the NF-κB activation.  
These data show that RIP-1 expression is required for TLR-3 cell death signals. 
Furthermore, these experiments demonstrate that RIP-1 is critical adapter molecule for 
activation and formation of the cell death-inducing TLR-3 signalling complex. Loss of RIP-1 
protects from all death signalling and interferes with formation of the death promoting 
signalling platform. 
 
3.1.7. RIP-1 overexpression induces cell death  
In previous experiments the crucial role of RIP-1 for the TLR3 cell death signalling was 
identified (Figure 17-19). Since downregulation of RIP-1 in HaCaT cells significantly reduced 
sensitivity to TLR3 induced cell death, the hypothesis arose that increased RIP-1 levels could 
sensitize cells to pro-cell death stimuli.  
To further investigate the impact of RIP-1 and its enzymatic activities for TLR3 cell death 
signalling pathways overexpression of wild type RIP-1 (WT) as well as the kinase dead 
mutant (K45A) or the cleavage site mutant (D324K) was performed (Figure 20 A). Therefore 
the respective cDNAs for inducible expression of wild type RIP-1 and it mutants were 
subcloned from the pcDNA 3 vector into the PF 5x UAS MCS W SV40 lentiviral vector by 
using NheI and XbaI (Figure 20 B). The successfully subcloned constructs were analyzed by 
specific restriction with Bam HI (Figure 20 C), and subsequently verified by sequencing. The 
vectors were used for generation of lentiviral supernatants and subsequent transduction of 
HaCaT cells.  
The overexpression of RIP-1 and its mutants was analyzed after treatment with different 
concentrations of H-Tamoxifen for 24h. In all three cell lines RIP-1 was overexpressed in 
comparable amounts upon treatment with 10nM and higher concentrations of H-Tamoxifen 
(Figure 21 A). Surprisingly the induced RIP-1 protein was slightly bigger then the 
endogenous one. Since 10nM of H-Tamoxifen was the lowest concentration sufficient for 
induction of RIP-1 expression at physiological level, and considering that high 
overexpression might induce non-specific effects, 10nM of H-Tamoxifen was used for 
subsequent experiments. 
Induction of wild type as well as the mutant variants of RIP-1 decreased the cell viability 
when compared to control cells (Figure 21 B panel 2), indicating that RIP-1 is a crucial 
regulator of cell death. To analyze the caspase- and RIP-1 kinase dependency of RIP-1 
induced cell death the pan-caspase inhibitor zVAD-fmk and the RIP-1 kinase inhibitor 
Necrostatin-1 were used. The inhibition of caspase activity partially blocked RIP-1 WT- and 
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CM-induced cell death, whereas in RIP-1 KD cells more than 70% of the cells were protected 
(Figure 21 B panel 3). This result demonstrates that RIP-1 kinase dead mutant-induced cell 
death is caspase-dependent, whereas when the kinase domain is active (RIP-1 WT and RIP-
1 CD) the observed cell death is not completely caspase dependent. The blocking of RIP-1 
kinase activity did not show any effect in all four cell lines (Figure 21 B panel 4). Whereas 
using of both caspase and RIP-1 kinase activity inhibitors fully protect all RIP-1 
overexpressing cell lines to cell death (Figure 21 B panel 5). 
These results demonstrate that RIP-1 and its enzymatic activities itself are substantial 
regulators of cell death. Furthermore overexpression of RIP-1 in general and RIP-1 with 
active kinase domain specifically activates caspase and RIP-1 kinase dependent types of cell 
death. In addition, RIP-1 KD overexpressing cells do not show complete protection in 
presence of caspase inhibitors, indicating that either other molecules are involved in the non-
apoptotic cell death or the endogenous RIP-1 expression in HaCaT cells promotes caspase 
independent cell death. Since even the lowest overexpression of RIP-1 as well as its mutants 
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Figure 20. Cloning of wild type and mutant variants of RIP-1 into the inducible 
expression vector system. A. Schematic domain structure of RIP-1. The sites of 
kinase and cleavage site mutations are marked. B. The map of the inducible lentiviral 
RIP-1 wild type construct as an example. C. 1µg of the final constructs were digested 
with Bam HI followed by separation on the agarose gel. 
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induced massive cell death further experiments with TLR3 ligand or IAP antagonist couldn’t 
be performed. Despite these experimental limitations, these gained results once again show 
that RIP-1 itself is a key molecule in cell death signalling and even can induce cell death by 
itself. 
 
3.2. The role of cIAPs in CD95L-induced cell death 
Previous studies have shown that cIAPs can inhibit CD95L- and TRAIL-induced apoptosis 
(McEleny et al., 2004; Wang et al., 2005). Since cIAPs regulate RIP-1 modifications induced 
by TNF-R1 and RIP-1 is one of the key players in CD95 signalling, the mechanism of DR cell 
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Figure 21. RIP-1 overexpression induces cell death in both caspase dependent and 
independent manner. A. The transduced cells were treated with indicated amounts of H-
Tamoxifen for 24h, followed by lysis and western blot analysis for RIP-1 expression, -
tubulin served as a loading control. B. The control, RIP-1 wild type as well as mutant RIP-1 
overexpressing cells were either left unstimulated, or pre-treated with 10nM of H-Tamoxifen 
for 12-18h followed by either separate or in combined treatment with 100 nM IAP 
antagonist (1h), zVAD-fmk (10µM; 1h), Necrostatin-1 (50µM, 1h) in triplicate wells for 24h. 
Viability of cells was analysed and statistical analysis was performed as described before. 
The summary of three independent experiments is shown, the error bars represent SEM.
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death in the context of IAP inhibition was investigated. In the previous part it was shown that 
cIAPs block TLR3-mediated cell death, whereas their absence enhances cell death and thus 
cell death proceeds in a caspase and RIP-1 kinase-dependent manner. In this part of the 
studies the impact of cIAPs on CD95L induced cell death will be examined. The aim of this 
part of the studies is thus to compare the role of IAPs in pro-death signalling initiated by 
membrane-bound receptors of different protein families (TLR3 and CD95).  
 
3.2.1. Loss of IAPs sensitizes to CD95L-induced cell death in both 
caspase-dependent and independent manner 
Death ligands, such as CD95L, are known to form apoptosis-competent signalling clusters, 
followed by recruitment to the cytoplasmic death domain–containing adaptor protein FADD, 
which in turn recruits procaspase-8. In context of this signalling complex, procaspase-8 is 
activated by dimerization, resulting in processing and release of the mature and active 
enzyme (Boatright et al., 2003). Previous studies have shown that cIAPs can inhibit CD95-
induced apoptosis (McEleny et al., 2004; Wang et al., 2005). Since the previous 
experiments, described above, have shown the relevance of IAPs for protection against 
apoptotic as well as non-apoptotic cell death in the absence of caspase activity during TLR3-
induced signalling, it was proposed that cIAPs could also negatively regulate CD95-induced 
cell death.  
Our experiments have shown that CD95L is inducing cell death in HaCaT cells, and this 
effect can be strongly enhanced by downregulation of cIAPs (Figure 22 A). To determine the 
morphology of the cell death, fluorescent microscopy studies were performed. Caspase 
inhibitor zVAD-fmk was used in order to check the caspase dependency of observed cell 
death. Upon stimulation with CD95L the first early apoptosis events (judging by 
morphological features, like membrane blebbing, and chromatin condensation) were 
observed after 4h, both in presence and in absence of IAP antagonist (Figure 22 B, upper 
panel). Although the cells could be fully protected from this cell death by blocking of 
caspases after 4h stimulation, the picture changed after 24h, indicating that non-apoptotic 
cell death proceeds with a prolonged kinetic. Thus a number of some late apoptotic events 
(blebbed membrane, condensed chromatin, although the membrane is already ruptured) 
upon CD95L stimulation in presence and absence of IAPs have been detected (Figure 22 B 
lower panel). Surprisingly CD95L-induced cell death could not be blocked by caspase 
inhibitor zVAD-fmk in the absence of IAPs (Figure 22 B lowest panel). However a change in 
cell death morphology was observed as indicated by a rounded shape, a lack of DNA 
condensation and a retarded disruption of cell membranes (Figure 22 B lowest panel).  
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To examine the role of cIAPs in CD95 death signalling in a more physiological setting the 
cytokine TWEAK was used. The results obtained with TWEAK for CD95 signalling were 
similar to the results obtained with IAP antagonist (Figure 22 C). The cells were sensitized to 
the CD95L cell death by both TWEAK and IAP antagonist at to a similar extent (Figure 22 C 
panel 2), this effect could be partially blocked by zVAD-fmk (Figure 14 C panel 3), whereas 
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Figure 22. IAP antagonist sensitizes HaCaTs to CD95L induced cell death in both 
caspase dependent and independent manner. A. Cells were incubated for 8 h and 
subsequently analyzed for hypodiploidy by FACS analysis (see Materials and methods). B. 
HaCaT cells were either pretreated with 10μM zVAD-fmk for 1h or 100 nM of the IAP 
antagonist for 30min. Cells were subsequently stimulated with 5U/ml CD95L for 4 or 24 h. 
5μg/ml Hoechst 33342 and 5pM SYTOX green were added for 15min at 37°C, immediately 
followed by transmission (left) or fluorescence (right) microscopy. One of two independent 
experiments is representatively shown. C. HaCaT cells were either pretreated or co 
stimulated with zVAD-fmk (10µM, 1h), Necrostatin-1 (50µM, 1h) IAP antagonist (100nM, 
1h) or TWEAK (0,5µg/ml, 1 h) and subsequently stimulated with 5 U/ml CD95L in triplicate 
wells for 24h. Viability of cells was analysed and statistical analysis was performed as 
described before. The summary of three independent experiments is shown, the error bars 
represent SEM. D. For analysis of the release of HMGB-1 protein into the supernatant, 
HaCaT cells were pre- or co-stimulated with 10μM zVAD-fmk for 1h and 100nM of the IAP 
antagonist for 30min and subsequently stimulated with 5U/ml CD95L for 24h. Cell-free 
supernatants as well as total cellular lysates were analyzed for HMGB-1 protein 
expression. -tubulin was used as a loading control. One of two representative experiments 
is shown. Experiments A, C and D were kindly provided by Dr. P. Geserick, experiment B 
was done together with Dr. P. Geserick. 
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Necrostatin-1 did not show much effect when used alone (Figure 22 C panel 4), and 
complete protection was achieved by both zVAD-fmk and Necrostatin-1 together (Figure 22 
C panel 5). These results indicate mechanistic similarities between TLR3 signalling pathways 
and CD95 induced cell death pathways and an important role of both caspase- and RIP-1 
kinase functions for cell death induced by CD95L in the absence of cIAPs. 
However, HMGB-1 was released upon CD95L stimulation in the presence and absence of 
IAP antagonist (Figure 22 D panel 3 and 4). Although in the presence of IAPs this release 
could be blocked by zVAD-fmk (Figure 22 D panel 5), in its absence HMGB-1 release was 
not inhibited by zVAD-fmk (Figure 22 D panel 6). These results demonstrate that cIAPs are 
not only critical players in TLR3 death signalling but also in CD95 cell death signalling 
pathways. The CD95L-induced cell death also requires both caspase and RIP-1 kinase 
activity in the absence of cIAPs.  
 
3.2.2. The role of RIP-1 and cFLIP isoforms in CD95-mediated cell 
death in presence of TWEAK  
To further investigate the CD95 signalling in the absence of cIAPs, induced by TWEAK, the 
long and short isoforms of caspase inhibitor cFLIP were overexpressed in HaCaT cells.  
The vector control transduced cells (Figure 23 A white bars) were sensitive to CD95L-
induced cell death (Figure 23 A, white bars, panel 2); which was inhibited by zVAD-fmk 
(Figure 23 A, white bars, panel 3), whereas addition of Necrostatin-1 was ineffective (Figure 
23 A white bars panel 4). In the presence of TWEAK the cells were more sensitive to CD95L 
(Figure 23 A white bars panel 7) and inhibition of caspases did not allow for full protection 
(Figure 23 A white bars panel 8). Similarly, inhibition of RIP-1 kinase activity (Figure 23 A 
white bars panel 9) alone was ineffective. In marked contrast, inhibition of both caspase and 
RIP-1 kinase activities could fully protect the cells (Figure 23 A white bars panel 10). In line 
with the data shown for TLR3 signalling in Figure 15, cFLIPL fully protected cells against cell 
death induced by CD95L, (Figure 23 A black bars) whereas TWEAK also induced necrosis in 
cFLIPS expressing cells in the absence of TLR-3 stimulation, which could be blocked by 
Necrostatin-1 (Figure 23 A; gray bars; lane 6 and 9). In contrast, a further increase of this cell 
death was observed in the presence of CD95L/TWEAK and zVAD/CD95L/TWEAK (Figure 
23 A compare panels 6, 7, and 8; gray bars). Furthermore, CD95L-induced cell death was 
fully blocked by necrostatin-1, indicating that cFLIPS promotes necrotic cell death whenever 
cIAPs are absent (Figure 23 A, gray bars; panels 9 and 10). These results again show that 
cFLIP isoforms contribute to antiapoptotic protection of the cells; whereas cFLIPS is a crucial 
regulator of the necrotic pathway.  
To further investigate the relevance of RIP-1 for CD95 death signalling, RIP-1 was 
downregulated in HaCaT cells. Interestingly, there was not much difference detected in 
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sensitivity to CD95L between control and RIP-1 downregulated cells. Although in the 
absence of IAPs, induced by TWEAK, a sufficient sensitization to CD95L in control cells, but 
not in RIP-1 knockdown cells was detected (Figure 23 B). 
Taken together, these data suggest that cIAPs block TLR3- and CD95L-induced cell death 
signalling in a RIP-1 dependent manner. Thus downregulation of cIAPs, either by synthetic 
IAP antagonists or by ligand induced degradation as exemplified by TWEAK, is able to 
overcome apoptosis resistance in CD95 apoptosis signalling. Moreover the observed 
similarities between CD95- and TLR3-mediated signalling led us to the conclusion that cIAPs 
are at the cross road of cell death signalling pathways induced by diverse and different 
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Figure 23. CD95L duplicates findings obtained with poly (I:C) A. For quantification 
and characterization of CD95L-induced cell death, HaCaT expressing cFLIPL and cFLIPS 
were either pre-treated or co-stimulated with zVAD-fmk (10µM, 1h), Necrostatin-1 (50µM, 
1h), or TWEAK (0,5µg/ml, 1h) and subsequently stimulated with 2,5U/ml of CD95L 
respectively for 24h in triplicate wells. Viability of cells was analysed by crystal violet 
staining and statistical analysis was performed as described before. The summary of 
three independent experiments is shown, error bars represent SEM. B. Cells expressing 
shRNA HRS, shRNA RIP-1 were pre-treated with TWEAK (0,5µg/ml, 1h) and 
subsequently stimulated with indicated concentrations of CD95L for 24h in triplicate wells. 
Viability of cells was analysed by crystal violet staining and statistical analysis was 
performed as described before. The summary of three independent experiments is 
shown, error bars represent SEM. These experiments were kindly provided by Dr. P. 
Geserick.  
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stimuli. The hypothesis arose, that there is a conserved cell death signalling platform, 
triggered by different stimuli. 
 
3.3. Role of cIAPs in TLR3 cell death in primary keratinocytes 
Our studies in A5RT3 and MET1 skin cancer cell lines, as well as HaCaT, which have 
mutation in both copies of the p53 gene, have shown the relevance of cIAPs for TLR3 
induced cell death signalling. The next goal of this study was to investigate the relevance of 
these findings for non-transformed and non-malignant primary human keratinocytes.  
 
3.3.1. Loss of cIAPs sensitizes primary keratinocytes to poly (I:C)-
induced cell death in a Caspase- and RIP-1-kinase dependent 
manner 
Primary keratinocytes significantly differ from transformed HaCaT cells. HaCaT cells for 
example have two copies of a mutated p53 gene, whereas in primary keratinocytes p53 is 
wild type. Moreover, HaCaT and primary keratinocytes differ by the pattern of expressed 
proteins: of main interest is that primary keratinocytes express high protein levels of XIAP in 
contrast to HaCaTs that lack XIAP (Figure 24 A). In addition, primary keratinocytes have high 
levels of cFLIPL, but not cFLIPS expression, and different donors of primary cells express 
different levels of cIAP1 and cIAP2. For our studies primary keratinocytes obtained from 
three different donors (donor E, donor I and donor L) were used.  
The first experiments showed that poly (I:C) can decrease cellular viability in primary 
keratinocytes of all three donors, although Donors I (Figures 24 B, panel 2) and L (data not 
shown, since it duplicated data form donor I) proved to be less sensitive than Donor E 
(Figure 25 A, panel 2). Interestingly, although an increase of cellular viability was detected by 
caspase inhibition (Figure 24 B for Donor I and Figure 25 A for Donor E, panels 3), the 
inhibition of RIP-1 kinase activity decreased viability (Figure 24 B for Donor I and Figure 25 A 
for Donor E, panels 4). Blocking of both caspase- and RIP-1 kinase, however, could not 
confer complete resistance to TLR3 induced cell death in all three donors (Figure 24 B for 
Donor I, and Figure 25 A for Donor E, panels 5). Downregulation of IAPs decreased cellular 
viability (Figure 24 B for donor I and Figure 25 B for Donor E, panels 6) in all three donors. 
TLR3 stimulation in the absence of IAPs further decreased cellular viability, with lesser 
amount of cell death in donors I and L (Figure 24 B panel 7 and Figure 25 A, panel 7). 
Inhibition of caspases in the absence of IAPs did not show any effect in donors I and L 
(Figure 23 B panel 8), but increased cellular viability in Donor E (Figure 25 A, panel 8). RIP-1 
kinase inhibition, in the absence of IAPs, did not show any effect on cellular viability in all 
donors (Figure 24 B and 25 A, panels 9). Inhibition of both caspase- and RIP-1 kinase 
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activities in the absence of IAPs protected viability in all three donors (Figures 24 B and 25 A, 
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Figure 24. Loss of cIAPs sensitizes primary keratinocytes to poly (I:C)-mediated 
apoptotic and non-apoptotic cell death is caspase and RIP-1K dependent manner. A. 
The analysis of 5µg of total cell lysates from HaCaT and primary keratinocytes (donors E, I 
and L) by Western-blot analysis for the respective proteins. -tubulin served as internal 
control for even loading. One of two representative experiments is shown. The stars indicate 
the nonspecific binding of the antibody. These blots were kindly provided by Dr. P. Geserick. 
B. Primary keratinocytes (donor I) were either separately or in combination pre-treated with 
100nM IAP antagonist (1h), zVAD-fmk (10µM; 1h), Necrostatin-1 (50µM, 1h), and 
subsequently stimulated with 2µg/ml of poly (I:C) in triplicate wells. The summary of five 
independent experiments is shown, error bars represent SEM. C. Primary keratinocytes 
(donors I and L) were either separately or in combination pre-treated with 100 nM IAP 
antagonist (1h), zVAD-fmk (10µM; 1h), Necrostatin-1 (50µM, 1h), and subsequently 
stimulated with 2µg/ml of poly (I:C) for 18h and subsequently analysed for hypodiploid DNA 
content by FACS. One representative experiment (donor I) of 2, performed for each donor is 
shown. D. For characterization of cell death morphologies, primary keratinocytes (donor I) 
were either pre-treated with QVD (10µM, 1h), Necrostatin-1 (50µM, 1h) or IAP antagonist 
(100nM, 30min) and subsequently stimulated with poly (I:C) (2µg/ml) for 24h. Cells were 
stained with Hoechst-33342 and SYTOX Green immediately followed by transmission and 
fluorescence microscopy. One representative (donor I) of a total of two independent 
experiments performed for each of the donors is shown.
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panel 10). These data indicate that the observed effects are donor-specific. IAPs critically 
regulate TLR3-induced cell death in primary keratinocytes, although signalling molecules 
such as caspases and RIP-1 kinase are involved in cell death regulation of TLR3-induced 
signalling. In contrast to the data in HaCaT, RIP-1 kinase activity is required for primary 
keratinocyte survival.  
To check if the observed decrease in cellular viability is due to increased cell death, 
hypodiploidy analysis (Figure 24 C) and live imaging using Hoechst and SYTOX-Green dyes 
(Figure 24 D) were performed. Upon treatment with poly (I:C), as well as in the absence of 
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Figure 25. Primary keratinocytes (donor E) are more sensitive to TLR3-induced 
cell death, than donors I and L and RIP-1 is essential for its execution. A. Primary 
keratinocytes from Donor E were either separately or in combination pre-treated with 
100 nM IAP antagonist (1h), zVAD-fmk (10µM; 1h), Necrostatin-1 (50µM, 1h), and 
subsequently stimulated with 2µg/ml of poly (I:C) in triplicate wells. Viability of cells was 
analysed as described before. B. Primary keratinocytes (donor E) were either separately 
or in combination pre-treated with 100 nM IAP antagonist (1h), QVD (10µM; 1h), 
Necrostatin-1 (50µM, 1h), and subsequently stimulated with 2µg/ml of poly (I:C) for 18h 
and subsequently analysed for hypodiploid content by FACS. C. For viability analysis, 
bulk infected primary keratinocytes (donor E) were either pre-treated with zVAD-fmk 
(10µM, 1h), Necrostatin-1 (50µM, 1h) or IAP antagonist (100 nM, 30 min) and 
subsequently stimulated with poly (I:C) (2µg/ml) for 24h followed by crystal violet 
t i i
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RIP-1 kinase activity, the cells were dying with prominent apoptotic features: membrane 
blebbing, chromatin condensation and increased amounts of hypodiploid nuclei in donors I 
and L (Figure 24 C and 24 D, left panel), as well as in Donor E (Figure 25 B). Blocking of 
caspase activity by respective inhibitors repressed hypodiploidy (Figure 24 C and 25 B) and 
morphological change of the dying cells (Figure 24 D). The cells first became rounded and 
swollen followed by membrane rupture (Figure 24 D). In the absence of IAPs the effects of 
TLR3 stimulation were further intensified, which increased cell death as determined by 
hypodiploidy analysis (Figure 24 C and 25 B). Moreover morphologically apoptotic cells were 
noted under those conditions (Figure 24 D, right panel). Surprisingly, blocking of RIP-1 
kinase function by Necrostatin-1 in the absence of IAPs increased the amount of TLR3-
induced apoptosis (Figure 24 D, right panel and Figure 24 C and 25 B). Inhibition of caspase 
activity by zVAD-fmk or QVD led to complete loss of hypodiploid nuclei also in the absence 
of IAPs (Figure 24 C and 25 D), whereas the dead cells acquired necrotic morphology. 
Absence of both caspase and RIP-1 kinase activity led to complete protection against both 
types of cell death, indicating the relevance of both enzymes for apoptosis and necrosis, 
respectively. Furthermore these results suggest that the observed loss of viable cells upon 
treatment with caspase and RIP-1 kinase inhibitors in the presence and absence of IAPs 
(Figures 24 B and 25 A) is not related to a cell death phenotype, but rather reflect an anti-
proliferative effect of the combination of inhibitors. 
The results gained for primary keratinocytes (donors I, L and E) clearly differ from analogous 
results in HaCaT cells. The HaCaTs did not show increased apoptosis in response to 
blocking of RIP-1 kinase activity in the absence of IAPs, in contrast to primary keratinocytes. 
These results indicate that RIP-1 kinase function seem to play an important role in protection 
against cell death in primary keratinocytes.  
 
3.3.2. The function of RIP-1 in TLR3-induced cell death in primary 
keratinocytes  
To further investigate the role of RIP-1 and the difference in cell death signalling between 
primary keratinocytes and HaCaT cells RIP-1 shRNA downregulated primary keratinocytes 
were generated. As described in Figure 17, downregulation of RIP-1 in HaCaTs led to 
complete protection from both types of TLR3-induced cell death in the absence of IAPs. To 
check if cell death protection in primary keratinocytes is controlled by the same mechanisms, 
RIP-1 was downregulated in primary keratinocytes (Donors I, L and E). The level of RIP-1 
downregulation in primary keratinocytes was comparable to the level of downregulation in 
HaCaTs (Figure 26 A). In contrast to HaCaT cells, the primary keratinocytes donors I and L 
(For L data is not shown, since it duplicates the data from donor I) were unable to protect 
from TLR3-induced cell death (Figure 26 B, white bar, panel 2). Moreover, surprisingly, RIP-1 
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downregulation did not protect from poly (I:C) induced cell death, when compared to control 
cells (Figure 26 B, panel 2). This indicates significant differences between TLR3-induced 
death signalling in primary keratinocytes and HaCaT cells. Furthermore RIP-1 proved to be 
not critical for TLR3-induced cell death in primary keratinocytes.  
Unexpectedly in the absence of caspase activity further sensitization of RIP-1 downregulated 
cells was noted, although partial protection of the control cells against TLR3-induced cell 
death (Figure 26 B, panel 3) was observed. This indicates that cell death in primary 
keratinocytes is partially dependent of caspases, although the RIP-1 is crucial for protection 
from caspase-independent cell death. The further decrease of RIP-1 kinase activity did not 
alter the cell death sensitivity in both control and RIP-1 knockdown cells (Figure 26 B, panel 
4). Inhibition of both caspases and RIP-1 kinase activity did fully protect, in difference to 
parental primary keratinocytes (compare Figure 26 B, panel 5 and Figure 24 B, panel 5). 
Inhibition of IAP activity did not influence the cell survival, indicating that IAP’s function is not 
required for survival of primary keratinocytes (Figure 26 B panel 6). In the absence of IAPs 
both control and RIP-1 downregulated cells were sensitized to TLR3-induced cell death 
(Figure 26 B, panel 7), in contrast to the results from HaCaTs (compare Figure 17 B). 
Therefore IAPs are critical factors for TLR3-induced cell death, whereas in primary 
keratinocytes further enzymatic analysis of the mode of all cell death is required to dissect 
this pathway. In the absence of both IAP and caspase activities the viability of RIP-1 
knockdown cells was sufficiently decreased, compared to the control cells, indicating the 
relevance of RIP-1 for protection from caspase-independent cell death (Figure 26 B, panel 
8). The decrease of RIP-1 kinase activity protected RIP-1 knockdown cells, whereas was 
ineffective in control cells (Figure 26 B, panel 9). This might indicate that Necrostatin-1 is not 
only inhibiting RIP-1 kinase, but may also target other, currently unknown, proteins, which 
are necessary for survival of primary keratinocytes.  
The combination of caspase and RIP-1 kinase inhibitors conferred the best protection in both 
control and RIP-1 knockdown cells from TLR3-induced cell death in the absence of IAPs 
(Figure 26 B, panel 10).  
Interestingly, in contrast to donors I and L, but in line with the data in HaCaT cells, RIP-1 
downregulation in Donor E protected these cells from TLR3-induced cell death in the 
absence of IAPs (compare Figures 26 B, 8 B and 16 C, black bars, panel 7).  
The analysis of the hypodiploid nuclear content in the control cell line have revealed the 
same effects as in the parental cells of donors I and L. Poly (I:C) induced apoptotic cell 
death, which was increased in presence of IAP antagonist and further increased in the 
absence of RIP-1 kinase activity, whereas the blocking of caspases led to nearly complete 
absence of hypodoploid DNA content (Figure 26 C, left panel). In contrast the RIP-1 
downregulated cell line has shown less apoptosis upon TLR3 stimulation in presence and 
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absence of IAPs, compared to the control cell line (Figure 26 C, right panel). These data 
suggest that RIP-1 as a whole protein is required for apoptosis execution in some donors of 
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Figure 26. RIP-1 protects primary keratinocytes (donors I and L) from poly (I:C) 
induced apoptosis in absence of IAPs. A. Primary keratinocytes donors L, E and I 
and HaCaT cells as a control were retrovirally transduced with HRS and RIP-1 specific 
shRNA. Knockdown of RIP-1 was analysed by Western-blot analysis. -actin expression 
served as an internal loading control. One representative of two independent 
experiments is shown. B. For viability analysis, bulk infected primary keratinocytes 
(donors I and L) were either pre-treated with zVAD-fmk (10µM, 1h), Necrostatin-1 
(50µM, 1h) or IAP antagonist (100 nM, 30 min) and subsequently stimulated with poly 
(I:C) (2µg/ml) for 24h followed by crystal violet staining. The summary of five 
independent experiments is shown, as described in materials and methods. C. 
Transduced primary keratinocytes (donors I and L) were either separately or in 
combination pre-treated with 100 nM IAP antagonist (1h), QVD (10µM; 1h), Necrostatin-
1 (50µM, 1h), and subsequently stimulated with 2µg/ml of poly (I:C) for 18h and 
subsequently analysed for hypodiploid DNA content by FACS. One representative 
experiment (donor I) of 2, performed for each donor is shown. 
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primary keratinocytes (see Figure 26 C, right panel); moreover RIP-1 is also required for 
protection from caspase-independent cell death. Contrasting data in HaCaT cells, RIP-1 
kinase function, in primary keratinocytes, is an important component of anti-apoptotic 
protection (Figure 26 C, left panel). Another hypothesis is that necrostatin-1 is targeting other 
molecules, which are responsible for anti-apoptotic protection. Donor E is different form the 
other two donors and much more resembles HaCaT, indicating that there are a least two 
different types of primary keratinocytes with different types of cell death signalling. 
 
3.4. The role of cIAPs in MAPK and NF-κB activation  
In the previous parts of the thesis the role of cIAPs in cell death pathways induced by TLR3 
and CD95 pathways in different cellular models was described. These receptors can also 
induce non-cell death pathways such as activation of NF-κB and MAPK (Stone et al., 2009). 
Activation of NF-κB is tightly connected to up-regulation of anti-apoptotic proteins such as 
cFLIP and cIAPs. In contrast cFLIP and cIAPs can also regulate NF-κB activation 
(Diessenbacher et al., 2008; Dohrman et al., 2005; Wachter et al., 2004). These processes 
are therefore tightly interconnected and can confer protection against apoptosis and 
potentially carcinogenesis (Stone et al., 2009). Therefore it is important to understand the 
influence of cIAPs on non-cell death signalling pathways for future therapeutic applications of 
IAP antagonist. 
 
3.4.1. Inhibition of cIAPs led to both canonical and non-canonical 
NF-κB activation  
To characterise the relevance of IAPs for modulation of non-cell death signalling pathways 
the canonical and non-canonical NF-κB activation pathways were analysed in HaCaT and 
SCC cells in presence of IAP antagonist and DL or poly (I:C). Therefore in initial experiments 
with another inhibitor of IAPs – IAP antagonist 2 (LBW242) was used at different 
concentrations and time points to detect time and dose dependency of NF-κB activation. The 
NIK stabilisation and p100 degradation were detected upon IAP inhibition (Figure 27 A) in 
HaCaT cells. These results are an indication for non-canonical NF-κB activation. This finding 
indicates that cIAPs are blocking non-canonical NF-κB activation in HaCaT cells. The 
stabilisation of NIK was detected at all concentrations used within 1h of treatment. 
Interestingly cIAP1 was degraded after 30min of treatment at all concentration, whereas 
cIAP2 was not affected by the lowest concentration of IAP antagonist 2. Interestingly after 
24h of treatment with IAP antagonist 2 NIK stabilisation was decreased, whereas cIAP2 
protein levels were increased in IAP antagonist 2-dependent manner (Figure 27 A). These 
results were repeated with IAP antagonist with HaCaT, A5RT3 and MET1 cells. The cells 
were treated with IAP antagonist and the levels of NIK and p100 were evaluated (Figure 27 
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B). In all three cell lines NIK stabilisation as well as p100 degradation upon IAP 
downregulation was observed. Taken together these results indicate that cIAPs are blocking 
non-canonical NF-κB activation in keratinocyte cell lines.  
To further characterise the impact of cIAPs on canonical NF-κB activation, HaCaT and 
A5RT3 cell lines were used and checked for DNA binding of p65/p50 heterodimers by EMSA 
(Figure 27 C). Increased amounts of p65/p50 heterodimer-DNA binding was detected in both 
cell lines after 24h of treatment with IAP antagonist. The results indicate that IAPs are also 
blocking the canonical NF-κB pathway.  
Taken together, the results suggest that IAPs do not only interfere with the cell death 
pathways but also control both canonical and non-canonical NF-κB activation pathways.  
 
Figure 27. IAPs are blocking canonical and non-canonical NF-κB activation in 
HaCaTs. A. HaCaT cells were treated with indicated concentrations of LBW242 for 
respective time. The lysates were loaded in amount of 5µg and analysed by Western blot 
for respective proteins. B. HaCaT, A5RT3 and MET1 cells were treated with 100nM of IAP 
antagonist for 4h, followed by Western-blot analysis of 5µg total cell lysates form respective 
proteins. β-tubulin served as internal control for even protein loading. One of three 
representative experiments is shown. C. A5RT3 and HaCaT cells were treated with 100nM 
of IAP antagonist for 24h and the nuclear lysates were used for NF-κB EMSA one of 2 
experiments is shown. Stars indicate nonspecific binding of the antibody and probe. 
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3.4.2. The role of IAPs for NF-κB and MAPK activation in HaCaTs, 
SCC and primary keratinocytes 
MAPK signalling is important for the control of normal skin development and homeostasis. Its 
deregulation promotes epidermal carcinogenesis (Khavari and Rinn, 2007). TRAIL is known 
to induce apoptosis in variety of tumour and transformed cells without toxicity to normal cells 
(Mahmood and Shukla, 2010), and the absence of IAPs sensitizes various cell lines to TRAIL 
induced cell death (Geserick et al., 2009). TRAIL is a known inducer of NF-κB (Falschlehner 
et al., 2007) and MAPK, such as JNK (Lin et al., 2000) and p38 (Morel et al., 2005). Thus 
TRAIL and IAP antagonist could be potentially used for cancer treatment. Therefore NF-κB 
as well as MAPK activation, induced by TRAIL in the absence of IAPs should be studied in 
order to predict the possible and potentially deleterial pro-carcinogenic effects.  
Since downregulation of IAPs led to increased canonical and non-canonical NF-κB 
activation, the influence of IAPs in DL-induced NF-κB as well as MAPK activation was 
studied in different cell lines. The first comparison was performed between HaCaT and 
primary keratinocytes (donor 11) (Figure 28), to check the difference between parental and 
spontaneously transformed keratinocytes. In both cell lines cIAP1 and cIAP2 were lost in 
time dependent manner upon TRAIL stimulation. In both cell types, cIAP1 was completely 
absent within 30min of IAP antagonist stimulation, whereas the level of cIAP2 was only 
reduced, but not completely degraded (which is consistent with the previous findings in 
HaCaT cells, compare Figure 9 B). 
The IκBα phosphorylation and degradation served as an indicator of canonical NF-κB 
activation. In both cell types TRAIL treatment led to increased p-IκBα level, whereas total 
IκBα was lowered, in line with the previously published kinetics (Leverkus et al., 2003). 
Interestingly the level of p-IκBα was also significantly increased upon IAP antagonist 
treatment alone, whereas the total level of IκBα remained largely unchanged. In the presence 
of IAP antagonist the TRAIL-induced IκBα phosphorylation and degradation was decreased 
in primary keratinocytes, whereas in HaCaT cells the level of IκBα activation remained the 
same. These data suggest that the activation of the canonical pathway of NF-κB is constantly 
suppressed by IAPs, whereas canonical TRAIL-induced NF-κB activation is partially 
suppressed in primary keratinocytes in the absence of IAPs.  
NIK stabilisation is one of the features of activation of the non-canonical NF-κB pathway. NIK 
stabilisation was not detected upon TRAIL stimulation, whereas NIK was rapidly stabilised in 
the absence of IAPs within 1 h of IAPs degradation. Although the absence of IAPs stabilizes 
NIK, further stimulation with TRAIL significantly repressed NIK stabilisation in both cell types. 
Thus cIAPs are important negative regulators of non-canonical NF-κB pathway, whereas 
TRAIL-induced signalling suppresses the spontaneous non-canonical NF-κB activation in 
absence of IAPs.  
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Other important non-cell death signalling pathways are the activation of MAPK, which can 
promote processes such as inflammation and carcinogenesis. The activity of MAPK in 
response to IAP downregulation and TRAIL stimulation were detected by phosphorylation of 
p38, JNK and HSP27, an important target protein of p38. Phosphorylation of HSP27, JNK 
and p38 activation were first detected after 1-2h of TRAIL stimulation and, in contrast to NF-
κB pathways, both MAPK were not activated in the absence of IAPs in both cell types. 
TRAIL-induced p38 and JNK activation, in the absence of IAPs, were unchanged in HaCaT 
and, interestingly, decreased in primary keratinocytes for both p38 and JNK.  
These data suggest that the presence of IAPs, in contrast to NF-κB pathways, does not 
affect MAPK activation. The TRAIL-induced MAPK activation is partially suppressed in the 
absence of IAPs in primary keratinocytes. Together these data indicate that IAPs are not 
crucial regulators of MAPK in primary keratinocytes and HaCaT cells.  
Next NF-κB and MAPK activation were compared in MET1 and A5RT3 cells (Figure 29) in 
order to check the difference between tumour cells (A5RT3 and MET1) and normal (primary 
keratinocytes), or immortalised (HaCaT) keratinocytes. A5RT3 is a part of the HaCaT tumour 
progression model, derived from HaCaT by introduction of the Harvey-ras oncogene (codon 
12 mutation); this cell line was proved to form metastatic tumours (Mueller et al., 2001). 
MET1 cell line is part of the MET model system; this cell line is derived from a primary skin 
Figure 28. TRAIL induced MAPK and NF-κB activation in presence and absence of 
IAPs in HaCaT cells and primary keratinocytes. HaCaT and primary keratinocytes 
(donor 11) were starved for 6h and either pre-treated with IAP antagonist for 30min or left 
untreated followed by stimulation with 500ng/ml of TRAIL for the indicated time periods. 
The cells were lysed and 5µg of total cellular proteins were analysed by Western blot for 
the respective proteins. -tubulin served as a control. 
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tumour. Furthermore, MET1 carry a number of aberrations typically seen in SCCs, although 
these cells are devoid of p53 mutations (Popp et al., 2000).  
In both cell lines cIAP1 protein was lost upon TRAIL stimulation, whereas cIAP2 was only 
lost by TRAIL stimulation in A5RT3, whereas in MET1 cells the cIAP2 level did not change 
significantly upon TRAIL stimulation. In both cases cIAP1 was rapidly degraded after 30min 
of IAP antagonist treatment, whereas cIAP2 was degraded only partially.  
In both cell lines the p-IκBα level was significantly enhanced and total IκBα level was lowered 
within 1h of TRAIL treatment, in line with data from HaCaT and primary keratinocytes. The 
level of p-IκBα was also significantly increased upon IAP antagonist treatment whereas the 
total level of IκBα was largely unchanged. In the presence of IAP antagonist the TRAIL-
induced IκBα phosphorylation and degradation was decreased in both cell lines (Figure 29), 
in line with the data in primary keratinocytes, but different from HaCaT (Figure 28). Thus, the 
activation of the canonical pathway of NF-κB is constantly suppressed by IAPs also in 
tumour cell lines. In contrast, whereas the canonical TRAIL induced NF-κB activation is 
partially suppressed in the absence of IAPs.  
Interestingly, NIK stabilisation was not detected upon TRAIL stimulation (Figure 29), similar 
to the data in HaCaT and primary keratinocytes (Figure 28), whereas the absence of IAPs 
stabilized NIK within 1 h (Figure 29). Although the absence of IAPs stabilised NIK, further 
stimulation with TRAIL significantly repressed NIK stabilisation in both cell lines, in line with 
data in HaCaT and primary keratinocytes. The non-canonical NF-κB pathway is also 
significantly suppressed by IAPs, although TRAIL-induced signalling suppresses the non-
canonical NF-κB activation.  
Figure 29. TRAIL induced MAPK and NF-κB activation in presence and absence of 
IAPs in MET1 and A5RT3 cell lines. MET1 and A5RT3 were starved for 6h and either 
pretreated with IAP antagonist for 30min. or left untreated followed by stimulation with 
500ng/ml of TRAIL for indicated time periods. The cells were lysed and 5µg were analysed 
by Western blot for respective proteins. -tubulin served as a control. 
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In both cell lines JNK and p38 as well as HSP27 were activated within 1-2h of TRAIL 
stimulation. In line with the data in HaCaT and primary keratinocytes, downregulation of IAPs 
did not influence p38 and JNK activation. In both cell lines TRAIL-induced p38 activation was 
unchanged or slightly increased in the absence of IAPs, in line with data from HaCaT cells. In 
the absence of IAPs, the TRAIL-induced JNK activation was slightly decreased in A5RT3, in 
line with data from primary keratinocytes, whereas in MET1 it was slightly increased.  
In general these data suggest that IAPs negatively regulate both canonical and non-
canonical NF-κB activation. TRAIL-induced signalling induces canonical, but not non-
canonical NF-κB activation. Although in the absence of IAPs TRAIL-induced signalling is 
decreased for both canonical and non-canonical NF-κB pathways, primary as well as tumour 
cells exhibit these features. On the opposite, p38 as well as JNK activation were induced 
only by TRAIL, but not by IAP degradation, indicating that MAPK pathway is independent of 
IAPs. Interestingly in primary keratinocytes activation of both MAPK pathways was 
decreased in the absence of IAPs, whereas in both tumour cell lines activation of these 
pathways was enhanced. This might indicate that simultaneous usage of both TRAIL and 
IAP antagonist on the skin tumours may cause increased inflammation in tumour but not in 
normal cells. The significance of these findings is to be evaluated in vivo settings.  
Diplom Genetikerin Feoktistova Maria Alexeevna 
The role of RIP-1 and cIAPs in apoptotic and non-apoptotic signalling via TLR3 and death receptors  
 80
4. Discussion  
4.1. cIAPs are critical regulators of TLR3-induced cell death in 
transformed keratinocytes and SCC cells  
TLR3 signalling is tightly connected to cellular proliferation, apoptosis resistance and tumour 
progression (for review see (Li et al., 2010)). Controversially, TLR3 was also shown to induce 
apoptosis in cancer cells (Salaun et al., 2006) indicating that TLR3 agonists (such as poly 
(I:C)) could be potentially used as anti-tumour agents. However, several melanomas are 
resistant to TLR3 agonists (Salaun et al., 2007), leading to the hypothesis that a number of 
intracellular molecules regulate TLR3-induced cell death pathways.  
For further understanding of these mechanisms, which determine TLR3 signalling outcome 
the role of IAPs was studied, since these proteins regulate cell death processes (Geserick et 
al., 2009; Varfolomeev et al., 2007). The goal of this study was to investigate the role of 
cIAPs in regulation of TLR3-induced cell death. While using a synthetic compound (IAP 
antagonist), siRNA targeting cIAPs or activation of signalling pathways (TWEAK) that 
antagonize the function of cIAPs, a dramatic increase in sensitivity of primary as well as 
immortalized keratinocytes (HaCaT) to poly (I:C)-induced cell death was observed. In line 
with a recent report (Weber et al., 2010), the results of this study now also show that cIAPs 
profoundly regulate TLR3-triggered cell death. IAP antagonist, which was used in this study, 
originally was established to disrupt the function of XIAP. In this study it was found that XIAP 
deficient HaCaT cells are substantially sensitized to poly (I:C) induced cell death. The data 
clearly show that cIAPs confer resistance to TLR3-induced cell death. Since HaCaT cells 
lack XIAP at the protein level, and TWEAK-FN14 signalling leaves XIAP levels unaffected 
(Wicovsky et al., 2009), the inhibition of cIAP function leads to the suggestion that cIAPs 
regulate TLR3-mediated cell death in a XIAP independent manner. In contrast the metastatic 
A5RT3 cells, that are more resistant to cell death induced by poly (I:C) treatment were not 
sensitized by TWEAK in a similar way. This result indicates the existence of other signalling 
pathways which regulate the TLR3 signalling, independent of IAPs.  
Furthermore, MET1 SCC cancer cells, which have high XIAP expression at the protein level 
and show less sensitivity to TLR3-induced cell death, can be further sensitized by IAP 
antagonist. In contrast, TWEAK failed to sensitize MET1 to poly (I:C) treatment, indicating 
the relevance of XIAP for protection against TLR3-induced cell death in this cell line.  
When discussing which molecules have greater impact for the cell death signalling pathways 
(cIAPs or XIAP) it has to be noted that the majority of the cell lines in the National Cancer 
Institute panel have overexpressed level of XIAP, when compared with matched normal 
tissue (Tamm et al., 2000). As well, XIAP overexpression has been correlated with poor 
prognosis in a variety of cancer types: adult and childhood acute myelogenous leukemia 
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(Tamm et al., 2000; Tamm et al., 2004), clear-cell renal carcinoma (Ramp et al., 2004), 
multiple myeloma (Nakagawa et al., 2006) and bladder cancer (Li et al., 2007). However, 
XIAP expression and the relative levels of other IAP family members vary between tumour 
lines. This suggests different regulation of these antiapoptotic genes between distinct types 
of cancer (Tamm et al., 2000). Moreover, mRNA levels of XIAP do not correlate with protein 
levels in the tumours, indicating post-transcriptional regulation of expressed proteins (IAP) 
(Dean et al., 2007). As well, evidence gained in this and other studies of our group in TLR3 
and DR signalling suggest that cIAP1 has a stronger impact to the antiapoptotic protection of 
the cells than cIAP2 (Diessenbacher et al., 2008; Geserick et al., 2009). Summing up – all 
three members of IAP family grant significant protection from cell death, and the quantitative 
impact of each molecule in these signalling is highly cell type dependent.  
Nonetheless, the observed sensitization of HaCaT as well as MET1 cells to TLR3-induced 
cell death by IAP depletion signifies that IAP downregulation could be used as a potential 
strategy to overcome the resistance of tumour cells to TLR3-induced cell death in a 
therapeutic setting.  
 
4.2. cIAPs negatively regulate apoptotic and necrotic TLR3-induced 
signalling by limiting caspase and RIP-1 kinase activity in HaCaT 
keratinocytes 
This study has shown the high relevance of cIAPs for regulation of TLR3-induced cell death 
signalling pathways. It has to be kept in mind for further possible usage of IAP antagonist 
and TLR3 ligand in anti-cancer therapy that the type of cell death is of critical importance: 
since apoptosis and necrosis utilize different ways of cleaning up the dead cells (Krysko et 
al., 2006), different consequences for the affected organ and organism might well be of 
critical importance (Festjens et al., 2006b; Greenhalgh, 1998). In transformed keratinocytes 
(HaCaT cells) the cell death induced by TLR3 in the absence of cIAPs had pronounced 
apoptotic features. In contrast, blocking of caspases dramatically changed the phenotype of 
the cell death giving it necrotic features (in the absence of cIAPs). This necrotic cell death is 
dependent on RIP-1 kinase activity, indicating RIP-1 as a key player in the necrotic cell 
death. This finding is in line with the landmark study that showed that necrotic cell death can 
be inhibited by RIP-1 kinase inhibitor Necrostatin-1 (Degterev et al., 2008). This observed 
switch to the necrotic cell death highlights cIAPs as negative regulators of RIP-1 kinase 
function and thus cell death resistance from TLR3 signals. RIP-1 in general plays significant 
role in the cell signalling e.g. RIP-1 knockout mice are born but die rapidly because of an 
increased sensitivity to TNF (Kelliher et al., 1998). RIP-1, and specifically its DD, was 
reported to be critical for CD95-mediated necrosis independent of NF-κB-inducing activity or 
RIP-1 kinase activity (Degterev et al., 2005; Holler et al., 2000). The precise role or potential 
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targets of the kinase activity of RIP-1 remain largely unknown (Hitomi et al., 2008), although 
a recent study claims a formation of RIP-1-RIP-3 complex, which regulates programmed 
necrosis and virus-induced inflammation (Cho et al., 2009). 
 Furthermore the downregulation of RIP-1 on the protein level in this study led to complete 
protection form both types of cell death induce by TLR3 in the absence of cIAPs. This 
indicates RIP-1 as a critical regulator of apoptosis signalling at the crossroad of all cell death 
pathways, induced by TLR3.  
 
4.3. cFLIPL and cFLIPS differentially regulate apoptotic and necrotic 
TLR3 signalling pathways in the absence of cIAPs 
The previous studies showed that cIAPs control apoptotic and necrotic TLR3-induced cell 
death signalling pathways. Furthermore, the inhibition of caspase activity in the absence of 
cIAPs induces a switch from apoptotic to necrotic type of cell death. The cFLIP proteins, 
cFLIPL and cFLIPS, are both inhibitors of caspase-8 (Kataoka, 2005; Scaffidi et al., 1999) in 
cell death signalling complexes (Geserick et al., 2008) and therefore both cFLIP isoforms 
were proposed as potent cellular factors providing tumour protection from apoptosis (Zhang 
and Fang, 2005). In this study the role of caspase-8 activation for TLR3 induced apoptotic 
and necrotic cell death was further investigated by means of overexpression of cFLIP 
isoforms. Expression of both cFLIP isoforms induced resistance to TLR3-induced apoptosis 
in the absence of cIAPs. Interestingly, the overexpression of cFLIPS, but not cFLIPL in the 
absence of cIAPs induced necrosis even in the absence of TLR3 stimulation. This indicates 
the critical relevance of cIAPs for protection of the cells against spontaneous necrotic cell 
death induced by cFLIPS. Interestingly, blocking of RIP-1 kinase function with chemical 
inhibitor completely protected these cells from cFLIPS induced necrosis in the absence of 
cIAPs. This again confirms RIP-1 kinase function as crucial component of necrotic signalling 
in the cell.  
The physiological relevance of this spontaneous necrosis is not clear to date, although recent 
studies have shown that viral variants of FLIP proteins (vFLIP), expressed by Human 
herpesvirus 8 (HHV-8), HVS8 (Nicholas, 2007), and cFLIPS isoform share high homology in 
the protein sequence as well as in their function (Thurau et al., 2009). For example the vFLIP 
isoform expressed by HHV-8 virus can inhibit caspase-8 activation (Glykofrydes et al., 2000) 
and protects from CD95L-induced cell death signalling pathways (Wu et al., 2004). 
Furthermore it was proposed that vFLIP from HHV-8 virus could be a molecule that promotes 
carcinogenesis of endothelial cells and leads to the formation of Kaposi's sarcomas (KS) 
(Thurau et al., 2009). In the context of cIAPs downregulation, vFLIP proteins could be critical 
factors of anti-tumour protection. The role of vFLIP proteins in the cell signalling and the 
possible role of IAPs in these signalling pathways will be the issue of future studies.  
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cFLIPL overexpression led to complete protection from apoptotic type of cell death, which 
was proposed before, since cFLIPL is known to block the cellular caspase activity (Kataoka, 
2005). Surprisingly cFLIPL overexpression also fully blocked the necrotic cell death pathway, 
which could be due to increased interaction between RIP-1 and cFLIPL (Dohrman et al., 
2005), or due to a changed stoichiometric ratio between RIP-1 and cFLIPL. This may result in 
the blockade of the RIP-1 kinase function. Moreover, inhibition of active caspase-8 mediated 
cleavage of RIP-1, by cFLIPL could influence the RIP-1 kinase function and therefore necrotic 
signalling.  The further hypothesis is described in chapter 4.4 of this thesis.  
The further insight to the mechanism of TLR3 signalling was in the understanding of receptor 
complex composition and the function of its elements.  
 
4.4. cIAPs control TLR3-induced cell death signalling by regulating 
the formation of intracellular complexes  
The concept of the formation of intracellular signalling complexes that triggers either cell 
death or other cellular responses was firstly studied in death ligand signalling pathways 
(Festjens et al., 2006a). The recruitment and the activation of pro- and anti-apoptotic proteins 
to membrane bound death receptor complexes (such as the DISC) (Peter and Krammer, 
2003) or to cytoplasmic intracellular complexes (complex II) are crucial for the cell signalling 
outcome (Dohrman et al., 2005). Growing evidence rose that the enzymatic activities of RIP-
1, cFLIP and caspase-8 play an important role either for cell death induction or cell survival. 
When TLR3-dependent signalling events were examined, it was found that cIAPs control the 
composition of TLR3 signalling complexes as well as the modification of molecules within 
that complex that ultimately regulates the outcome of cell near responses (Figure 30). 
Activated TLR3 leads to formation of an intracellular complex that contains RIP-1, caspase-8, 
cFLIP isoforms, FADD and TRIF. The formation of this signalling platform results in caspase-
dependent apoptosis induction (Figure 30, gray area). This cell death can be blocked by 
caspase inhibitors such as zVAD-fmk, cFLIPL and cFLIPS, which indicates the crucial role of 
caspase-8 activation in such pro-apoptotic complexes.  
The presence of IAPs blocks formation of intracytoplasmic signalling platform, which in this 
study is called “RIP-1 complex”, containing RIP-1, Caspase-8, FADD and cFLIP (Figure 30 
compare white and pink areas). This spontaneously formed complex is necessary but 
insufficient for cell death induction. Since the adaptor molecule TRIF is lacking in this 
complex, we propose that upstream signalling via TLR3 receptor is required to trigger the 
formation of the pro-apoptotic and necrotic signalling platform (Figure 30, green area).  
At endogenous protein levels TRIF was found in the caspase-8-interacting complex in this 
study. Previous findings in TRIF knockout mice (Kaiser and Offermann, 2005; Yamamoto et 
al., 2003) or siRNA-mediated TRIF knockdown cells (Weber et al., 2010) showed that the 
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adaptor function of TRIF in apoptotic TLR3 signalling is required. The findings of this study 
now further extend these data and show that in poly (I:C)/IAP antagonist-stimulated cells the 
interaction of FADD and TRIF as well as RIP-1 that are bound to caspase-8 are dramatically 
Figure 30. The role of cIAPs during TLR3-mediated cell death in HaCaTs.  
cIAPs block formation of a cytoplasmic Caspase-8-bound complex. The complex 
contains the initiator Caspase-8, RIP-1, cFLIP, and FADD and is able to bind to the 
cytoplasmic domain of TLR3 via TRIF. This signalling platform induces cell death in a 
caspase-dependent as well as caspase-independent manner. In the absence of RIP-1, 
the formation of this complex is suppressed, and therefore further signalling is blocked. 
cFLIPL also suppresses caspase-8 complex formation by competition with Caspase-8 
for binding to FADD. cFLIPL protects from apoptotic as well as non-apoptotic cell death. 
cFLIPS leads to massive formation of a cytoplasmic caspase-8 bound complex (without 
TRIF) with active RIP-1 in the absence of cIAPs independent of TLR3 stimulation. RIP-
1 kinase activity in this complex is the reason for a constitutive sensitivity to treatment 
with IAP antagonist. cFLIPS overexpression protects from TLR3 induced apoptosis, but 
not from necrotic-like cell death. 
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increased. This is ultimately sufficient to promote apoptotic and necrotic cell death (Figure 
30, green area). 
Furthermore, other reports suggested that TRIF-RIP-1 interaction is critical for TLR3-induced 
pro-inflammatory signalling (Meylan et al., 2004) and cell death (Kaiser and Offermann, 
2005). Results of this study now indicate that cIAPs suppress TLR3 mediated cell death 
induction by limiting RIP-1 recruitment. In addition, this RIP-1/caspase-8 complex favours 
apoptotic cell death, but inhibition of caspase activity unmasks the alternative RIP-1 kinase 
activity dependent form of cell death. The role of RIP-1 in TLR3 signalling is controversially 
discussed, since RIP-1 has proved to be an essential molecule for execution of cell death as 
well as for many other signalling pathways such as NF-B activation (for review see 
(Declercq et al., 2009)). However, when RIP-1 expression was reduced, a decrease in 
cytoplasmic complex formation was observed, and such cells were fully resistant to both 
apoptotic and necrotic cell death (Figure 30, orange area). Thus results of this study 
identified a number of RIP-1 functions in TLR3 signalling. RIP-1 acts not only as an 
indispensible adapter molecule, but is also critical for cell death induction, whereas the 
kinase function of RIP-1 is solely required for necrotic cell death.  
To further understand the role of caspase activation in TLR3 signalling, the impact of the 
endogenous caspase inhibitor cFLIP and its isoforms on caspase-8 inhibition within these 
cytoplasmic complexes was studied. Results of this study support the concept that cFLIP 
isoforms differentially regulate TLR3-induced cell death signalling. Noteworthy both cFLIP 
isoforms suppressed TLR3-triggered apoptotic cell death, and upon overexpression of both 
isoforms the amount of cFLIP in caspase-8 complex was increased. cFLIPS can promote 
necrosis in the absence of cIAPs upon TLR3 stimulation (Figure 30 blue area), as well as 
without any TLR3 stimulation (Figure 30 right pink area). This necrotic cell death is critically 
dependent on RIP-1-kinase activity and RIP-1 recruitment to the caspase as well as RIP-1 
complexes is increased. In addition, high cFLIPL levels not only correlate with resistance of 
cells to apoptotic but also to caspase-independent cell death correlating with reduced RIP-1 
recruitment to the cytoplasmic complex (Figure 30, yellow area). The hypothesis is that, 
cFLIPL may interfere in caspase-8-mediated RIP-1 cleavage in the cellular signalling 
platform, which contains cFLIP isoforms and caspase-8 as shown for CD95 signalling 
pathway (Geserick et al., 2009). Future mechanistic studies are required to elucidate this 
point in more detail. 
The composition of the cytoplasmic complexes, formed upon TLR3 stimulation, has crucial 
relevance for the cell fate. The increased amount of cFLIP isoforms in the complex leads to 
anti-apoptotic protection, whereas the increased amount of RIP-1 promotes necrosis. Future 
studies will now aim to discover other components of these complexes, relevant for the cell 
signalling. 
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4.5. cIAPs control apoptotic and necrotic cell death induced by 
CD95L 
In recent years the death receptors in general (Mahmood and Shukla, 2010; Russo et al., 
2010) and CD95 specifically (Gerspach et al., 2009; Wicovsky et al., 2009) were studied as 
potential targets for tumour treatment. Growing evidence indicates that cIAPs regulate death 
ligand induced cell death and non-apoptotic signalling pathways (Geserick et al., 2009; 
Varfolomeev et al., 2007). Data gained in this study with IAP antagonist and TWEAK-FN14 
supports these findings. Upon CD95 stimulation HaCaT cells activate the apoptotic pathway, 
whereas the reduction of cIAPs level in the cell leads to significant increase of apoptotic cell 
death, indicating the essential relevance of cIAPs for the regulation of CD95-induced 
apoptosis. The blocking of caspases by chemical inhibitors or cFLIPS overexpression also 
unmasked the necrotic cell death pathway, which was controlled by RIP-1 kinase activity, 
further supporting the position of RIP-1 as a key necrotic regulator. The downregulation of 
RIP-1 by shRNA did not influence CD95-induced apoptosis, but significantly decreased the 
CD95-induced cell death in the absence of IAPs. Furthermore cFLIPL isoform blocked both 
apoptotic and necrotic cell death induced by CD95L. Taken together these results nearly 
duplicate the data gained in the study of TLR3 signalling, indicating that the role of cIAPs is 
broader and involves for both TLR3 and CD95 signalling pathways.  
Recent studies have shown that the formation of cytoplasmic complexes upon TNF 
(Varfolomeev and Vucic, 2008), CD95L or TRAIL (Geserick et al., 2009) stimulation is also 
enhanced by loss of IAPs. These studies have proposed that cIAPs inhibit the recruitment of 
RIP-1 to these complexes and therefore protect the cells from DR-induced apoptosis as well 
as necrosis mediated by RIP-1 kinase activity (Geserick et al., 2009). Intriguingly, cFLIPL, but 
not the cFLIPS isoform inhibited the formation of the cytoplasmic complex (Geserick et al., 
2009). Taken together these findings indicate common activation mechanism of apoptosis as 
well as necrosis (in the absence of caspase activity) which are suppressed by cIAPs under 
physiological conditions.  
 
4.6. cIAPs are suppressors of RIP-1 complex formation  
This study together with other works of our group (Geserick et al., 2009) show, that two 
distinct groups of receptors (DR and TLR) share similar mechanisms of the molecular 
machinery of cell death pathways. This indicates that signalling platform could prove 
important for a larger number of cell death pathways. The current hypothesis is that cIAPs 
are constantly ubiquitinating RIP-1, which may either lead to subsequent proteasomal 
degradation of RIP-1 (Figure 31 left part). Alternatively cIAP-mediated ubiquitination, most 
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likely by Lys63, may provide critical for inhibition of formation of such a signalling platform. 
This RIP-1 complex, which contains RIP-1, caspase-8, FADD and cFLIP, but is unable to 
induce cell death by itself (Figure 31 middle part) is a major finding of this thesis. When 
cFLIPS isoform is recruited to the RIP-1 complex it can promote activation of RIP-1 kinase 
and therefore induce necrotic cell death. In the absence of IAPs, which can also be mediated 
by TWEAK (Vince et al., 2008), the RIP-1 complex, is spontaneously formed (Figure 31 
middle part). Although the RIP-1 complex is unable induce cell death by itself, its formation 
simplifies the cell death signalling via other cellular signals. Upon stimulation of the 
respective receptor (e.g. DR or TLR3) the RIP-1 complex is able to bind to these receptors, 
followed by posttranslational modification of the molecular components and further 
dissociation of the complex from the receptor (Figure 31 right part). This dissociation of the 
c
omplex from the receptor was shown for DR signalling (Geserick et al., 2009) and will be a 
subject of future studies in the TLR3 signalling pathway. These dissociated complexes are 
called “complex II” (Geserick et al., 2009) (Figure 31 right part). It can trigger cell death in 
both caspase and RIP-1 kinase dependent manner. Understanding of the regulation and 
composition of such RIP-1 complexes might prove highly useful in the attempt to design 
novel therapeutic strategies that are needed to overcome cell death resistance, such as for 
tumour therapy or virus elimination from an infected host. 
 
Figure 31. Cell death signalling in the absence of IAPs. IAPs block formation of a RIP-1 
complex, which does not induce cell death by itself, but simplifies formation of receptor 
complexes (TLR3 and TRAIL), which leads to intensive formation of “second complexes” 
which leads to cell death.  
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4.7. cIAPs and XIAP protect primary keratinocytes from TLR3-
induced apoptotic and non-apoptotic cell death  
The probable use of IAP antagonists, combined with TLR3 or death receptor agonists as 
treatment for tumours, should always relate to studied in primary keratinocytes in this thesis. 
Beside the obvious differences between primary keratinocytes and the model SCC cell lines, 
such as wild type p53 and the likely absence of chromosomal aberrations in primary 
keratinocytes (Boukamp, 2005), there are also several other differences. For example, 
primary keratinocytes have high levels of cFLIP expression and therefore are resistant to 
TRAIL-induced cell death (Leverkus et al., 2000). In contrast, the sensitivity of primary 
keratinocytes to TLR3 in this study was on the same level as in HaCaT (immortalised 
keratinocytes). An additional important difference of primary keratinocytes is that they 
express high levels of XIAP, which is also expressed by MET1 cells, but is absent in HaCaT 
and the derived cell line A5RT3. Similar to the data in the SCC models, primary keratinocytes 
were further sensitized to TLR3-induced cell death by the absence of IAPs, and cell death 
showed apoptotic features. Whereas blocking of caspases also revealed the cryptic necrotic 
pathway (Figure 32, blue field). This necrotic cell death was also dependent on RIP-1 kinase 
activity, duplicating the findings in the immortalised keratinocytes. Intriguingly and in contrast 
to the SCC cell lines, blocking of RIP-1 kinase functions in the presence and absence of 
IAPs led to an increase of apoptotic cell death, indicating the crucial relevance of RIP-1 
kinase function for antiapoptotic protection of primary keratinocytes (Figure 32, blue field). 
Intriguingly the combined inhibition of RIP-1 and caspase activity could not grant full 
protection against TLR3-iduced cell death in the presence as well as in the absence of IAPs. 
This indicates that there are other TLR3 pro-death signalling pathways, which are not 
mediated by caspases or RIP-1 kinase function. One of the possibilities could be the 
activation of IFN regulatory factors (IRF) 3, 5 and 7 upon stimulation of TLR3 (Boo and Yang, 
2010). Activation of these factors can be induced by binding of TRAF3 to TRIF and further 
association of TRAF3 into a complex with IKKε and TBK1 (Hacker and Karin, 2006). IRF5 is 
a strong transcription activator for IFN-α production, and IRF7 can induce IFN-α and also 
IFN-β preferentially (Boo and Yang, 2010). The IFNs in turn can induce apoptosis in various 
cell types (Chawla-Sarkar et al., 2003).  
Furthermore, RIP-1 downregulation did not induce protection from TLR3-induced cell death 
both in presence and absence of IAPs in two of three donors, although morphologically the 
induced cell death had more necrotic than apoptotic features. Interestingly blocking of RIP-1 
kinase function in RIP-1 knockdown primary keratinocytes induced strong protection against 
TLR-3-induced cell death (Figure 32, green field). The complete protection as found in 
HaCaT was not achieved in the absence of combined caspase and RIP-1 kinase activity. 
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These results suggest that in HaCaT immortalised keratinocytes the signalling is performed 
otherwise, compared to primary keratinocytes. The possible explanation could be the high 
XIAP expression in primary keratinocytes, which is absent in HaCaTs, and XIAP function is 
also targeted by IAP antagonist. The role of XIAP in keratinocyte cell death processes is 
aimed to dissect in the future by using TWEAK. Moreover, the other RIP family members, 
like RIP-3 could influence these signalling pathways. RIP-3 can interact with TRIF and RIP-1 
via its RHIM (Declercq et al., 2009; Kaiser and Offermann, 2005) and is known to induce 
necroptosis (Cho et al., 2009; Feng et al., 2007; He et al., 2009; Zhang et al., 2009). 
Therefore in RIP-1 knockdown cells RIP-3 could be recruited to the TLR3 cytoplasmic 
signalling complex and promote the necrosis shift (Figure 32, green area). The role of RIP-3 
in the cell death signalling in SCC as well as in primary keratinocytes will be a topic of future 
separate studies.  
Figure 32.The role of IAPs in TLR3-mediated cell death in primary keratinocytes. 
Blue field: TLR3 induces apoptosis in the primary keratinocytes, independent of RIP-1 
expression level. The absence of IAPs sensitizes the cells to TLR3-induced apoptosis 
and blocking of RIP-1 kinase function is increasing the effect, whereas the blocking of 
caspases changed the cell death type to necrosis. Green field: RIP-1 downregulated 
cells are sensitive to TLR3 induced cell death in the presence and absence of IAPs. 
Although in the absence of IAPs these cells suffer necrosis upon TLR3 stimulation, which 
is partially reduced by blocking of RIP-1 kinase function and is promoted by blocking of 
caspase functions. 
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Summing up the data in primary keratinocytes, the combined use of TLR3 stimulation and 
IAP antagonist as a therapeutic agent is debatable, since primary keratinocytes were shown 
to be as sensitive as immortalised cell lines, whereas the tumour and metastatic cells proved 
to be insensitive, or at least less sensitized by IAPs downregulation. Although, more 
extended studies are needed to solve these perplexing issues, why primary keratinocytes 
react differently, as compared to tumour cells in respect to inhibition of RIP-1 kinase activity.  
 
4.8. The impact of IAPs for the control of non-apoptotic signals 
activation in TRAIL stimulated primary keratinocytes and SCC cell 
lines 
TRAIL is proposed to be a probable anticancer therapeutic agent, since the primary 
keratinocytes proved to be more resistant to TRAIL-induced apoptosis, when compared to 
immortalised keratinocytes and cancer cells (Leverkus et al., 2000). IAPs proved to play an 
important role for TRAIL-induced cell death (Geserick et al., 2009). Therefore the combined 
use of TRAIL and IAP antagonist appears possible as anti-tumour strategy. Since NF-κB 
activation is tightly connected to up-regulation of anti-apoptotic proteins, such as cFLIP and 
cIAPs (Chiron et al., 2009; Wang et al., 1998), NF-κB induced signalling can activate 
apoptosis resistance and therefore carcinogenesis (Stone et al., 2009).  
TLR3 as well as DR signals affect a wide range of physiological and pathophysiological 
processes in human patients such as autoimmune diseases and cancer progression (Huang 
et al., 2008; Suhir and Etzioni, 2010). NF-κB dependent suppression of apoptosis or the 
creation of an inflammatory microenvironment that promotes growth, survival and potentially 
metastasis of tumour cells has been proposed (Li et al., 2010).  
In this study it was shown that TRIAL, in presence of IAPs, is inducing only canonical NF-κB 
activation (Figure 33, yellow area). IAPs are regulating non-canonical NF-κB activation 
(Figure 33, compare yellow and violet areas) (Varfolomeev et al., 2007), probably by 
promoting NIK degradation. Also, IAPs block spontaneous activation of the canonical NF-κB 
pathway. Some studies propose that NIK, which is a part of the non-canonical NF-κB 
pathway, may as well regulate the canonical NF-κB signalling by yet unknown mechanism 
(Varfolomeev and Vucic, 2008) (Figure 33, violet are). Interestingly TRAIL-induced signalling 
in the absence of cIAPs showed partially blocked canonical and completely blocked non-
canonical NF-κB pathways. Therefore the combined usage of TRAIL and IAP antagonist on 
keratinocytes should have repressed NF-κB induction and, consequently should not lead to 
following inflammation or expression of antiapoptotic proteins. Thus our data support the 
combined use of TRAIL and IAP antagonist as an anti-tumour therapy, although our data 
about RIP-1 kinase function in primary keratinocytes clearly merit cautious testing in this 
context  
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In contrast to NF-κB pathways, MAPK signalling is not auto-activated upon IAP depletion, 
although TRAIL treatment leads to p38 and JNK MAPK activation (Song and Lee, 2008) in 
primary as well as in SCC cell lines. Interestingly, TRAIL resistance in malignant cells was 
shown to be differentially mediated by p38, whereas in normal cells, resistance was 
mediated by NF-κB (Steele et al., 2006). In this study it was shown that cancer MET1 and 
A5RT3 cells display increased p38 activation upon TRAIL stimulation in the absence of IAPs. 
In contrast, p38 activation was unchanged in HaCaT cells and decreased in primary 
keratinocytes. The hypothesis is that this could be one of the reasons for reduced sensitivity 
of MET1 and A5RT3 to TRAIL in the absence of IAPs, compared to HaCaT cells data, which 
was shown in (Geserick et al., 2009). In contrast, TRAIL-induced activation of JNK seems to 
be not influenced by the absence of IAPs in SCC cell lines, whereas in primary keratinocytes 
the absence of IAPs reduces the TRAIL-induced JNK activation.  
Figure 33. Canonical and non-canonical NF-κB activation in presence and absence of 
IAPs. IAPs block non-canonical NF-κB activation by promotion of NIK degradation. IAPs 
block spontaneous NF-κB activation. TRAIL signalling blocks spontaneous activation of both 
pathways 
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Taken together these results suggest that in order to increase the sensitivity of tumour cell to 
TRAIL, inhibition of IAPs could be combined with p38 chemical inhibitors, like SB203580. 
However the detailed study of TRAIL-induced p38 activation and the interplay of MAPK and 
IAPs and its role in anti-tumour therapy must be the object of future studies. 
 
4.9. Perspectives 
The current study has clearly demonstrated the crucial role of IAPs, RIP-1, and cFLIP 
variants in the regulation of TLR3 as well as DR signalling. Based on studies of this thesis, a 
number of intriguing questions arise: 
 The RIP-1 complex formation and modification of its components 
This study has shown cIAPs as negative regulators of intracellular RIP-1 complex formation. 
The regulation and composition of such RIP-1 complexes will be the topic of further studies. 
These future studies might prove useful to come to novel therapeutic strategies to overcome 
cell death resistance, such as tumour therapy or virus elimination from an infected host. 
 RIP-3 and its role in cell death signalling 
RIP-3 is another RIP family member, which also has a kinase and intermediate domain with 
a RHIM, although RIP-3 is lacking a death domain. Furthermore, RIP-3 can interact with 
TRIF and RIP-1 via its RHIM (Declercq et al., 2009; Kaiser and Offermann, 2005). RIP-3 is 
also known to induce necroptosis (Cho et al., 2009; Feng et al., 2007; He et al., 2009; Zhang 
et al., 2009). Consequently, in this study RIP-3 was proposed as a potential candidate for 
recruitment to TLR3 signalling complexes in the absence of RIP-1 and promotion of necrosis 
shift of the cell death signalling pathway. Clarifying the role of RIP-3 will be important for the 
understanding of cell death signalling in general, and specifically for necrotic signalling, 
induced by different membrane-bound receptors.  
 Role of cIAPs in DR and TLR3 signalling in primary keratinocytes  
This study has identified the IAP proteins as crucial regulators of cell death signalling in 
primary keratinocytes, although the exact role of cIAPs and XIAP requires further 
elaboration. Using TWEAK as alternative for IAP inactivation is one of the ways to address 
this question.  
 The role of p38 activation in protection of tumour cells from apoptosis. 
This study has also revealed that IAPs inhibit TRAIL-induced p38 activation in tumour cells, 
which were not, or were only partially sensitive to TLR3 and DR stimulation in presence and 
absence of IAPs. Since TRAIL resistance in malignant cells was shown to be differentially 
mediated by p38 (Steele et al., 2006), a potential role of p38 in cell death protection of the 
tumour cells as well as the role of IAPs in this process will be compelling future tasks to 
understand the interplay of cell death and inflammatory signalling pathways.   
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6. Appendix 
6.1 Abbreviations 
% (v/v)   percent by volume 
% (w/v)   percent by mass 
4-HT    4-Hydroxytamoxifen 
aa    amino acids 
AIF    Apoptosis-Inducing Factor 
AP-1   Activating Protein 1  
BAD   Bcl-2-associated death promoter 
BAK   Bcl-2 homologous antagonist/killer 
BCC   Basal Cell Carcinoma 
Bcl-2    B-cell lymphoma 2 
Bcl-X   Bcl-2-like protein 1 
BIM   Bcl-2-like protein 11 
BIR    Baculoviral IAP Repeat 
BMF   Bcl-2-modifying factor 
CARD     Caspase Activation and Recruitment Domain 
Caspase   Cysteinyl-Aspartate Specific Protease 
CD95    =FasL (FS7-associated cell surface antigen) 
CD95L    =FasL (FS7-associated cell surface antigen Ligand) 
cFLIP    cellular FLICE-Inhibitory Protein 
cIAP    cellular Inhibitor of Apoptosis Protein 
CIAP    Alkaline Phosphatase from calf intestine 
CICD   Caspase-independent cell death  
CM   Cleavage mutant 
DD   Death Domain 
DED   Death Effector Domain 
DISC    Death Inducing Signalling Complex 
D-MEM   Dulbecco’s Modified Eagle Medium 
DNA    deoxyribonucleic acid 
dNTPs    Deoxynucleoside Triphosphate Set 
DR    death receptor 
E1   ubiquitin activating enzyme 
E2    ubiquitin conjugating enzyme 
E3    ubiquitin ligase enzyme 
E.coli    Escherichia coli 
EDTA    ethylenediaminetetraacetic acid 
ERK   extracellular-signal-regulated kinase 
Expo    exposition 
F-    Flag (tag) 
FADD    Fas-Associated Death Domain protein 
FBS    Fetal Bovine Serum 
Fc    Fragment crystallizable 
FLICE   FADD-like interleukin-1 beta-converting enzyme 
GFP    Green fluorescent protein 
HaCaT   human adult low calcium temperature (keratinocytes) 
HEK 293T   Human Embryonic Kidney 293 large T transformed 
HF    His-Flag (tag) 
HHV-8   Human herpesvirus 8 
HRP    Horseradish peroxidase 
HRS   Hyper random sequence 
HVS8   herpesvirus saimiri 8 
IFN   Interferon 
IgG    Immunoglobulin G 
IκB    Inhibitor of NF-κB 
IKK    Inhibitor of κB Kinase 
IL   Interleukin 
IP    Immunoprecipitation 
IRF   IFN regulatory factor  
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JNK   c-Jun N-terminal kinase 
KD    Kinase Death 
kDa    kilo Dalton 
KS   Kaposi sarcoma 
LUBAC   The linear ubiquitin chain assembly complex 
Mal   MyD88-adapter-like 
MAPK    Mitogen-Activated Protein Kinase 
MW    Molecular Weight 
MyD88-  Myeloid differentiation primary response gene (88) 
NOXA   Phorbol-12-myristate-13-acetate-induced protein 1 
NEMO   NF-κB Essential Modulator 
NF-κB   Nuclear Factor 'kappa-light-chain-enhancer' of activated B-cells 
NIK    NF-κB-Inducing Kinase 
PAGE    Polyacrylamide Gel Electrophoresis 
PBS    Phosphate-Buffered Salines 
PCR    Polymerase chain reaction 
PI   Propidium Iodide 
PUMA   BH3-only protein, p53 upregulated modulator of apoptosis 
PVDF    Polyvinylidene fluoride 
QVD   (Q-VD-OPH) Q-Val-Asp(non-omethylated)-OPh   
R    Receptor 
RHIM   RIP homotypic interaction motif 
RING    Really Interesting New Gene 
RIP    Receptor-Interacting Protein 
SAPK   stress-activated protein kinase 
SCC   Squamous cell carcinoma 
SDS    Sodium Dodecyl Sulfate 
SEM    Standard Error of Mean 
shRNA    Small hairpin RNA 
SiRNA    Small interfering RNA 
SMAC/DIABLO  Second Mitochondrial Activator of Caspases/Direct IAP Binding protein with 
Low pI 
TAE    Tris-acetate-EDTA 
TAK1    Transforming Growth Factor-β (TGF-β)-Activated Kinase 1 
TBK1   TANK-binding kinase 
TIR   Toll/IL-1 receptor domain 
TL    Total Lysate 
TLR   Toll-like receptor 
TNF    Tumor necrosis factor 
TRADD   TNF Receptor Associated Death Domain 
TRAF    TNF Receptor Associated Factor 
TRAIL    TNF-related apoptosis-inducing ligand 
TRIF   TIR-domain-containing adapter-inducing interferon-β 
TWEAK  Tumor necrosis factor-like weak inducer of apoptosis 
U     Unit 
UBA    Ubiquitin-Associated (domain) 
UBD   Ubiquitin binding domain 
UV    Ultra Violet 
vFLIP   viral FLICE-Inhibitory Protein 
WT   Wild type 
XAF1   X-linked IAP-associated factor 1  
XIAP    X-linked IAP 
ZVAD-fmk   z-Val-Ala-DL-Asp(OMe)-fluoromethylketone 
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